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Abstract 
Fast dispersible tablets (FDTs) are solid single-unit dosage forms that are placed in the mouth 
and allowed to disperse or dissolve in the saliva without the need of water. The basic approach 
to formulating FDTs consists of adding a superdisintegrant to a tablet formulation. These  
tablets offer both the advantages of  conventional tablets and liquid dosage forms along with 
distinctive properties which include accurate dosing, ease of administration, quick onset of 
action, enhanced bioavailability, and increased patient adherence.  
 FDTs have been found to be effective in remedying therapeutic in-adherence caused by 
dysphagia (swallowing difficulties) particularly in paediatric and geriatric subjects. There is a 
strong correlation between therapeutic success and patient adherence especially with 
HIV/AIDS treatment regimens, consequently the dosage form should be patient friendly and 
devoid of unappealing characteristics.  This study aimed at developing a cost effective fast 
dispersible tablet of lamivudine using alternative excipients and conventional techniques. Only 
conventional tablets and oral liquid dosage forms of lamivudine are available on the South 
African market. 
Two natural polymers reported to have superdisintegrating properties were selected to serve as 
multipurpose excipients in this study. The polymers were identified, characterised and 
compared using thermal, spectroscopic and micromeritic analytical tools. The polymer that 
displayed the best characteristics in terms of  micromeritic, tableting and disintegrating 
properties was retained and used for the optimum formulation.  
The optimum formulation was composed of  150 mg of lamivudine, 23% w/w unripe banana 
powder and 2% w/w magnesium stearate. FDTs of lamivudine were obtained using the 
compression technique with and without wet granulation. The tablets were assessed as per the 
United States Pharmacopoeia (USP) guidelines and other evaluation procedures pertaining to 
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FDTs. The wet granulated tablets were found to be less friable and thus more resilient than the 
directly compressed tablets. In-vitro disintegration of the wet granulated tablets occurred 
within 50±3 sec in deionised water (pH 7) and 35±2 sec in a phosphate buffer solution (pH 
6.8). Consequently, the innovative tablets fulfilled the core requirement of FDTs i.e. rapid 
disintegration.  
Drug release studies were carried out by analysing dissolution aliquots of  the innovative tablets 
using a validated High Performance Liquid Chromatography (HPLC) method,  and comparing 
them to Aspen Lamivudine®, a conventional tablet of lamivudine presently on the South 
African market. Complete dissolution in deionised water (pH 7) was attained within 10 minutes 
and 30 minutes for the innovative tablets and Aspen Lamivudine® respectively.  
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Chapter 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
This chapter is an overview of the research problem of this project. It gives the 
reader a glimpse of what this study offers. The key themes of the project are 
prefaced. The motivation behind this investigation, the aim and the set 
objectives are clearly elaborated. 
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1.1 Problem and background 
Human immunodeficiency virus infection and acquired immune deficiency 
syndrome (HIV/AIDS) contribute tremendously to the global burden of disease with sub-
Saharan Africa being the region with the highest prevalence rate in the world. Southern Africa 
is the most affected region and is widely regarded as the epicentre of the global HIV 
epidemic.[1] With an estimated 7.03 million people living with HIV/AIDS in 2016, roughly 
12,7 % of the total population, South Africa is the country with the highest number of people 
living with HIV/AIDS in the world.[2]  Since the late 1990s, HIV/AIDS has progressed from a 
fatal illness to a chronic manageable disease due to the development of several drugs that can 
halt the replication of the causative virus at various steps of its lifecycle. Some of these drugs 
include abacavir, emtricitabine, lamivudine, tenofovir, and zidovudine.[3] 
Lamivudine is a synthetic nucleoside analogue indicated for the treatment of  HIV-1 infection 
in combination with other antiretroviral agents.[4] Lamivudine appears on the essential 
medicine list of South Africa, and it is one of the first line antiretroviral drug treatments in the 
country.[5] A combination of zidovudine and lamivudine is often used as a post exposure 
prophylaxis for individuals and health care workers after accidental contact with HIV 
contaminated tissues or fluids.[6]  
Several formulations of Lamivudine can be found on the South African pharmaceutical market 
in the form of tablets and syrups. Although tablets and syrups are conventional oral dosage 
forms and are widely accepted, they have several drawbacks which may dissuade patients from 
taking them based on individual factors.[7] 
Self-administration, accurate dosing, compactness and ease of manufacture account for the 
popularity of tablets amongst other dosage forms. One important disadvantage of tablets is the 
difficulty some patients have in swallowing them (dysphagia). Roughly a third of the 
http://etd.uwc.ac.za/
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population (mostly paediatrics and geriatrics) has swallowing difficulties.[8] Dysphagia is 
prevalent in geriatric patients due to damage in the head and neck anatomy as a result of ageing, 
as well as changes in neural and physiologic mechanisms supporting swallowing function, and 
in paediatric patients due to their underdeveloped muscular and nervous systems. Difficulties 
in swallowing solid dosage forms is also prompted by upper respiratory tract affections such 
as laryngitis and the unavailability of potable water (especially in developing countries).[9] The 
United Nations Children's Fund (UNICEF) reports that 17 countries in Africa including 
Somalia and Ethiopia are drought stricken with children being at a higher risk. Also, recent 
developments in the drought-stricken Cape Town metropole have seen water restrictions and 
rationing being implemented due to the probability of the town running out of potable water if 
stringent measures are not taken.  
Although syrups and other oral liquid formulations somehow address the problem of 
dysphagia, several practical issues may arise from their use which include instability of the 
active pharmaceutical ingredient, spillage, bad taste, inaccurate dosing, bulkiness, 
transportation and storage.[10] 
The issues enumerated above can dissuade patients from taking their medications, 
consequently, they may become in-adherent to the prescribed therapy. Adherence to 
medication is a crucial part of patient care and indispensable for attaining therapeutic goals. In 
the case of HIV/AIDS, inadherence to therapy can lead to drug resistance and virologic 
treatment failure.[11] The World Health Organisation (WHO) 2003 report on medication 
adherence states that “increasing the effectiveness of adherence interventions may have a far 
greater impact on the health of the population than any improvement in specific medical 
treatment”[12] In an attempt to increase patient adherence by mitigating the drawbacks of oral 
liquid formulations (syrups, solutions, emulsions and suspensions) and conventional tablets, 
http://etd.uwc.ac.za/
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orally disintegrating dosage forms such as fast dispersible tablets have been developed and 
have attracted a great deal of attention.[13] 
Fast dispersible tablets are solid single-unit dosage forms that are placed in the mouth, and 
allowed to disperse or dissolve in the saliva without the need of water and provide a quick onset 
of action. Other appellations for fast dispersible tablets include: quick dissolves, fast melts, fast 
dissolving, fast disintegrating, rapid-dissolve, or orally dissolving tablets.[14] The fast 
dissolving solid dosage form turns into a soft mass or liquid form to facilitate swallowing; 
consequently, the risk of choking is reduced considerably.[15] Fast dispersible tablets offer both 
the advantages of solid dosage forms and liquid dosage forms along with distinctive properties 
which include accurate dosing, ease of administration, quick onset of action, enhanced 
bioavailability, and increased patient compliance.[16] A dispersible tablet is flexible and can be 
prescribed across all age groups; this simplifies the task of prescribers and reduces the work 
load of manufacturers as one dosage form suits all.[17] 
The basic approach in the development of fast dispersible tablets is the use of 
superdisintegrants which provide rapid tablet disintegration in the mouth.[15] Over the past few 
years, new pharmaceutical excipients have been introduced referred to as “superdisintegrants”. 
A “superdisintegrants” is an excipient, which is incorporated into an oral solid dosage form 
blend to speed up disintegration i.e. the breakdown of the compact mass into smaller fragments 
that can be easily swallowed. Superdisintegrants are relatively more effective at lower 
concentrations with greater disintegrating efficiency and mechanical strength.[18] 
Superdisintegrants are classified into two categories based on their source i.e. natural and 
synthetic. Natural superdisintegrating agents are preferred over their synthetic counterparts 
because they are comparatively cheaper, facilely available, non-toxic in nature, eco-friendly 
and capable of a myriad of chemical modifications.[19] 
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Several methods of preparing fast dispersible tablets have been described to date, including 
lyophilisation, moulding, and the compression of wet powders to construct highly porous 
structures. Although these methods are effective, they are time consuming and technically 
difficult, often requiring special processing equipment. Furthermore, although tablets produced 
by these methods disintegrate rapidly, they are usually very weak and friable. The mechanical 
strength of the tablets may not be sufficient to endure packaging, transportation, and patient 
handling. Tablets obtained by the conventional compression method are less friable but 
disintegrate more slowly.[20] The compression method, with or without wet granulation, is a 
convenient and cost-effective way to prepare tablets with sufficient structural integrity. 
Formulating fast dispersible tablets using conventional compression is attractive because of the 
low manufacturing cost and ease of technology transfer.[20] 
1.2 Aim and objectives 
The aim of this project was to develop a cost effective fast dispersible tablet of lamivudine 
using alternative excipients and conventional techniques. The motivation behind this study is 
the unavailability of an oral dosage form of lamivudine on the South African market that caters 
for the “missing middle” i.e. patients who suffer from dysphagia, bedridden patients and 
patients who are reluctant to take syrups or conventional tablets for one reason or the other. In 
order to fulfil this aim, the following objectives were set: 
1. To select suitable natural polymers to be used as superdisintegrants 
2. To characterise the selected natural polymers. 
3. To assess the compatibility of lamivudine with the selected natural polymers by 
analysing 1:1 drug-excipient mixtures using differential scanning calorimetry (DSC) 
and Fourier transform infrared spectroscopy (FTIR). 
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4. To formulate a fast dispersible tablet of lamivudine by direct compression using the 
natural polymer that displays the desired micromeritic and tableting properties. 
5. To determine whether the selected natural polymers can be used as multipurpose 
excipients (binder, disintegrant, diluent and lubricant) by assessing the various powders 
blends for flowability and compressibility and evaluating the resultant tablets. 
6. To assess the innovative tablets according to the United Stated Pharmacopoeia (USP) 
prerequisites and comparing them to a lamivudine tablet brand on the South African 
market. 
7. To design, develop and validate a high performance liquid chromatography (HPLC) 
method for assaying lamivudine in the innovative tablets. 
8. To perform drug release studies of the innovative tablets and branded tablets using the 
validated HPLC method to analyse the samples. 
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Chapter 2 
Literature review 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter gives an account of published work pertaining to the research 
problem of this project. The following themes are explored in this section: human 
immunodeficiency virus (HIV), lamivudine, problems associated with 
conventional oral dosage forms, fast dispersible tablets, various formulation 
techniques of fast dispersible tablets and disintegrants. 
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2.1 Human immunodeficiency virus (HIV) 
2.1.1 Background  
The human immunodeficiency virus (HIV) is a member of the retrovirus family. It is a single-
stranded ribonucleic acid virus with an icosahedral nucleocapsid and a lipid envelope. HIV-1 
and HIV-2 are the two main types of HIV.[1] Although both types are known to cause acquired 
immune deficiency syndrome (AIDS), HIV-2 is less virulent and less transmissible than HIV-
1. The HIV-2 group is confined to West Africa, while the HIV-1 group is spread across the 
globe and its various subtypes are responsible for the AIDS pandemic.[2] HIV is transmitted by 
sexual contact, by contact with infected blood or body fluids containing blood, and by infected 
mother to infants (intrapartum, perinatally, or peripartum through breast milk).[3] 
2.1.2 Epidemiology  
HIV is a major contributor to the global burden of disease, especially in sub-Saharan Africa. 
According to the joint United Nations programme on HIV/AIDS (UNAIDS), there were 
roughly 36.7 million people living with HIV/AIDS at the end of 2015. The majority of people 
living with HIV are in low and middle income countries. In 2015, About 66 % of new HIV 
infections occurred in Sub-Saharan Africa with an estimated 25.6 million people living with 
HIV.[4] South Africa has the highest number of people living with HIV in the world. In 2016, 
South Africa had an estimated overall HIV prevalence rate of 12,7% of the total population. 
The total number of people living with HIV in 2016 was estimated to be 7.03 million.[5] 
2.1.3 Pathogenesis 
The main target of HIV is the cluster of differentiation 4 (CD4) T lymphocytes; the virus enters 
by interacting with CD4 and the chemokine coreceptors (CCR5 or CXCR4). Other cells 
bearing CD4 and chemokine receptors are also infected, including resting CD4 T cells, 
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monocytes, macrophages, and dendritic cells.[6] A range of host proteins interact with HIV 
proteins or HIV deoxyribonucleic acid (DNA) to either counter or enhance virus replication in 
a specific cell type. The innate immune response to HIV is mediated by natural killer cells to a 
large extent and is also crucial for virus control.[7] The peculiarity of the HIV infection is the 
progressive depletion of CD4 T cells as a result of an increase in reduction and decrease in 
production thereof.[8]  
In most patients, there are no symptoms of HIV infection, or its complications, for several 
years. This asymptomatic phase is characterised by ongoing viral replication, and progressive 
CD4 cell depletion. The average patient has a viral load set-point of 30,000 copies/ml of HIV-
1 ribonucleic acid and loses 50 CD4+ T cells per year.[1] The absolute value of the CD4 count 
is the best-established surrogate marker to predict time to AIDS, risk of specific opportunistic 
infections, or death, especially once counts have fallen from the normal range of 800–1200 to 
≤300.[9] 
2.2 Antiretroviral therapy 
Since the late 1990s, HIV has progressed from a fatal illness to a chronic manageable disease 
due to the development of combination antiretroviral therapy regimens capable of suppressing 
viral replication. There are more than 25 licensed drugs available that halt the replication of the 
virus at various steps of its lifecycle. Current antiretroviral therapy regimens are more suitable 
than the initial protease inhibitor based regimens in that they are dosed less frequently, they are 
less toxic, have a lower pill burden and are more effective in viral load reduction.[10] 
Standard antiretroviral therapy regimens consist of two nucleoside reverse transcriptase 
inhibitors (emtricitabine or lamivudine together with abacavir, tenofovir, or zidovudine) with 
a non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor. 
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Several effective nucleoside reverse transcriptase inhibitor-sparing regimens can be used if 
intolerance or resistance to nucleoside reverse transcriptase inhibitors develops.[1] 
2.3 Lamivudine 
Lamivudine (Figure 2.1) is a synthetic nucleoside analogue with activity against hepatitis B 
virus (HBV) and human immunodeficiency virus (HIV). Lamivudine is indicated for the 
treatment of HIV-1 infection in combination with other antiretroviral agents.[11] 
                                       
Figure 2.1: Structure of Lamivudine 
With a molecular formula of C8H11N3O3, lamivudine has a molecular weight of 229.26 g/mol. 
The melting point occurs between 160-162 °C. At 20 °C, the white powder is soluble in water 
to an extent of 70,000 mg/L. The partition coefficient (LogP) of lamivudine is -9.54 at 25 °C.  
Lamivudine is a class I drug based on the biopharmaceutical classification system which entails 
that it is highly soluble and highly permeable.[12] 
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2.3.1 Dosing and status in South Africa 
Lamivudine is a schedule 4 medication (prescription only). Therapy should be initiated by a 
physician experienced in the management of HIV-1 infection. Several generic formulations of 
lamivudine are available on the South African market in the form of conventional tablets and 
solutions for oral use. The recommended dosage of lamivudine in adults and adolescents over 
16 years of age is 300 mg daily, administered either as 300 mg once daily or 150 mg twice 
daily.[13] Lamivudine appears on the essential medicine list of South Africa, and it is one of the 
first line antiretroviral drug treatments in the country. A combination of zidovudine and 
lamivudine is often used as a post exposure prophylaxis for individuals and health care workers 
after accidental contact with HIV contaminated tissues or fluids.[14]  
2.3.2 Mechanism of action of Lamivudine 
Intracellularly, lamivudine is phosphorylated to its active metabolites lamivudine triphosphate 
(L-TP) and lamivudine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse 
transcriptase (RT) via deoxyribonucleic acid (DNA) chain termination after incorporation of 
the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by 
HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian 
DNA polymerases alpha and beta, and mitochondrial DNA polymerase.[11] 
2.3.3 Clinical efficacy 
The efficacy of lamivudine has been investigated in several randomised, prospective clinical 
trials combined with other antiretroviral agents. These studies have shown substantial reduction 
in plasma HIV RNA and a surge in CD4 cell counts when used in combination with other 
nucleoside analogues and either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a 
protease inhibitor( PI). In recent studies by intention-to-treat analysis more than 75% of 
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participants achieved plasma HIV RNA less than 50 copies/ml after 48 weeks of combination 
antiretroviral therapy.[15] 
2.3.4 Absorption and bioavailability  
Lamivudine is promptly absorbed following oral administration. Bioavailability ranges 
between 80 and 85%. Peak plasma concentrations occur within 1 hour after administration. In 
healthy participants, at a therapeutic dose of 150 mg twice daily, mean steady-state Cmax and 
Cmin of lamivudine in plasma were 1.2 μg/ml and 0.09 μg/ml, respectively. The mean area 
under the curve (AUC) over a dosing interval of 12 hours is 4.7 μg.h/ml. At a therapeutic dose 
of 300 mg once daily, mean steady-state Cmax, Cmin and 24h AUC are 2.0 μg.h/ml, 0.04 μg/ml 
and 8.8 μg.h/ml, respectively.[12] 
2.3.5 Distribution 
The estimated volume of distribution is 1.3 l/kg. The experimental half-life ranges between 5 
to 7 hours. The mean systemic clearance of lamivudine is roughly 0.32 l/h/kg, with 
predominantly renal clearance (greater than 70 %) via the organic cationic transport system. 
Protein binding is minimal.[11] 
2.3.6 Metabolism and elimination 
The active moiety intracellular L-TP has a prolonged half-life in the cell (16 to 19 hours) 
compared to the plasma half-life. Lamivudine is mainly cleared unchanged by renal 
excretion.[12] 
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2.3.7 Pregnancy and lactation 
Lamivudine is assigned FDA Pregnancy category C status, i.e. risk cannot be ruled out. No 
increased risk of birth defects has been reported for Lamivudine. 
Lamivudine is excreted into the breast milk of lactating mothers. Due to the potential for HIV 
transmission and adverse effects caused by lamivudine in nursing infants, HIV- infected 
mothers should be discouraged from breastfeeding.[11] 
2.3.8 Adverse effects 
At the onset of treatment; nausea, vomiting, headaches, abdominal pain, fatigue and diarrhoea 
may occur. These reactions are usually trivial and short-lived. 
The following adverse effects have been reported in controlled clinical trials and case series 
during treatment of HIV-1 infection with lamivudine.[15] 
Table 2.1: Adverse effects of Lamivudine 
System Adverse Effects Occurrence 
Blood and Lymphatic Neutropenia Uncommon 
Nervous Insomnia and headache Common 
Gastrointestinal Nausea and diarrhoea Common 
Skin and subcutaneous tissue Hair loss Common 
General Fatigue Common 
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2.4 Fast dispersible tablets 
2.4.1 Background 
Tablets and capsules are considered as conventional dosage forms since they are widely 
accepted i.e. between 50-60% of all dosage forms. Self-administration, accurate dosing, 
compactness and ease of manufacture account for the popularity of tablets amongst other 
dosage forms. One important disadvantage of solid dosage forms is the difficulty in swallowing 
(dysphagia) or chewing in some patients especially paediatric and geriatric patients.[16] 
Dysphagia is prevalent in geriatric patients due to hand tremors, fear of choking, and in 
paediatric patients due to their underdeveloped muscular and nervous systems. Difficulties in 
swallowing solid dosage forms is also prompted by the unavailability of potable water, ailments 
such as diarrhoea, allergic conditions, common cold and other upper respiratory tract 
infections.[17] Roughly a third of the population (mostly paediatrics and geriatrics) has 
swallowing difficulties, resulting in poor compliance to solid dosage form drug therapies which 
leads to poor therapeutic outcomes. For these reasons, fast dispersible tablets (FDTs) have 
attracted a great deal of attention.[18] 
Fast dispersible tablets are solid single-unit dosage forms that are placed in the mouth and 
allowed to disperse or dissolve in the saliva without the need of water and provide a quick onset 
of action.[19]  
It has been established that rapid dissolution yields a faster drug absorption (applicable to the 
unionized form of drug) thus a quick onset of action. Some drugs are absorbed in the oral 
cavity, pharynx and oesophagus as the saliva transits into the stomach. Thus, the bioavailability 
of a drug formulated as a fast dispersible tablet is considerably higher than a conventional 
tablet. The disintegration time of fast dispersible tablets is generally considered to be less than 
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one minute. The fast dissolving solid dosage form turns into a soft mass or liquid form to 
facilitate swallowing; consequently, the risk of choking is reduced considerably.[20] 
2.4.2 The need for developing fast dispersible tablets 
Dysphagia 
Tablets and capsules are the most popular and preferred dosage forms for oral drug 
administration due to their convenience, ease of administration and economical aspects. [21] 
However, some individuals have difficulties in swallowing solid dosage forms, thus they may 
resort to modifying the dosage form to facilitate swallowing. When individuals find it difficult 
to swallow their medications, they may desist from taking their medication, incorporate them 
to food substances that may reduce the efficacy of the drug, and/or modify the dosage form. 
Solid dosage form modification may involve splitting, crushing, chewing tablets, or opening 
capsules.[22] The potential problems associated with modification of dosage forms are well 
reported in literature, e.g. undesirable effects, increased toxicity, decreased efficacy, alongside 
legal implications that arise as result of altering a particular dosage form.[23] 
 Paediatrics  
The absence of paediatric friendly dosage forms limits the use of certain medications that are 
potentially beneficial to children. Despite the fact this has been a long-standing issue, little 
attention has been paid to resolve it until recently [14]. Optimisation of oral drug delivery is one 
of the biggest setbacks in paediatric pharmacology. Although children above six years of age 
can be trained to swallow solid dosage forms, most find it cumbrous until they reach 
adolescence. Even though modifying solid oral dosage forms to meet the needs of children has 
been a common practice in paediatric healthcare, it is undoubtedly not an ideal alternative.[24] 
Crushing tablets to mix them with food or water may decrease the rate or extent of drug 
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absorption. Despite the fact that breaking tablets is a widespread practice and is acceptable for 
some medications, it can however introduce significant dose inconsistency. In the case of drugs 
with a narrow therapeutic index, this inconsistency may be sufficient to produce significant 
changes in clinical response.[25] When it is deemed necessary to cut a tablet, caregivers should 
receive adequate counselling on how to effectively carry out this task, including the appropriate 
use of a pill cutter. Caregivers involved in dose preparation should be knowledgeable about the 
disposal of unused medications and the danger of continuous exposure to carcinogenic and 
teratogenic drugs.[26]  
A way of minimising the issues enumerated above is to have a pharmacist prepare an 
extemporaneous oral solution or suspension.  However, a relatively simple change in the 
process, such as switching to a sugar-free suspending agent, incorporating a flavourant, or 
generic substitution, may affect the stability of the final product or the absorption properties of 
the drug. Although preparing extemporaneous formulations is common practice in developed 
countries, it may be limited in some parts of the world lacking basic resources such as potable 
water.[27] Oral liquid formulations provide a more reliable, ready-to-use preparation for 
paediatrics but bioequivalence with solid oral dosage forms is not guaranteed. The drawbacks 
associated with the currently available formulations call for the need to develop products that 
are easily administered and capable of providing desirable and steadfast serum drug 
concentrations. Over the past few decades, several alternatives to conventional dosage forms 
have been introduced in an attempt to resolve these issues. Orally disintegrating tablets as well 
as prolonged released tablets and films are suitable for children unable to swallow tablets and 
capsules.[28] 
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Geriatrics  
Changes in swallowing function as a result of age predispose geriatric patients at risk for 
dysphagia for two main reasons. Firstly, healthy ageing gradually damages head and neck 
anatomy, as well as neural and physiologic mechanisms supporting swallowing function. Such 
mechanisms of naturally diminishing functional reserve contribute to swallowing alterations in 
healthy older adults which are known as presbyphagia. Secondly, diseases associated with 
aging including neurological (e.g. Parkinson’s, Alzheimer’s disease and stroke) and non-
neurological diseases (e.g. gastro-oesophageal reflux disease) may trigger swallowing 
disorders. Lastly, geriatric patients suffering from multiple chronic diseases are often treated 
with complex polypharmacy regimens, and some medications may trigger the onset of 
swallowing disorders by several different mechanisms. The clinical repercussions of dysphagia 
are complex and potentially precarious. Swallowing disorders could lead to poor therapeutic 
adherence and menial therapeutic outcomes.[29, 30] 
Adherence  
Therapeutic adherence is generally considered as a major factor in achieving desired 
therapeutic goals. In the case of HIV and AIDS, poor therapeutic adherence has the potential 
to adversely impact therapeutic outcomes on multiple levels. Inadherence to antiretroviral 
therapy (ART) can result to less effective viral suppression, which can adversely affect the 
health of the patient, and trigger resistance to a drug or a group of drugs. This can affect the 
cost of treatment as well as therapeutic outcomes. [31] 
When patients are unable to take their medications due to swallowing difficulties, therapeutic 
adherence is considerably reduced. There is a correlation between adherence to therapy and 
good health, thus in-adherence can adversely affect health, with significant costs for the patient, 
the government or medical schemes. According to the health belief model, patients carry out 
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their own cost-benefit analysis for each treatment they are offered, weighing up the expected 
benefits (usually symptomatic relief) against the severity of their symptoms and the perceived 
risks of treatment (side effects, dependence, time and effort involved, and stigma) according to 
their lay beliefs and the information at their disposal.[32] One of the roles of healthcare 
professionals is to encourage people to feel capable of taking their medications. The concept 
of concordance stipulates that healthcare professionals must understand patients’ experiences 
and behaviours towards their diseases and treatment in order to help them to adhere to the 
prescribed therapy. [33] 
Manufacturing and marketing factors  
It is customary practice for manufacturers to optimise and design a new dosage form for a 
specific drug when the drug approaches the end of its patent life. A new dosage form allows a 
manufacturer to extend market uniqueness, product differentiation, value-added product line 
extension, and extend patent protection, while offering patients a more suitable dosage form. 
This leads to a surge in income, whilst targeting undertreated and underserved patients. [34] 
Effectiveness factor  
Dispersion of the dosage form in the mouth leads to pre-gastric absorption of the dissolved 
drug (Figure 2.2). Buccal, pharyngeal and gastric regions are potential absorption sites for 
several drugs. The main advantage of pre-gastric absorption is the avoidance of first pass 
hepatic metabolism which increases bioavailability. Additionally, safety profiles may be 
improved for drugs that produce substantial amounts of toxic metabolites as a result of first-
pass liver metabolism and gastric metabolism and for drugs that have a considerable fraction 
of absorption in the oral cavity and pre-gastric segments of the gastrointestinal tract (GIT).[35] 
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Figure 2.2: Effectiveness of fast dispersible tablets[35] 
2.5 Development of fast dispersible tablets 
The basic approach in the development of fast dispersible tablets is the use of 
superdisintegrants which provide rapid tablet disintegration in the buccal cavity. [20]. 
2.5.1 What are Superdisintegrants?  
Over the past few years, new pharmaceutical excipients have been introduced referred to as 
“Superdisintegrants”. A “Superdisintegrant” is an excipient, which is incorporated into an oral 
solid dosage form blend to speed up disintegration i.e. the breakdown of the compact mass into 
smaller fragments that can be easily swallowed. This process is sought for immediate release 
products where rapid release of the product is desired. Superdisintegrants are relatively more 
effective at lower concentrations with greater disintegrating efficiency and mechanical 
strength. Superdisintegrants play a significant role in the dissolution and disintegration of 
tablets. It is imperative to choose an optimal superdisintegrant concentration so as to ensure 
rapid disintegration and high dissolution rates of tablets.[36]  
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The rapid disintegrating effect of superdisintegrants is as a result of water absorption and 
swelling. Swelling of superdisintegrants leads to an increase in the wetted surface of the carrier, 
this enhances the wettability and dispersibility of the system, thus promoting disintegration and 
dissolution. The optimal concentration of the superdisintegrant can be selected according to the 
critical concentration of the disintegrant. Below this concentration, the rate of tablet 
disintegration is directly proportional to the concentration of the superdisintegrant, whereas 
above this concentration the disintegration time remains almost constant or even increases.[37] 
2.6 Various techniques for preparing fast dispersible tablets 
 Disintegrant addition  
This method involves the incorporation of an optimum concentration of a superdisintegrant 
into the formulation blend to achieve rapid disintegration or dissolution. The yield is similar to 
conventional tablets with a higher percentage of disintegrants, lower hardness and higher 
friability.[38]  
Freeze drying or lyophilisation  
The drug is dissolved or dispersed in an aqueous solution of a carrier. The mixture is poured 
into the wells of preformed blister packs. Liquid nitrogen is applied to the blisters packs in 
order to freeze the drug solution. The frozen blister packs are kept in refrigerated cabinets to 
continue the freeze-drying. The resultant tablets are highly porous, have high specific surface 
area, dissolve rapidly and show enhanced absorption and bioavailability.[39]  
Moulding  
A water-soluble ingredient with a hydro-alcoholic solvent is used and is moulded into tablets 
under a pressure lower than that used in conventional tablet compression. The moulded tablets 
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are relatively less compact compared to compressed tablet, and their high porosity enhances 
disintegration and dissolution. Therefore, drug absorption is increased.[40] 
Sublimation  
Inert solid ingredients that volatilise rapidly like camphor, urea, ammonium bicarbonate, 
ammonium carbonate, and hexamethylenetetramine are incorporated into the formulation 
blend and the mixture is compressed into tablets. The volatile excipients are then removed via 
sublimation, which produces a porous structure.[41] 
Spray-Drying  
Hydrolysed and non-hydrolysed gelatines are used as supporting agents, mannitol as a diluent, 
sodium croscarmellose or sodium starch glycolate as disintegrating agents and an acidic 
excipient (e.g. citric acid) and or alkali excipient (e.g. Sodium bicarbonate) to promote 
disintegration or dissolution. This disintegration time of the tablet is roughly 20 seconds when 
immersed in an aqueous medium.[42] 
Mass-Extrusion  
This technique involves softening the active blend using a solvent mixture of water soluble 
polyethylene glycol and methanol. The softened mass is expelled through the extruder or 
syringe to get a cylindrical shape of the product into even segments using a heated blade to 
form tablets. The dried product can be used to coat granules of bitter tasting drugs, thereby 
making them more palatable. [43] 
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 Direct compression  
Conventional tableting equipment, facilely available excipients and a limited number of 
processing steps are involved in direct compression. It is the most cost effective tablet 
manufacturing technique.[44]  
 Cotton candy process  
Polysaccharide matrices are formed by the concurrent action of flash melting and spinning. 
This candy floss matrix is then milled and blended with active ingredients and excipients after 
re-crystallization and then compressed to fast dispersible tablets. The tablets can accommodate 
high doses of active ingredient and display enhanced mechanical strength.[45]  
Compaction 
a) Melt granulation  
This is done by incorporating a hydrophilic waxy binder (super polystate) PEG-6-stearate. 
Super polystate not only acts as binder and increase physical resilience of tablet, but also 
enhances tablet disintegration. The tablet melts in the mouth and solubilises rapidly leaving no 
residue.[46] 
b) Phase-transition process  
This technique involves compressing a powder containing two sugar alcohols with high and 
low melting points, and subsequently heating the powder at a temperature between their 
melting points. The tablet hardness is increased after the heating process due to increase of 
inter particle bond induced by phase transition of lower melting point sugar alcohol. Increased 
compactibility and thus sufficient hardness gained by the formulation. [47] 
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Nanonisation  
The drug size is reduced to nano-size by milling the drug using a proprietary wet-milling 
technique. The nano-crystals of the drug are stabilized against agglomeration by surface 
adsorption on selected stabilisers which are then incorporated into fast dispersible tablets. This 
technique is used for poorly water soluble drugs. It leads to an increase in bioavailability and 
reduction in dose, cost effective manufacturing process, conventional packaging due to 
exceptional durability and wide a range of doses (up to 200 mg of drug per unit).[40] 
Fast dissolving films  
A non-aqueous solution is prepared containing a water-soluble film forming polymer (pullulan, 
carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyl ethyl cellulose, hydroxyl 
propylcellulose, polyvinyl pyrrolidone, polyvinyl alcohol or sodium alginate), drug and other 
taste masking ingredients are used to form a film after the solvent has evaporated. In the case 
of a bitter drug, resin adsorbate or coated micro particles of the drug can be incorporated into 
the film. The dissolution of the film is within 5 seconds, the drug is delivered instantly with a 
pleasant after taste. [48] 
2.7 Requirements for fast dispersible tablets  
The following are the desired criteria for fast dispersible tablets.[49, 50] 
 The tablets should disintegrate or dissolve in the mouth within few seconds, and not 
require water to be swallowed. This requirement highlights the effectiveness of a FDT 
since the tablet is conveniently administered, the risk of choking is drastically reduced, 
and the active pharmaceutical ingredient (API) is made available for absorption 
promptly.  
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 The tablets should allow for high drug loading. This speaks particularly to medications 
that require a relatively high amount of the API in a single dosage unit such as 
antibiotics (e.g. amoxicillin 500mg ), oral anti-diabetic drugs (e.g. metformin 500 mg) 
and antiretroviral drugs (e.g. lamivudine 150 mg and efavirenz 600 mg) 
 The active ingredient should be compatible with the excipients used in the formulation. 
This is very crucial since drug-excipient incompatibilities can adversely affect the 
integrity and the therapeutic activity of the API. 
 Should be palatable. Since FDTs come into close proximity with the tongue for a 
substantial amount of time, it is thus imperative for the tablets to leave a pleasant taste 
in the mouth. Adequate taste masking techniques should be employed for bitter and 
unpleasantly tasting drugs. 
 Little or no residues should remain in the mouth after oral administration. This suggests 
that the FDT should be formulated with excipients which disintegrate into fine non-
gritty particles and leave a pleasant mouth-feel. Also, the tablet size and the amount of 
excipients used should be kept minimal.  
 Should be resilient enough to withstand the manufacturing process and post 
manufacturing handling. FDTs are usually more porous and less resilient than 
conventional swallow tablets so as to ensure rapid disintegration. Consequently, a 
suitable tablet hardness which confers adequate resilience to the tablet whilst allowing 
for instantaneous disintegration should be sought.  
 Should not be affected by environmental conditions such as temperature and humidity. 
FDTs are usually prone to moisture due to their relatively high porosity and the 
hygroscopicity of the excipients used. This can be quite problematic in tropical regions 
such as Central and West Africa which are characterised by high levels of humidity. 
Consequently, adequate moisture proof packaging should be designed for FDTs. 
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 Should be manufactured at a low cost using conventional manufacturing techniques. 
This entails the use of cheap facilely available excipients and simple manufacturing 
processes. 
2.8 Desired characteristics of fast dispersible tablets  
Since the administration of FDTs differs from that of conventional tablets, FDTs should 
possess several unique characteristics as enumerated below.  
 Fast disintegration  
FDTs should disintegrate in the mouth without the need for water. The saliva of the patient 
provides the disintegration medium. The disintegrated dosage form should form a soft paste or 
suspension providing a pleasant mouth feel and ease of swallowing. Generally, a tablet should 
disintegrate within a minute in order to fulfil the criterion for fast disintegration, but 
instantaneous disintegration is highly sought.[51]  
Taste of active ingredients 
Since FDTs dissolve or disintegrate in the patient’s mouth, the drug is in close proximity with 
the tongue. There should be little or no residues in the mouth after swallowing. A pleasant taste 
is one of the key factors for patient acceptance. Taste masking should be employed for bitter 
and poor tasting drugs. Taste masking excipients should be kept as low as possible in order not 
to increase the tablet mass. The taste-masking technology employed should be compatible with 
the FDT formulation [42].  
Drug properties  
 The tablet properties should not be significantly affected by the drug properties. Several drug 
properties can negatively impact the performance of FDTs. For example, the hygroscopicity, 
bulk density, compressibility, solubility, particle size, and crystal morphology of a drug can 
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considerably influence the characteristics of the resultant tablet, such as tablet strength and 
disintegration. The FDT technology employed should be flexible enough to accommodate 
distinctive properties of individual drugs. [52]  
 Tablet strength and porosity  
The porosity of FDTs is usually maximised to ensure fast tablet disintegration and dissolution. 
The key factors are rapid water absorption or wetting, and break down of agglomerated 
particles into smaller particles for fast dissolution. For quick disintegration to take place, the 
excipients should have a high wettability and the tablet matrix should be highly porous. Since 
tablet strength is directly proportional to compression pressure, and porosity is inversely 
proportional to compression pressure, it is important to find the porosity that allows fast water 
absorption while maintaining high mechanical strength. Moreover, low compression pressure 
yields soft and friable FDTs, thus unsuitable for packaging in conventional blisters or 
containers. A technique to enhance tablet mechanical strength without decreasing tablet 
porosity or requiring special packaging to handle fragile tablets should be employed.[51] 
Moisture sensitivity  
FDTs should have low sensitivity to humidity. Tackling the issue of moisture sensitivity can 
be very challenging since most excipients employed in the formulation of FDTs are highly 
water soluble to ensure quick dissolution and a good mouth feel. Highly water soluble 
excipients are susceptible to moisture; some are deliquescent at high humidity. An adequate 
packaging or other strategy should be employed to shield FDTs from various environmental 
conditions. [51] 
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2.9 Advantages of fast dispersible tablets  
FDTs offer both the advantages of solid and liquid oral dosage forms along with distinctive 
properties which include: 
 Accurate dosing 
As unit solid dosage forms, they provide dosing accuracy, easy manufacturing and 
transportability, good physical and chemical stability and an ideal alternative for paediatric and 
geriatric patients.[49] 
 Enhanced bioavailability 
Bioavailability of drugs is enhanced due to quick dissolution and absorption from the buccal 
cavity, pharynx and oesophagus.[52] 
Quick onset of action 
FDTS provide rapid onset of therapeutic action as tablet are instantly disintegrated alongside 
quick dissolution and absorption in the mouth.[53] 
Patient compliance 
Little or no water is needed to swallow FDTs. Hence, it is convenient for patients who are 
traveling and do not have immediate access to water.[51] 
Ease of administration 
Since FDTs are easily swallowed, they are an ideal alternative for patients who cannot swallow, 
such as paediatrics, geriatrics, stroke victims, bedridden patients and psychiatric patients. [51] 
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Obstruction free 
The risk of suffocation in airways due to physical obstruction when swallowed is considerably 
reduced, thus providing enhanced safety and compliance.[49] 
Enhanced palatability 
Good mouth-feel, especially for paediatric patients as taste masking techniques can be 
employed to attenuate the unwanted taste of drugs.[49] 
Simple packaging 
Conventional packaging such as blister packs can be used for FDTs.[51] 
Business avenue 
Provide new business opportunities in the form of product differentiation, line extension, 
uniqueness and life cycle management.[51] 
Cost effectiveness 
FDTs are manufactured at low cost since conventional formulation processes and material are 
employed.[52] 
2.10 Challenges in formulating fast dispersible tablets  
Mechanical strength and disintegration time  
FDTs are formulated to disintegrate within a minute. While doing so, maintaining a good 
mechanical strength is a prime challenge. Many FDTs are fragile and they are prone to damage 
during packing, transport or handling by patients. It is evident that increasing the mechanical 
strength of the tablet will delay the disintegration time. So, a good compromise between these 
two parameters is always essential.[54]  
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Taste masking  
Many drugs have a bitter taste. A FDT constituting of a bitter or poor tasting drug will adversely 
impact patient compliance and acceptance for the dosage form. So, effective taste masking of 
bitter drugs must be done so that the taste of the drug is not felt in the mouth.[55] 
Hygroscopicity 
Many orally disintegrating dosage forms cannot uphold physical integrity under normal 
conditions of temperature and humidity as they are hygroscopic. Hence, they need protection 
from humidity which demands specialised product packaging.[56]  
Mouth-feel 
FDTs should not break down into large fragment in the mouth. The disintegrated particles 
should be as small as possible. Little or no residues should be left in the mouth after 
swallowing. The incorporation of cooling agents and flavours enhances the mouth-feel.[57]  
Amount of drug 
The choice of technology employed in the formulation of FDT is motivated by the amount of 
drug to be used per single dosage form.[57]  
Cost 
The technology used for FDTs should be acceptable in terms of the cost of the final product. 
Certain FDTs that require special technologies and specific packaging increase the cost of 
production remarkably.[54] 
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Tablet size 
The diameter of the easiest tablet to swallow has been reported to be 7-8 mm, while tablets that 
are easily handled have diameters greater than 8 mm. Consequently, it is difficult to attain a 
tablet size that can be easily handled and easily swallowed.[54] 
2.11 Limitations of fast dispersible tablets 
Due to the high porosity of the tablet matrix, FDTs usually possess unsatisfactory mechanical 
strength. Consequently, careful handling is vital during manufacturing, transportation and 
administration. 
The tablets may leave an unpleasant taste and or grittiness in the mouth if not formulated 
properly.  
Drugs with larger doses are usually difficult to formulate as FDTs e.g. Rifampicin (600 mg) 
and Ethambutol (1000 mg).[55, 58] 
2.12 Direct compression of fast dispersible tablets 
Fast absorption of water into the tablets and disintegration of aggregated particles into 
individual components for instantaneous dissolution are the most important characteristics of 
FDTs. Attaining a highly porous tablet is the most common strategy to ensure fast 
disintegration, which will ensure fast water absorption into the matrix. For this to be possible, 
the excipients used should have high ‘‘wettability’’ to enhance water penetration into the tablet 
matrix. However, the porosity of a tablet is inversely proportional to the compression pressure, 
which in turn is directly proportional to the mechanical strength of the tablet. Therefore, it is 
important to find the optimum porosity that allows both fast water absorption and high 
mechanical strength. Furthermore, low compression pressure causes FDTs to become too 
fragile for packaging in conventional blisters or bottles. A formulation strategy is necessary to 
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enhance tablet mechanical strength without compromising porosity or necessitating special 
packaging.[59] 
Several methods of preparing FDTs have been described to date, including lyophilisation, 
moulding, and the compression of wet powders to construct highly porous structures. Although 
these methods are effective, they are time consuming and technically difficult, often requiring 
special processing equipment. Furthermore, although tablets produced by these methods 
disintegrate rapidly, they are usually very weak and friable. The mechanical strength of the 
tablets may not be sufficient to endure packaging, transportation, and patient handling. Tablets 
obtained by the conventional compression method are less friable but disintegrate more 
slowly.[56] 
The compression method, with or without wet granulation, is a convenient and cost-effective 
way to prepare tablets with sufficient structural integrity. Formulating FDTs using 
conventional compression is attractive because of the low manufacturing cost and ease of 
technology transfer. However, tablet presses were originally designed to make conventional 
tablets with high mechanical strength. When making conventional tablets, maintaining high 
tablet porosity is not a primary concern, and high compression force is applied to achieve high 
tablet strength.[56]  
2.13 Excipients used in the direct compression of fast dispersible tablets  
A direct compression FDT powder blend usually comprises of a disintegrant, diluent, lubricant, 
flow aid, flavourant, sweetener, and occasionally a colourant. Most FDTs on the market use 
mannitol as a diluent. Directly compressible grades of mannitol display sought properties, such 
as; sweetness, mouth feel, solubility, and rapid dispersion as a result of wicking. Hence, 
mannitol has gained popularity for FDTs over other diluents typically used in direct 
compression such as lactose.[60] 
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FDT formulations usually contain high levels of superdisintegrants to ensure rapid tablet 
disintegration. Depending on the level and properties of the active pharmaceutical ingredient 
and the desired release profile, the concentration of the superdisintegrant used can be between 
10–20 % of the weight of a single tablet. Consequently, the choice of superdisintegrant is 
critical when formulating a FDT.[60] 
As with most direct-compression formulations, additional excipients such as flow aids and 
lubricants are likely to be included. Since the tablet is meant to disintegrate in the buccal cavity, 
flavourants and sweeteners are often incorporated to mask unpleasant tastes of actives. A 
colourant can be added to enhance the aesthetic appeal of the tablet and to aid identification.[60] 
2.13.1 Requirements for excipients used in fast dispersible tablets 
Since FDTs are designed to disintegrate in the mouth, the dosage form should have a pleasant 
taste with the formation of a smooth paste or suspension after disintegration so that patients 
should have a good mouth feel. Excipients with good water solubility will enhance 
disintegration and dissolution. Pharmaceutical grade saccharides such as xylitol, lactose, 
glucose, mannitol, and sucrose are often used to formulate FDTs. Mannitol is one of the most 
common excipients used for this dosage form because of its water solubility and non-
hygroscopic nature. It also produces a unique cooling sensation in the mouth and has a pleasant 
taste when chewed or dissolved. Sugars can be used as diluents, binders, and or enhancing 
agents hence they are not categorized with respect to a single specific function. Consequently, 
sugars are often incorporated into FDT formulations to serve several purposes.[61] 
The particle size of the excipients in a FDT must be considered. The smaller the particle size, 
the better the patients’ compliance as larger particles leave a ‘‘gritty’’ feel in the mouth. Smaller 
particles ensure a smooth tablet surface, which also enhances aesthetic appeal. Nonetheless, 
smaller particles may impart poor material properties such as poor flowability, high 
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segregation, moisture sensitivity, and or low porosity of the tablet matrix. It is therefore 
important for the formulator to strike a balance with the properties of the powders to achieve 
processability, stability, optimal therapeutic adherence and efficacy.[60] 
2.14 Disintegrants 
A disintegrant is an excipient added to a tablet formulation to enhance the fragmentation of the 
tablet matrix when in contact with water. Fast disintegration of the tablet matrix in the mouth 
eases swallowing and increases the surface area of the tablet particles, thereby increasing the 
rate of absorption of the drug to achieve the desired therapeutic outcomes. Every marketed 
tablet has a certain level of disintegrant and it is important to investigate which and how much 
disintegrant is necessary for a given tablet formulation. Disintegration is triggered when a small 
amount of water or saliva comes into contact with the solid dosage form (wetting) and 
penetrates the tablet matrix by capillary action. Therefore, the material properties of 
pharmaceutical excipients and also the matrix structure including pore size and distribution 
need to be considered for successful formulation development. Since most disintegrants swell 
to some extent, swelling pressure is generally considered the main factor for tablet 
disintegration.[39]  
Rapid swelling without an increase in viscosity (gel formation) is one of the most sought 
properties of disintegrants. A high viscosity will slow disintegration by hindering the 
penetration of water into the tablet matrix. There are several disintegrants on the market which 
can be considered in the formulation of FDTs. Some of which include crospovidone (cross-
linked PVP), croscarmellose (cross-linked cellulose), sodium starch glycolate (cross-linked 
starch), and low-substituted hydroxypropyl cellulose.[62,63] 
Most disintegrants are water insoluble materials that swell on contact with water, therefore 
excessive disintegrant addition can lead to grittiness following tablet disintegration. The 
http://etd.uwc.ac.za/
37 
 
appropriate disintegrant concentration should be carefully investigated for a given FDT 
formulation. The processing technique employed, and the purpose of the formulation influence 
the choice of the disintegrant.[62,64] 
2.14.1 Mechanism of action of disintegrants  
Tablets break into individual particles by one or more of the mechanisms listed below 
Porosity and capillary action (wicking)  
Capillary action is always the first step in tablet disintegration. A suitable aqueous medium 
into which a tablet is placed penetrates into the tablet and replaces the air adsorbed on the 
particles there by weakening intermolecular bonds and breaking the tablet into smaller particles 
(Figure 2.3). The hydrophilicity of the drug and tableting conditions affect the rate and extent 
at which the tablet absorbs water. For these types of disintegrants, maintenance of a porous 
structure and low interfacial tension towards aqueous fluid is vital which helps in disintegration 
by creating a hydrophilic network around the drug particles.[65, 66] 
 
 
 
 
 
Figure 2.3: Illustration of tablet disintegration due to wicking 
 
 
The disintegrant pulls water into the tablet 
matrix via the pores which results in the 
weakening of interparticulate bonding 
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Swelling  
Swelling is the general mechanism of tablet swelling. Tablets with high porosity show poor 
disintegration due to lack of adequate swelling force (Figure 2.4). On the other hand, sufficient 
swelling force is exerted in tablets with low porosity. It is important to note that if the packing 
fraction is very high, fluid is unable to penetrate the tablet and disintegration is slowed down.[64] 
                              
Figure 2.4: Illustration of tablet disintegration due to swelling 
Due to disintegrating particles/particle repulsive forces  
Another mechanism of disintegration which attempts to explain the swelling of tablets made 
with non swellable disintegrants. Guyot-Hermann has proposed a particle repulsion theory 
based on the observation that non-swelling particle also cause disintegration of tablets. The 
electric repulsive forces between particles constitute the mechanism of disintegration and water 
is required for it (Figure 2.5). Researchers found that repulsion is secondary to wicking.[67] 
 
 
Particles swell and break up the matrix 
from within. The localised stress caused by 
swelling spreads throughout the matrix 
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Figure 2.5: Illustration of tablet disintegration due to repulsive forces  
Due to deformation: elastic recovery  
As a result of stored potential energy, most materials which undergo plastic deformation during 
compression try to return to their original shape as soon as possible. Return to the initial shape 
is not possible in the tablet matrix. As soon as water penetrates into the tablet matrix and the 
forces which hold the particles together are reduced, those particles gain the ability to return to 
their original shape (Figure 2.6)[68] 
                                        
Figure 2.6: Illustration of tablet disintegration due to deformation  
Water is drawn into the pores and particles 
repel each other as a result of electrical 
forces 
Particles swell to precompression size and 
break up the tablet matrix 
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Due to the release of gases  
Carbon dioxide is released within tablets on contact with water due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The generation of pressure within 
the tablet matrix accounts for tablet disintegration. These disintegrants are mainly used when 
the need to formulate a very rapidly disintegrating or dissolving tablet arises, as these 
disintegrants are highly sensitive to slight changes in humidity level and temperature, strict 
control of environment is required during manufacturing of the tablets. The effervescent blend 
is either added immediately prior to compression or can be added in two separate fractions of 
formulation.[69] 
By enzymatic action 
In this case, enzymes present in the body act as disintegrants. The cohesive effect of the binder 
is destroyed by enzymes thus enhancing disintegration. As a result of swelling, pressure exerted 
in the radial direction causes the tablet to burst, or the speeded uptake of water leading to a 
considerable increase in the volume of granules to promote disintegration.[70] 
Because of heat of wetting (air expansion)  
When disintegrants with exothermic properties are wetted, localized stress is generated due to 
capillary air expansion which helps in disintegrating the tablet. This explanation however is 
limited to only a few types of disintegrants and cannot describe the action of most modern 
disintegrating agents.[69] 
2.15 Superdisintegrants 
The term superdisintegrant refers to substances which achieve disintegration faster than the 
substances conventionally used. A solid oral dosage form disaggregates into smaller particles 
that dissolve more rapidly than in the absence of such disintegrants. Superdisintegrants are 
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usually used at low level in solid oral dosage forms, typically between 1-10% of the total weight 
of a given dosage form.[63] The disintegration of dosage forms depends on various physical 
factors of superdisintegrants which are enumerated below.[64] 
 Percentage of superdisintegrant in the formulation. The activity of superdisintegrants 
increases with increasing superdisintegrant percentage below their critical 
concentration. Above this concentration, no further increase or a decrease in their 
disintegrating activity can be observed.  
 Proportion of superdisintegrants used. The extent to which the material properties of 
the superdisintegrant impart the properties of the tablet is dependent on the portion of 
the tablet comprised of the superdisintegrant.  
 Compatibility with other excipients. The occurrence of physical or chemical 
incompatibilities between the superdisintegrant and the other excipients can adversely 
influence the integrity and the stability of the tablet.  
 Presence of surfactants. Surfactants are added to enhance the disintegration of tablets 
containing hydrophobic constituents. The absence of surfactants in a tablet containing 
hydrophobic constituents can negatively impact the disintegrating activity of the 
superdisintegrant. 
 Hardness of the tablets. The rate of disintegration is inversely proportional to tablet 
hardness due to the decrease in the number and size of pores on the tablet surface which 
enhance the penetration of water  into the tablet matrix. Since the swelling of 
superdisintegrants is dependent on the wettability of the tablet, increase in tablet 
hardness can thus lead to a decrease in super disintegrating activity.  
 Nature of drug substances. The presence of poorly soluble and hydrophobic 
constituents in a tablet can impede the activity of a superdisintegrant by countering 
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interactions between water and the tablet. The reverse is true for hydrophilic and highly 
soluble substances.  
2.15.1 Selecting a superdisintegrant  
Although the superdisintegrant mainly enhances the rate of disintegration, when used at high 
levels it can also affect mouth feel, tablet hardness, and friability. Thus, several factors must 
be considered when selecting a superdisintegrant.[60] 
Disintegration  
The disintegrant must quickly wick saliva into the tablet to generate the volume expansion and 
hydrostatic pressures necessary to provide rapid disintegration in the mouth.[60] 
Compactability  
In order to avoid the need to use specialise packaging, it necessary to formulate tablets with 
adequate hardness at a given compression force to produce resilient tablets while enhancing 
production speed. Consequently, a more compactable disintegrant will yield stronger and less-
friable tablets.[60] 
Mouth-feel 
In order to ensure patient compliance, FDTs must be palatable. Large particles can result in a 
gritty feeling in the mouth. Consequently, smaller particles are preferred. If the tablet forms a 
gel-like consistency on contact with water, it produces a gummy texture that many patients find 
distasteful.[60] 
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 Flow 
As far as direct compression is concerned, content uniformity and good flow are vital in 
attaining drug content uniformity. In typical tablet formulations, superdisintegrants are used at 
2–10 % of the formulation blend. In cases where the superdisintegrant concentration is 
considerably higher, the flow properties of the superdisintegrant become more important 
because of the greater impact on the flow characteristics of the total blend.[71,72] 
2.15.2 Types of superdisintegrants 
Superdisintegrants can be classified into two categories on the basis of their source: 
1 Natural Superdisintegrants 
2 Synthetic Superdisintegrants 
Natural superdisintegrants  
Presently, there is a number of plant based pharmaceutical excipients and various researchers 
have explored the utility of some of these plant-based materials as pharmaceutical 
superdisintegrants. These superdisintegrating agents are natural in origin and alternative over 
synthetic substances because they are comparatively cheaper, easily available, non-irritating 
and non-toxic in nature. Therefore, natural gums and mucilage have been extensively used in 
the field of novel drug delivery for their easy availability, cost effectiveness, eco-friendliness, 
emollient, and non-irritant nature and non-toxicity, capable of a myriad of chemical 
modifications, potentially degradable, and compatible due to their natural origin.[73, 74]  
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Advantages of natural superdisintegrants 
The advantages of natural superdisintegrants include: 
Biodegradability  
They are biodegradable compared to their synthetic counterparts since they are naturally 
sourced and are produced by living organisms.[75] 
Biocompatibility and non-toxicity 
They are mainly plant materials made up of reiterating sugar polysaccharides. As such, they 
are compatible with the human body and non-toxic.[75] 
Low cost  
Since they are naturally sourced, the cost of production is considerably less compared to 
synthetic superdisintegrants. Many developing countries are dependent on agriculture, and 
there are substantial financial investments on agriculture.[50] 
Environmental-friendly processing  
There are many types of natural compounds obtained from different plant sources which are 
widely utilised in the pharmaceutical industry and collected in immensely large quantities due 
to the simple production processes involved.[50] 
Local availability (especially in developing countries) 
In some developing countries, the government promotes the cultivation of plants to be used as 
pharmaceutical excipients. It thus provides the facilities for large scale production, like gum 
and mucilage because of their wide applications in industries.[75] 
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Patient tolerance as well as public acceptance 
The lower incidence of adverse effects and allergenicity associated with the use of natural 
superdisintegrants compared to their synthetic counterparts has been reported.[75] 
Examples of natural polymers used as superdisintegrants  
All these polymers are approved by the US Food and drug administration (FDA). The FDA 
recognizes these polymers as GRAS (Generally Recognized as Safe) 
Gellan gum  
Approved as a food additive in the European community under the number E 418, with ADI 
(acceptable daily intake) confirming its status as a safe food additive. The Gellan gum food 
grade fully meets the standards and the purity criteria issued in different regions of the world 
or internationally, such as the Food Chemicals Codex, the US Pharmacopoeia, and the 
European Directives.[76] 
Chitin and Chitosan 
Chitin (β-(1→4)-N-acetyl-D-glucosamine) is a natural polysaccharide obtained from the 
exoskeleton of crustaceans such as shrimps and crabs, and cell walls of fungi. It possesses an 
amino group covalently linked to an acetyl group as compared to a free amino group in 
chitosan. Chitosan is produced commercially by the deacetylation of chitin. Chitosan is the best 
known natural polysaccharide used for its myriad of applications in the pharmaceutical 
industry.[77] 
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Gum Karaya 
Gum karaya is a vegetable gum produced as an exudate by trees of the genus Sterculia. 
Chemically, gum karaya is an acid polysaccharide composed of the sugars galactose, rhamnose, 
and galacturonic acid. The high viscosity nature of the gum limits its uses as binder and 
disintegrant in the development of conventional dosage form. Gum karaya has been 
investigated for its potential as a tablet disintegrant. Different results showed that modified 
gum karaya produces rapid disintegration of tablets.[78] 
Agar and treated agar 
The dried gelatinous substance obtained from Gelidium amansii (Gelidanceae) and several 
other species of red algae like Gracilaria (Gracilariaceae) and Pterocladia (Gelidaceae).  
Agar is yellowish-grey or white to proximately colourless, odourless with mucilaginous taste 
and is available in the form of digests, sheet flakes, or coarse powder. Agar consists of two 
polysaccharides, agarose and agar pectin. Agarose is responsible for gel vigour and agar pectin 
is responsible for the viscosity of agar solutions. The high gel vigour of agar makes it a potential 
disintegrant candidate.[79] 
Fenugreek seed mucilage 
Trigonella foenum-graceum commonly known as fenugreek is a herbaceous plant of the 
leguminous family. Fenugreek seeds contain a high percentage of mucilage. Although it does 
not dissolve in water, mucilage forms a viscous tacky mass when exposed to fluids. Like other 
mucilage-containing substances, fenugreek seeds swell up and become slick when they are 
exposed to fluids.[79]  
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Soy polysaccharide 
Soy polysaccharide does not contain any starch or sugar. A study evaluated soy polysaccharide 
(a group of high molecular weight polysaccharides obtained from soy beans) as a disintegrant 
in tablets made by direct compression using lactose and dicalcium phosphate dihydrate as 
fillers. Cross-linked sodium carboxymethyl cellulose and corn starch were utilized as control 
disintegrants. Soy polysaccharide performed well as a disintegrant in direct compression 
formulations with results similar to cross-linked carboxymethyl cellulose.[76] 
Mango peel pectin 
Mango peel which constitutes 20–25% of the mango processing waste was found to be a good 
source for the extraction of high quality pectin, suitable for the preparation of film, and 
acceptable jelly. Pectin is an involute hetero-polysaccharide which is a hydrophilic colloid. A 
study found that mango peel pectin is a prospective superdisintegrant candidate. Although not 
as more efficient than synthetic superdisintegrants, its good solubility and higher swelling 
index makes it suitable to be utilised in the formulation of FDTs.[80, 81] 
Examples of synthetic superdisintegrants  
Croscarmellose Sodium  
It is modified cellulose and is a cross linked polymer of carboxymethylcellulose. The 
disintegration rate of croscarmellose sodium is higher than that of sodium starch glycolate and 
the mechanism of disintegration also differs. Cross linking makes it hydrophilic, insoluble, 
highly absorbent, resulting in exceptional swelling properties and its unique fibrous nature 
gives it excellent water wicking abilities. It is used in oral pharmaceutical formulations as a 
superdisintegrant for granules, tablets and capsules. Concentrations of croscarmellose sodium 
range between 1-5% w/w of the formulation blend.[82, 83] 
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Sodium starch glycolate  
It is a cross linked polymer of carboxymethyl starch. Although sodium starch glycolate can be 
synthesised from a wide range of native starches, potato starch is commonly used as it yields 
the product with the best disintegrating properties. The introduction of large hydrophilic 
carboxymethyl groups aims at disrupting the hydrogen bonding within the polymer structure. 
This allows water to penetrate into the molecule thereby making the polymer cold water 
soluble. The aim of the cross-linking is to reduce both the water-soluble fraction of the polymer 
and the viscosity of dispersion in water. The natural pre-dried starches swell in water to the 
extent of 10-20 per cent and the modified starches increase in volume by 200-300 per cent in 
water. Tablets formulated by using these superdisintegrants usually disintegrate within two 
minutes.[82, 84] 
Cross-linked polypyrrolidine  
Crospovidones are synthetic, insoluble, cross-linked homopolymers of N-vinyl-2- pyrrolidone. 
When inspected under a scanning electron microscope, crospovidone particles appear as 
granular and are highly porous. Due to its high crosslink density, crospovidone swells rapidly 
in water without gelling. The unique particle morphology of Crospovidones makes them highly 
compressible. Crospovidone is used as superdisintegrant at low concentration levels (2- 5%) in 
direct compression and in wet and dry granulation processes.[82, 85] 
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2.16 Banana  
2.16.1 Taxonomical classification 
 
 
 
 
 
 
2.16.2 Description 
Musa paradisiaca is a herbaceous plant (up to 9 m long) with a robust tree-like pseudostem 
and a crown of large elongated oval deep-green leaves (up to 365 cm in length and 61 cm in 
width). Each plant produces a single inflorescence 15-20 cm long, concave, dark red in colour 
and somewhat fleshy. Fruits are oblong, fleshy, 5-7cm of length in the wild form and longer in 
the cultivated varieties. Musa sapientum is a tree-like perennial herb that grows 5 - 9 m in 
height with a tuberous rhizome (Figure 2.7). The inflorescence is big with a reddish-brown 
bract. The fruit pulp is fleshy, juicy and contains numerous seeds. From its native south-western 
Pacific home, the banana plant spread to India around 600 BC and later on it spread all over 
the tropical regions. It is possibly the world's oldest cultivated crop and the most common 
tropical fruit. [86] 
 
 
Kingdom             Plantae 
Phylum              Magnoliophyta 
Class                         Liliopsida 
Order                         Zingiberales 
Family                         Musaceae 
Genus                         Musa 
Species             Musa paradisiaca, Musa sapientum 
Common name   Banana 
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Figure 2.7: Banana tree with young fruits and inflorescence  
2.16.3 Cultivation and distribution 
About 300 varieties of bananas are grown of which a vast majority are spread throughout 
tropical and subtropical countries.[86]  
2.16.4 Traditional uses 
The fruit of M. paradisiaca and M. sapientum is traditionally used in diarrhoea (unripe), 
dysentery, intestinal lesions in ulcerative colitis, diabetes (unripe), in sprue, uraemia, nephritis, 
gout, hypertension, and cardiac disease.[87]. 
2.16.5 Pharmacological activities 
Reduced risk of high blood pressure  
Bananas are reported to be one of the best sources of potassium, an essential mineral for 
maintaining normal blood pressure and heart function. A medium-sized banana provides 350 
mg of potassium. A number of studies have demonstrated the effectiveness of potassium rich 
foods in reducing blood pressure. The FDA has endorsed claims from the banana industry of 
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its ability to reduce the risk of hypertension and stroke. The FDA asserts that consuming foods 
containing high amounts of potassium and low amounts of sodium considerably reduces the 
risk of high blood pressure and stroke. Additionally, potassium plays an important role in 
maintaining fluid and electrolyte balance in biological cells. Researchers have reported that 
some phytochemicals found in banana act similarly to some antihypertensive drugs. A group 
of researchers studied six popular banana varieties and found that they all possess ACE 
(angiotensin converting enzyme) inhibitory properties, though unripe bananas displayed a 
weaker inhibition than the ripe ones. A 10% drop in blood pressure was observed in subjects 
who consumed bananas daily for two weeks.[88] 
Reduced risk of stroke  
Scientists suggest that individuals who have a low potassium intake are prone to strokes. A 
study of 5,600 people aged over 65 found that those with the lowest potassium intake were 
50% more likely to suffer a stroke. Foods rich in potassium like bananas may lower the risk of 
stroke, however more substantial evidence is required to confirm whether increasing potassium 
in the diet can prevent strokes.[88]  
Restore normal bowel activity  
Bananas can help restore normal bowel function and help alleviate diarrhoea and constipation 
because of its high content of non-digestible fibres (including alpha glucans, hemicellulose, 
and cellulose). The high content of pectin in bananas which is water absorbent confers them a 
bulk producing ability. Bananas are an excellent source of fructooligosaccharide, a prebiotic 
which enhances the growth of probiotics (beneficial bacteria) in the colon. These beneficial 
bacteria produce vitamins and digestive enzymes that improve our ability to absorb nutrients, 
plus compounds that protect the body against unfriendly microorganisms. In a study, 57 babies 
(5-12 months) with persistent diarrhoea of at least 14 days duration were administered a week’s 
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treatment with a rice-based diet containing either green banana, apple pectin or the rice diet 
alone. Treatment with both green banana and apple pectin resulted in a 50% reduction in stool 
weights, indicating that the babies were absorbing significantly more nutrients.[89] 
Protection from ulcers and heartburn remedy  
Bananas are well known for their antacid properties that confers protection against gastric 
ulcers and ulcer damage. Leucocyanidin, a flavonoid found in banana, has been found to 
considerably increase the thickness of the gastric mucous membrane. Bananas are effective in 
alleviating heartburn due to their potential to neutralise acid. In an animal study, a simple 
mixture of banana and milk significantly suppressed acid secretion.[90]  
Protection against neurodegenerative diseases (Alzheimer’s disease)  
Researchers at Cornell University investigated the effects of orange, banana, and apple extracts 
on neuron cells and found that the phenolic phytochemicals of the fruits prevented 
neurotoxicity on the cells. Apples were found to contain the highest content of protective 
antioxidants, followed by bananas then oranges. These results suggest that introducing fresh 
oranges, bananas, and apples in our diet along with other fruits may protect neuron cells against 
oxidative stress-induced neurotoxicity and may play an important role in reducing the risk of 
neurodegenerative disorders such as Alzheimer’s disease.[88] 
Cholesterol lowering effect  
It has been demonstrated through animal studies that bananas have the potential to lower 
cholesterol. The dietary fibre component of banana is responsible for its cholesterol-lowering 
effect. Ripening doesn’t alter the amount of dietary fibre in the pulp.[91] 
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Kidney health  
Bananas have been shown to enhance kidney function. This is as a result of the high potassium 
content of banana. A normal intake of potassium suppresses calcium excretion in the urine and 
minimizes the risk of kidney stones. The results of a Swedish population based prospective 
study (13.4 years) of 61,000 women aged 40-76, show that women eating more than 75 
servings of fruits and vegetables per month (which translates into 2.5 per day) cut their risk of 
kidney cancer by 40%. Among the fruits, bananas were especially protective. Women eating 
bananas four to six times a week halved their risk of developing the disease compared to those 
who did not eat this fruit.[88] 
Immunity booster  
Bananas contain 25 % of the recommended daily allowance (RDA) for vitamin B6, necessary 
for the synthesis of red blood cells and antibodies as well as aiding in the metabolism of fat. 
Additionally, vitamin B6 serves as an immunity booster. Consequently, bananas strengthen the 
body defence against infectious diseases. An average sized banana contains about 15% of the 
RDA for vitamin C, one of the strongest antioxidants.[88] 
2.16.6 Adverse effects  
The presence of tryptophan in banana combined with the high carbohydrate content is believed 
to affect the consumer’s state of awareness influencing brain activity and triggering sleepiness. 
Consuming bananas and alcohol simultaneously may aggravate migraines. Thus, it is not 
advisable to consume bananas with alcohol. Few people have been reported to be allergic to 
bananas.[88] 
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2.16.7 Nutritional value of banana 
Bananas are an excellent source of potassium. Potassium can be found in a variety of fruits, 
vegetables, and even meats, however, a single banana provides 23% of the potassium required 
daily amount. Potassium is beneficial to the muscles as it helps maintain their proper 
functioning and prevents muscle spasms.[88]  
Bananas are an excellent source of vitamins, including:  
1. A - helps in maintaining healthy bones, teeth, soft tissue, among others  
2. B6 - enhances the body's immune system, promotes heart health, brain health, among others  
3. C - aids in healing, growth of tissue, ligaments, among others  
4. D – enhances Calcium absorption 
2.16.8 Phytochemical profile 
Carbohydrates have been isolated from M. sapientum. Catecholamines such as norepinephrine, 
serotonin, dopamine, tryptophan, indole compounds, and pectin have been found in the pulp. 
Several flavonoids and related compounds (Leucocyanidin, quercetin and its 3-Ogalactoside, 
3-O-glucoside, and 3-O-rhamnosyl glucoside) were isolated from the unripe pulp of plantain. 
Serotonin, nor-epinephrine, tryptophan, indole compounds, tannin, starch, iron, crystallisable 
and non-crystallisable sugars, vitamin C, B-vitamins, albuminoids, fats, mineral salts have been 
found in the fruit pulp of M. paradisiaca and M. sapientum. Acyl steryl glycosides such as 
sitoindoside-I, sitoindoside-II, sitoindoside-III, sitoindoside-IV and steryl glycosides such as 
sitosterol gentiobioside, sitosterol myo-inosityl- β-D-glucoside have been isolated from fruits 
of M. paradisiaca. Cellulose, hemicelluloses, arginine, aspartic acid, glutamic acid, leucine, 
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valine, phenylalanine and threonine have been isolated from the pulp and peel of M. 
paradisiaca [92]. 
2.16.9 Properties of unripe banana powder 
Banana is rich in carbohydrate with starch being the principal component of unripe banana 
accounting for about 70 to 80% dry weight basis. Its high starch content accounts for its use as 
a tablet disintegrant.[93] The starch undergoes important changes during ripening and the 
average starch content drops in the pre-climacteric (prior to starch breakdown) period to less 
than 1% at the end of the climacteric period, when sugars, mainly sucrose, accumulate to more 
than 10% of the fresh weight of the fruit. Banana starch has been reported to be resistant to α- 
amylase and glucoamylase hydrolysis and has been shown to possess health benefits similar to 
dietary fibre. It has been shown to prevent colorectal cancer, lower the risk of heart disease, 
and influence metabolic and inflammatory bowel diseases such as diabetes and diverticulitis 
[94]. 
Recent studies have reported the binding properties of banana starch obtained from the unripe 
fruit of Musa sapientum in comparison with official corn starch Banana starch was found to 
compare favourably with corn starch as the binding agent in tablet formulations although the 
tablets produced had lower crushing strength and faster disintegration time, suggesting its 
potential usefulness when fast tablet disintegration is desired. However, no work has been done 
to evaluate the physicochemical and material properties of banana starch to determine their 
functional properties and their usefulness. Moreover, the disintegrant properties of the starch 
have remained largely uninvestigated.[95] 
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2.16.10 Unripe banana powder as a superdisintegrant 
Singh MC et al prepared and evaluated powders of the unripe fruit of various varieties of Musa 
pariadisiaca  for angle of repose, bulk density, tapped density, Carr’s index, Hausner ratio, 
swelling capacity, hydration capacity and moisture content. Angle of repose ranged from 28.2º 
to 32.5º, which indicates good flow property. Bulk density ranged from 0.38 to 0.45 g /cm2. 
Tapped density ranged from 0.5 to 0.68 g /cm2. Carr’s index ranged from 24 to 33.82% which 
indicates poor compressibility of the powder. Hausner ratio revealed good flowability. The 
moisture content for all the powders was within 0.53 to 0.72% w/w.[96] 
Hamsanandini J et al formulated orodispersible liquisolid compacts of Meloxicam using unripe 
banana powder as a superdisintegrant. The in-vitro dispersion time was found to be in the range 
of 36.66±1.52 - 96.66±1.52 seconds. The mean disintegration time for all evaluated tablets was 
found to be 2 minutes, which is aligned with pharmacopoeial requirements. The disintegration 
time was found to be in the range 35.00±1.00 - 88.00±2.00 seconds. The disintegrating effect 
of unripe banana powder was investigated by varying the concentration of the polymer. From 
the results, it was deduced that the disintegrating effect of unripe banana powder is inversely 
proportional to the amount used in the formulation.[97] 
Arun Raj R undertook a comparative evaluation of potato starch and unripe banana powder as 
disintegrants in a tablet formulation of Aceclofenac. It was observed that the percentage release 
of tablets containing banana powder and potato starch was higher as compared to tablets 
formulated with microcrystalline cellulose.[98] 
Sathali  AH and Suganya M designed fast dispersible tablets of Amiodarone HCL using a 
variety of synthetic and natural superdisintegrants.  Five formulations were prepared using 2%, 
3%, 4%, 6%, 8%  w/w of unripe banana powder as a superdisintegrant. The cumulative 
percentage of drug release showed 95.9%, 96.9%, 98.07%, 98.24%, 99.07% respectively at 
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12.8 seconds. The formulation containing 8% unripe banana powder showed maximum drug 
release (99.07%) at 12.8 seconds [99].   
Saudagar R.B developed and evaluated mouth dissolving tablets of Lisinopril using varying 
concentrations of unripe banana powder as a superdisintegrant. It was observed that the tablets 
formulated with unripe banana powder as sole disintegrant showed nearly identical and 
improved results in terms of wetting time, disintegrating time in-vitro dispersion time, water 
absorption ratio and percentage drug release as compared to the tablets formulated with 
synthetic superdisintegrants. Studies revealed that unripe banana powder can be used on its 
own as a disintegrant in the formulation of mouth dissolving tablets of some drug candidates 
such as Lisinopril. It was thus deduced that preferring superdisintegrants of natural origin over 
their synthetic counterparts should be motivated by their cost effectiveness and nutritive 
potential.[100] 
 
Figure 2.8: Unripe banana powder  
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2.17 Ispaghula  
2.17.1 Taxonomical classification of ispaghula  
 
 
 
 
 
 
2.17.2 Description 
The name Isabgol is derived from two Persian words ‘Isap’ and ‘ghol’ meaning horse ear, 
denoting the characteristic shape of the seed. The Plantago genus comprises of around 200 
species of herbs and sub-shrubs which are mainly cultivated in temperate regions and few 
tropical regions.[101] About ten species are recorded in India, of which Plantago ovata is 
important for its seeds. Family Plantaginaceae is a stemless woolly annual herb which attains 
a height of 30-45 cm. Leaves are narrowly linear or filiform appearing whorled due to the short 
terete stem. The spikes are 1.2-4 cm long and about 0.5 cm broad, cylindrical to ovoid in shape 
and bear between 45-70 flowers. Flowers are bisexual, tetramerous, anemophilous and 
protogynous and as such favouring outcrossing. The fruits are ellipsoid capsules, about 8 mm 
long, obtuse, membranous, glabrous, upper half coming off as a blunt conical lid and seeds are 
ovoid-oblong, boat-shaped, smooth, rosy-white being concave on one side and convex on the 
other. The concave side of the seed is covered with a thin white membrane produced by fusing 
of the outer layer of the ovule together with the inner epidermis, forming the seed coat.[102]. 
Kingdom             Plantae 
Phylum             Magnoliophyta 
Class                         Magnolipsida 
Order                         Lamiales 
Family               Plantaginaceae 
Genus                         Plantago 
Species             Ovata 
Common name  Psyllium, ispaghula, isabgol 
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The seed epidermis is made of polyhedral cells whose walls are thickened by a secondary 
deposit which is the source of mucilage. On mechanical milling, the coating of  the seed 
provides the husk, a membranous covering of the seed, white to light pink in colour, translucent 
and odourless (Figure 2.9). The husk absorbs moisture and forms a tasteless mucilaginous 
substance which constitutes the drug.[103]  
 
      
Figure 2.9: Plantago ovata. Left: plant. Middle: seeds, Right: husk 
2.17.3 Distribution and cultivation 
Plantago ovata is commonly distributed in the Mediterranean coastal region, Sinai, Isthmus 
desert, east of the Nile, North Africa. India, Iran, Pakistan, countries of the Arabian Peninsula 
and West Asia, extending up to Sutlej and Sind in West Pakistan. P.ovata is also distributed 
throughout Arabia on sandy and silty soil, often in shady and damp locations. The crop was 
introduced to India during the 16th century. It is cultivated as a cash crop in various parts of 
India and on a limited scale in some areas of west Pakistan.[104] 
2.17.4 Traditional uses 
In traditional medicine, dried seeds and husk are regarded as emollient, demulcent and safe 
laxative mainly beneficial in chronic constipation, chronic diarrhoea and dysentery.[105] Seed 
husk of blonde psyllium has been used in European and Asian herbal medicine for chronic 
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constipation since the 16th century.[101] It does not irritate the intestine and is specific in its use 
when the mucous membrane is disturbed by inflammatory affections. Seeds are considered as 
cooling and diuretic and recommended for use in febrile conditions and in the affections of the 
kidney, bladder and urethra. A decoction of seeds is prescribed in cough and cold and a dressing 
of crushed seeds are useful for rheumatic and glandular swelling.[106] The mucilage of the dried 
seed is used externally as an emollient. The seed coat of the dried seed is taken orally as a bulk 
laxative. An Infusion of the dried seed is taken orally for urinary tract inflammations.[107]  
2.17.5 Phytoconstituents 
Psyllium husk contains a high quantity of hemicellulose, composed of a xylan backbone linked 
with arabinose, rhamnose, and galacturonic acid units (arabinoxylans). Phytochemical analysis 
of Plantago species showed their high potential to produce a myriad of secondary bioactive 
metabolites, i.e. sterols, phenols, alkaloids, iridoids, phenols and cumatines that are useful in 
treating human diseases. The seed consists of 35% soluble and 65% insoluble polysaccharides 
(lignin, hemicellulose and cellulose). Psyllium is classified as a mucilaginous fibre due to its 
powerful ability to form a gel in water. This ability comes from its role as the endosperm of 
the P. ovata seed, where it functions to retain water in order to prevent the seed from drying 
out [108]. 
 Psyllium seeds contain over 30% of hydrocolloidal polysaccharide (mucilage) in the outer 
seed coat, fixed oils, tannin, aucubin glycoside (iridoid), sugars, sterols and protein. This 
mucilage is colloidal in nature and its composition varies with the conditions of preparation. It 
is mainly composed of xylose, arabinose and galacturonic acid with rhamnose and galactose. 
Two polysaccharide fractions have been separated from the mucilage. One of them is soluble 
in cold water and on hydrolysis yields D-xylose (46%), an aldobiouronic acid (40%), L-
arabinose (7%) and insoluble residue (2%); the other fraction is soluble in hot water forming a 
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highly viscous solution which sets to a gel on cooling and yields on hydrolysis D-xylose (80%), 
L-arabinose (14%), aldobiouronic acid (0.3%) and traces of D-galactose.[109] 
2.17.6 Pharmacological activity 
Irritable Bowel Syndrome (IBS) 
Plantago ovata is widely used for the treatment of inflammatory bowel disease (IBD). P. ovata 
seeds ameliorated the development of colonic inflammation in transgenic rats as evidenced by 
an improvement of intestinal cytoarchitecture, significant decrease in some of the pro-
inflammatory mediators and higher production of short-chain fatty acid. [110] 
Antihypertensive effect 
 The alcoholic extract of P.ovata seeds exhibits cholinergic properties. It has been found to 
reduce blood pressure in anaesthetized cats and dogs, inhibit the isolated and perfused hearts 
of rabbits and frogs and stimulate intestinal movement in rabbits, rats and guinea-pigs. The 
activity of the extract on smooth muscle is inhibited by atropine.[102] 
Cholesterol-lowering effect  
The seed oil has the ability to reduce cholesterol level of serum in rabbit. The use of linoleic 
acid-rich oil obtained from embryo has been suggested as a dietary hypocholesterolemic agent 
in place of corn oil. Feeding of the embryo oil as dietary supplement for lowering serum 
cholesterol level gave promising results in experimental animal.[103] 
Hypoglycaemic effect 
The aqueous extract of P. ovata seeds reduced hyperglycaemia in type 1 and 2 diabetes in rats. 
These properties show that this extract can be used in the treatment of diabetes.[111] 
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2.17.7 Ispaghula as a superdisintegrant 
The seed husk of Plantago ovata comprises of a high amount of a xylan known as arabinoxylan, 
which is made up of 74.8% xylose and 23.2% arabinose. Arabinoxylan with a molar mass of 
364,470 g/mol shows high swelling capacity in water and thus accounts for the tremendous 
disintegrating effect of Plantago ovata husk and mucilage. This polysaccharide based hydrogel 
is biocompatible and non-toxic; hence it would be a good candidate for the design of novel 
drug delivery systems. The hydrogels of arabinoxylan contain ferulic acid which demonstrates 
antioxidant and anticancer properties. Xylans are the most common hemicelluloses found in 
plants such as cereals, herbs and grasses. The isolation techniques, structures and properties of 
naturally occurring xylans have been studied over the past few years. Despite their properties 
and myriads of applications, xylans are not yet available in industrially required quantities for 
large scale processing. [112] 
Prakash Goudanavar et al designed and evaluated fast disintegrating tablets of Granisetron 
HCL with natural and synthetic polymers. The formulation which contained 5% w/w of 
Plantago ovata as superdisintegrant showed better drug release as compared to the other 
formulations.[113] 
Patil et al formulated and evaluated fast dissolving tablets of Candesartan cilexetil using 
Plantago ovata and croscarmellose sodium as superdisintegrants. The swelling index of 
Plantago ovata mucilage was found to be more than that of its synthetic counterpart 
croscarmellose sodium. Plantago ovata formulations showed faster drug release compared to 
croscarmellose formulations. This is due to the relatively higher swelling index of Plantago 
ovata mucilage.[114] 
Shirsand SB et al  designed fast disintegrating tablets of Prochlorperazine maleate by the direct 
compression technique using varying concentrations of Plantago ovata mucilage and 
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crospovidone as super-disintegrants along with microcrystalline cellulose. Mannitol was used 
as a filler to enhance mouth feel. The percentage loss in mass when assessing the friability of 
the tablets was found to be below 1%, this is an indication of good mechanical resilience. 
Hardness of the tablets was found to be around 2.63 kg/cm. Water absorption ratio and wetting 
time, which are imperative criteria for judging the ability of disintegrants to swell in the 
presence of a minute amount of water were found to be in the range of 50-86% and 11-47 s, 
respectively. Overall, the formulations containing 8% w/w of Plantago ovata mucilage and 
60% w/w of microcrystalline cellulose showed an in vitro dispersion time ranging from 8 to 10 
s.[115] 
In an investigation, fast disintegrating tablets of amlodipine besylate were designed by the 
direct compression method using varying concentrations of Plantago ovata mucilage as a 
superdisintegrant. The formulated tablets were evaluated for weight variation, friability, 
hardness, disintegration time, dissolution, and drug content. The optimised formulation showed 
in vitro disintegration time of 11.69 seconds with rapid in vitro dissolution within 16 
minutes.[116] 
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2.18 Formulation and evaluation of fast dispersible tablets 
The formulation of fast dispersible tablets using the direct compression technique is very much 
similar to that of conventional tablets. However, supplementary processes might be required 
when botanically sourced superdisintegrants are employed. Prescribed evaluation procedures 
used for conventional tablets can be used for fast dispersible tablets alongside additional tests 
that lay emphasis on tablet dispersion. 
2.18.1 Preformulation studies 
This phase consists of characterising the excipients and the active pharmaceutical ingredient 
(API). The extent to which the ingredients are characterised, and the choice of characterisation 
techniques are influenced by the nature of the project, the nature of the ingredients and the 
amount of literature available. The following steps are usually followed. 
Characterisation of the active pharmaceutical ingredient 
The physicochemical properties of the API are identified or determined; these generally include 
molecular weight and size, density, solubility (in various solvents and different pH media), 
melting point, boiling point, pH and LogP. Thermal  analytical tools such as hot stage 
microscopy (HSM), differential scanning calorimetry (DSC) and thermogravimetric analysis 
(TGA) are widely used and are highly accurate in determining the melting point, boiling point 
and purity of compounds.[117-119] Key functional groups of the API can be identified with 
spectroscopic techniques such as Fourier transform infrared spectroscopy (FTIR)[120]. Another 
step consists of determining the micromeritic properties of the API powder using conventional 
assessment techniques.  This step is imperative because it guides the selection of key tableting 
variables such as the type and amount of excipients to be added and the compression force to 
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be employed. The powder properties commonly assessed include, bulk density, tapped density, 
angle of repose, compressibility index and Hausner ratio.[121]  
Characterisation of the excipients 
The excipients are assessed and characterised in the same manner as the API. In the case of 
botanically sourced excipients, a number of additional processes are required. Usually, 
extraction and purification steps are needed prior to characterising these excipients. 
Characterisation tests pertaining to botanically sourced excipients generally include, 
organoleptic analysis, microbiological load, moisture content, ash value and phytochemical 
analysis.[122] Spectroscopic analytical  techniques  such as FTIR, vibrational spectroscopy,  
nuclear magnetic resonance spectroscopy (NMR), as well as chromatographic methods have 
proven to be effective in analysing the constituents of botanically sourced excipients.  
Drug-excipients compatibility  
This step consists of identifying physical or chemical incompatibilities that may arise from 
combining the API with the excipients. These incompatibilities can adversely affect the 
stability of the tablet and the therapeutic activity of the API. Thermal analytical tools (HSM, 
DSC) and spectroscopic techniques (FTIR) can be used to identify and predict these 
incongruities.[123]  
2.18.2 Powder blending 
The API is mixed with the excipients in the desired proportions and the micromeritic properties 
of the powder blends are determined. The micromeritic properties of the powder blends hint at 
the need for adding compression aids or altering the proportion of some excipients. Table 2.2 
provides examples of commonly used excipients and the role they play in fast dispersible 
tablets. 
http://etd.uwc.ac.za/
66 
 
Table 2.2: Excipients commonly used in fast dispersible tablet formulations[124] 
Excipients  Function Examples 
Superdisintegrant Increases the rate of disintegration 
and hence enhances dissolution. 
Some superdisintegrants are 
multipurpose excipients 
Microcrystalline cellulose, 
crospovidone, sodium starch 
glycolate, pregelatinised 
starch  
Flavouring agent Increases palatability thereby 
increasing patient acceptability 
and therapeutic adherence  
Vanilla, peppermint, 
strawberry, anise oil 
Sweeteners or sugar-
based excipients 
Exhibit high aqueous solubility 
and can be used as fillers. Enhance 
taste and mouth-feel  
Aspartame, dextrose, 
mannitol, fructose  
Surfactant Reduces surface tension and hence 
enhances tablet solubilisation 
Sodiumdoecylsulphate, 
sodiumlaurylsulphate 
Binder Confers resilience and maintains 
the integrity of the tablet prior to 
administration 
Polyvinylpyrrolidone (PVP), 
Polyvinylalcohol (PVA) 
Colourants Enhances the aesthetic appeal of 
the tablet 
Amaranth, red iron oxide  
Lubricant Reduces friction and wear  
between the die and punches of the 
tablet press 
Magnesium stearate, liquid 
paraffin, talc, magnesium 
lauryl sulphate 
Filler  Increases bulk of tablet and  may 
serve other functions  
Mannitol, xylitol, sorbitol, 
pregelatinised starch  
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2.18.3 Compression  
This entails applying sufficient pressure to the powder blend in order to obtain tablets with 
satisfactory compactness and hardness. The most intricate part of this phase is to find a suitable 
compression force that confers sufficient hardness to the tablets whilst allowing the tablets to 
disintegrate instantly given that the rate of disintegration is inversely proportional to the 
compression force employed. Fast dispersible tablets are usually compressed using relatively 
lower compression forces so as to obtain adequately porous tablets.[54] Tablet resistance to 
crush and disintegration time are two key parameters that are used to assess the suitability of 
the compression force used.  
2.18.4 Evaluation and quality control 
Fast dispersible tablets are evaluated using the same tests and procedures prescribed for 
conventional tablets alongside key tests that lay emphasis on tablet dispersion and palatability. 
Parameters used to evaluate fast dispersible tablets include, hardness, weight uniformity, 
tensile strength,  friability, durability, taste, porosity, in-vitro dispersion time, wetting time, 
water absorption ratio, in-vitro disintegration time and dissolution. Disintegration and 
dissolution are crucial parameters for fast dispersible tablets since they demarcate them from 
conventional swallow tablets. Stability testing is also necessary in order to assess the need for 
optimising the product, estimate a suitable shelf-life for the product, identify potential 
incompatibilities between the ingredients and recommend suitable packaging and storage 
conditions.[125] 
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2.18.5 Packaging and storage 
The choice of packaging used for fast dispersible tablets is influenced by their level of 
resistance to mechanical stress. Highly porous and less rigid  fast dispersible tablets require 
specialised packaging in order to prevent mechanical damage; this includes packing tablets 
with peelable backing foil, or dome-shaped blisters which prevent the tablets from moving 
vertically. Fast dispersible tablets with sufficient mechanical strength are generally packed in 
bottles or push-through blisters. Fast dispersible tablets should be stored in a dry place in 
moisture impervious packaging since they are highly porous and contain moisture sensitive 
excipients.[126]  
2.19 High performance liquid chromatography (HPLC) methods for lamivudine assay 
Several techniques have been used for the assay of lamivudine of which chromatography is the 
technique of choice due to its high sensitivity. Chromatography is a technique used to separate 
and purify compounds based on their polarity. The high performance liquid chromatography 
(HPLC)  system consists of four main components which are enumerated below. 
 A column referred to as the stationary phase which is composed of substances like silica 
functionalised with non-polar long carbon chains. 
 The analyte i.e. the drug being assayed 
 Injectors to inject samples of the analyte into the column. 
 The mobile phase. The mobile phase is a solution which moves through the column and 
serves as a carrier for the samples. It is generally composed of water and an organic 
solvent such as acetonitrile, a phosphate buffer or methanol in a given ratio.  
Compounds are identified, purified or separated by HPLC based on the time required for 
individual components to be eluted from the column. The amount of time required to elute a 
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component from the column subsequent to injection is referred to as the retention time (Rf) 
which is determined by its polarity.[127] As the concentration of the solvent in the column 
increases, the concentration of water decreases. This enhances the non-polarity of the mobile 
phase. Non-polar compounds in the sample adhere strongly to the carbon whilst the polar 
compounds adhere weakly. 
Four key articles were selected to compile a suitable HPLC method for this study. There were 
remarkable similarities amongst the reviewed assessment techniques with regards to sample 
preparation, mobile phase and stock solutions. Literature reports that mobile phases consisting 
of acetonitrile or 0.015 M potassium dihydrogen ortho-phosphate with methanol have been 
used for the HPLC assay of lamivudine. The mobile phases reviewed had a two phase system 
with a polar and a non-polar solvent e.g. methanol (non-polar) and water (polar) in a 50:50 or 
30:70 ratio. Orthophosphoric acid in water has also been used to assay lamivudine.[127-129] 
The reviewed data showed that mixtures of methanol with pH values adjusted with 
orthophosphoric acid yielded adequate and clearly defined peaks.  Data accuracy was tested by 
means of recovery studies by adding a known amount of the assayed drug to a drug solution of 
a known concentration (e.g. 80%, 100% and 120%) prior to HPLC analysis. Each sample was 
tested in triplicate and the recovery values obtained were high suggesting that the results 
obtained were accurate. Precision was tested by using six similar standard solutions and 
analysing them using HPLC. This was all completed and repeated on the same day. The relative 
standard deviation was determined, and the results were within an acceptable range.[127-129]  
The reviewed HPLC methods (Table 2.3) were found to be speedy, precise and accurate, thus 
a good point of reference for the development and design of a suitable HPLC method for the 
assay of lamivudine tablets formulated using natural polymers 
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Table 2.3: Summary of reviewed literature of HPLC methods for lamivudine assay[129-132] 
Variables assessed Method 1 Method 2 Method 3 Method 4 
Mobile phase  Acetonitrile, 
methanol and  
water 
Potassium 
dihydrogen ortho-
phosphate, 
acetonitrile 
Methanol, ortho-
phosphoric acid, 
acetonitrile 
Water, ortho-
phosphoric 
acid, methanol   
Mobile phase ratio 30:45:25 45 to 55 30:70 or 70:30 50:50 
Use of internal 
standard solution 
None Yes 
(Carbamazepine) 
Yes Yes (Efavirenz, 
Lamivudine, 
Zidovudine) 
Was sample 
pulverised? / 
Solvent used to 
dissolve powder? 
Yes / methanol Yes / methanol Yes / methanol Yes / methanol 
Formulation Combination 
dose tablet 
Combination dose 
tablet 
Combination 
dose tablet 
Combination 
dose tablet 
Column  Phenomenex 
Luna C18 
column 
HiQ Sil C18V 
column 
Inertsil ODS-3 
c18 column 
Xterra C18 
(150 mm × 4.6 
mm, 5μ) 
column 
Method validation Accuracy, 
precision, 
linearity, UV 
detection 
Recovery studies 
and relative 
standard deviation 
achieved. 
Accuracy, 
precision and 
linearity studies 
Accuracy, 
precision, 
linearity, 
recovery studies, 
relative standard 
deviation 
Accuracy, 
precision, 
linearity, 
recovery 
studies, relative 
standard 
deviation 
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Chapter 3 
Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
 
In this chapter, the materials and methods used for the formulation of 
fast dispersible tablets of lamivudine are discussed. A clear 
description of analytical techniques and procedures is provided. This 
chapter gives a breakdown of the project in a chronological order i.e. 
sourcing of materials, preformulation studies, formulation and quality 
assessment of the product.  
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3.1 Materials   
Lamivudine 
Pure lamivudine powder was donated by Aspen Pharmacare (batch number: LV1400913; 
expiry date: August 2018). Lamivudine was used as the active pharmaceutical ingredient of the 
innovative tablets. 
Banana 
Unripe bananas of the genus Musaceae were purchased from a local retailer (Food lover’s 
market). The bananas were used to prepare unripe banana powder which was used as a 
superdisintegrant.  
Ispaghula husk  
Ispaghula husk was purchased from a local retail pharmacy (Clicks pharmacy). The husk was 
milled into a powder and used as a superdisintegrant.  
Magnesium stearate  
Magnesium stearate is the magnesium salt of stearic acid. The light white powder was added 
to the formulation blends in order to enhance the flowability of the powders and to prevent 
adhesion to the punches and die. The magnesium stearate used in this study was of analytical 
grade. 
Talc  
A clay mineral composed of hydrated magnesium silicate. Talc was used as a dusting powder 
to reduce friction on the punches and die during powder compression. The talc used in this 
study was of analytical grade. 
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Comparator  
Aspen Lamivudine® 150 mg tablet (Batch number: A851174; Expiry date: June 2018) was 
used as a standard for comparison. 
Phosphate buffer solution  
A 6.8 phosphate buffer solution (PBS) was used for in-vitro dispersion and disintegration 
studies. The PBS was prepared as follows: 
Sodium chloride: 8 g  
Potassium chloride: 0.2 g 
Disodium hydrogen phosphate: 1.44 g 
Potassium dihydrogen phosphate: 0.24 g 
Deionised water: 1000 ml 
Hydrochloric acid (0.1 M): qs 
The salts were accurately measured and ground in a mortar using a pestle. The salts were 
transferred to a graduated beaker containing 800 ml of UV sterilised deionised water. The 
solution was stirred until the salts were fully dissolved. 0.1 M HCL was added to the solution 
dropwise whilst  stirring and measuring the pH. When the desired pH was attained, the solution 
was adjusted to 1000 ml using deionised water.  
All other reagents used in this study were obtained from the chemical company Sigma-Aldrich. 
They were all analytical grade reagents. 
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3.2 Preparation of the natural polymers 
Unripe banana powder 
Unripe bananas of the genus Musaceae were peeled and the edible part of the fruit was sliced. 
The sliced pulp was washed with distilled water and 0.2 % w/w of methyl paraben was added 
as a preservative. The pulp was ground using a domestic blender and dried in a convection 
oven at 45 ºC for 24 hours. The dry pulp was pulverised in a mortar, sieved using sieve No.80 
(177µm), and stored in an airtight container with a desiccant (silica gel packets).[1] 
Ispaghula husk powder 
Ispaghula husk was milled using a domestic dry blender. The milled husk was sieved using 
sieve No.80, and the powder was stored in an airtight container with silica gel. 
3.3 Extraction of relevant constituents from the natural polymers 
The relevant constituents responsible for the disintegrating effect of the natural polymers were 
extracted and characterised. In the case of unripe banana powder, its high starch content 
accounts for its disintegrating properties.[2] The hemicellulose arabinoxylan is responsible for 
the disintegrating effect of ispaghula husk powder.[3] 
Extraction of starch from unripe banana powder 
Dehydrated banana powder (20 g) was suspended in 100 ml of distilled water and agitated for 
12 hours at room temperature using a magnetic stirrer. The mixture was filtered using mesh 
200. The residue was washed with distilled water, and the filtrate was centrifuged at 1000 x g 
for 30 minutes at room temperature. The supernatant was discarded, and the wet mass was 
dried in a convection oven at 40 ºC for 12 hours. The dried mass was pulverised in a mortar, 
sieved using sieve No.80, and stored in an airtight container with a desiccant.[4] 
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Extraction of arabinoxylan from ispaghula husk powder 
Ispaghula husk powder (7 g) was soaked in distilled water in the ratio 1:50 (husk to water). The 
suspension was allowed to macerate for 24 hours at room temperature. The pH of the 
suspension was increased to 13 by adding concentrated NaOH dropwise to solubilise 
arabinoxylan. The insoluble fibrous matter was removed by sieving the alkali extract through 
mesh 200 (74µm). Acetic acid was added to coagulate the mucilage at pH 3. The translucent 
gelatinous mass obtained was washed several times with distilled water to remove excess acetic 
acid.[3] The gel was frozen at -80ºC and freeze dried for 5 days. The white powder obtained 
was pulverised in a mortar, sieved through sieve No.80, and stored in an airtight container with 
a desiccant. 
3.4 Characterisation of the natural polymers 
3.4.1 Organoleptic evaluation  
Sensory appraisal of the natural polymers was conducted in order to determine their 
macroscopic properties and overall aesthetics. An assessment of taste, colour, odour and texture 
was recorded. 
3.4.2 Phytochemical analysis [5, 6] 
This assessment was conducted to gain an insight of the chemical composition of the natural 
polymers from a qualitative perspective. Phytochemicals can have potentially beneficial or 
detrimental therapeutically significant effects.  Samples of unripe banana powder and ispaghula 
husk powder were evaluated for the presence of carbohydrates, saponins, phenols, proteins, 
tannins, lipids, flavonoids and steroids. 
http://etd.uwc.ac.za/
92 
 
Iodine starch test: 1 g of powder was dissolved in 15 ml of distilled water. The solution was 
boiled until a mucilage was obtained. Few drops of 2N iodine solution were added to 2 ml of 
the mucilage. A dark blue colouration was an indication of the presence of starch. 
Foam test (Test for saponins): 1 g of powder was dissolved in 10 ml of distilled water in a 
test tube. The test tube was sealed and agitated vigorously. The appearance of a permanent 
froth was a positive test for saponins. 
Phenols: an aqueous extract of the polymer was treated with FeCl3. A dark colouration was an 
indication of the presence of phenols. 
Biuret test (test for proteins): a small amount of powder was added to 4% NaOH and few 
drops of 1% CuSo4 were added.  The appearance of a violet or pink colour was an indication 
of the presence of proteins. 
Tannins: An aqueous extract of the polymer was treated with FeCl3.  A dark colouration was 
an indication of the presence of tannins. 
Lipids: 10 ml of 96% ethanol were added to 1 g of powder in a test tube and agitated. The 
solution was diluted with distilled water and the appearance of a cloudy emulsion was an 
indication of the presence of lipids. 
Flavonoids: four pieces of magnesium ribbons were added to the ethanolic extract of the 
powder sample. Few drops of concentrated hydrochloric acid were added to the extract and 
agitated. The appearance of a reddish colouration was an indication of the presence of 
flavonoids 
Steroids (Liberman-Burchard test): 1g of powder sample was dissolved in dry chloroform 
and several drops of acetic anhydride were added followed by 2 drops of concentrated sulphuric 
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acid. A pink, purple or dark colouration was an indication of the presence of steroids such as 
cholesterol. 
Monosaccharides (Benedict’s test): 1 g of powder was dissolved in 10 ml distilled water and 
placed in a test tube. Few drops of Benedict’s reagent were added, and the test tube was placed 
in a hot water bath for 10 minutes. A reddish, yellowish or greenish colouration indicated the 
presence of reducing sugars. 
3.4.3 Microbiological limit test 
This assessment was carried out to quantitatively estimate the number of microbial colony 
forming units (CFU) present in the natural polymers. Botanically sourced powders offer a 
propitious environment for microorganisms to thrive due to the presence of essential nutrients 
and moisture. The bioburden of a naturally sourced powder provides an insight on the safety, 
integrity, and stability thereof.  
The microbiological load of the natural polymers was determined by using the spread plate 
method. 1 g of powder was dispersed in 9 ml of distilled water and three serial dilutions were 
made. Nutrient agar was dissolved in distilled water, sterilised at 121ºC using an autoclave, 
and allowed to set in petri dishes. The petri dishes were then inoculated with 1 ml of the test 
sample. To determine fungal activity, the dishes were incubated at 25 ºC for 72 hours. To assess 
bacterial growth, the dishes were incubated at 37 ºC for 24 hours. [7] 
3.4.4 Swelling Capacity 
It is important to assess the propensity and the extent at which natural polymers used as 
superdisintegrants swell when in contact with water as this behaviour hints at their 
disintegrating properties. 
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The swelling capacity of the natural polymers was estimated by a modification of the method 
of Bowen and Vadino.[8] The tapped volume occupied by 1 g of the powder Vx was recorded. 
The powder was then dispersed in a graduated cylinder containing 85 ml of distilled water, and 
the volume was made up to 100 ml with additional water. The suspension was allowed to stand 
for 24 hours, after which the volume of the sediment Vy was estimated. The swelling capacity 
was determined as follows: 
Swelling capacity: Vy/Vx 
The mean of three determinations was calculated. 
3.4.5 Determination of pH 
This analysis was carried out in order to estimate the acidity or basicity of aqueous dispersions 
of the natural polymers. The pH of a 1% aqueous dispersion was determined using an electronic 
pH metre.                                                                                                                                              
3.5 Thermal analysis 
Thermal  analytical tools have the ability to characterise the physical structure and properties 
of materials. The following thermal analytical techniques were used to investigate the thermal 
behaviour of lamivudine and the natural polymers.  
3.5.1 Loss on drying 
This analysis was done to estimate the amount of moisture present in the natural polymers. In 
view of the fact that water is essential for microbial growth, the stability and shelf life of a 
naturally sourced powder is substantially affected by its moisture content. 
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The moisture content of the natural polymers was estimated using a halogen moisture analyser. 
1 g of powder was heated to a maximum temperature of 105 ºC for 5 minutes and the percentage 
loss in mass was recorded. The analysis was carried out in triplicate. 
3.5.2 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry is a thermal tool that measures the difference in the amount 
of heat required to increase the temperature of a sample and reference as a function of 
temperature. The sample and reference are kept roughly at the same temperature throughout 
the analysis, and the heat flow in and out of the sample is measured by a calorimeter. A 
differential calorimeter measures the heat of a sample relative to a reference. The temperature 
programme for a DSC analysis is commonly designed in such a way that the sample holder 
temperature increases linearly as a function of time. The analysis only requires a few 
milligrams of the sample. The availability, speed and simplicity of DSC make it one of the 
most used thermal analysis techniques. [9] 
DSC thermograms were obtained using a Perkin Elmer DSC 7 instrument under nitrogen purge. 
A ±3 mg powder sample was placed in an aluminium pan, sealed, pierced to provide a vent 
hole and heated at a rate of 10 °C/min within the temperature range of 35 to 600 °C. 
3.5.3 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (TGA) is a thermal analysis method in which changes in physical 
and chemical properties of materials are measured as a function of increasing temperature with 
constant heating rate, or as a function of time with constant temperature and/or constant mass 
loss. TGA can provide information about physical phenomena, such as second-order phase 
transitions, including absorption, adsorption, desorption, sublimation, and vaporisation. 
http://etd.uwc.ac.za/
96 
 
Similarly, TGA can be used to elucidate chemical phenomena including chemisorption, 
decomposition, and solid-gas reactions (e.g., oxidation or reduction).[10] 
TGA thermograms were obtained using a Perkin Elmer Pyris TGA. ±3 mg of powder sample 
was heated in a crucible under constant nitrogen purge within the temperature range of 30 ºC 
to 600 ºC, at the heating rate of 10 ºC min-1. 
3.5.4 Hot stage microscopy (HSM) 
Hot stage microscopy (HSM) is a technique that couples microscopy and thermal analysis to 
elucidate the thermal behaviour of materials as a function of temperature and time. Besides 
providing information about particle size and particle morphology, HSM allows one to 
visualise melting and other transitions when heating a sample. It offers a unique means of 
visually following thermal changes. Amongst others, HSM can be used to assess: crystal 
growth, melting, sublimation, evaporation and interactions between different compounds.[11] 
Observations were made during heating using a HSM Mettler Toledo model connected to an 
Olympus BX-50 Microscope. Approximately 0.1 mg of sample was placed on a glass slide 
with coverglass using silicone oil as a medium. Silicone oil was used because of its resistance 
to decomposition at high temperatures and its inertness. The sample was heated within the 
temperature range of 20 to 400 ºC at a rate of 10 ºC min-1. 
3.6 Spectroscopy  
The extent at which materials emit or absorb light and other radiation depending on the 
wavelength of the radiation can be used to apprehend the functional configuration of a given 
material.  
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3.6.1 Fourier transform infrared spectroscopy (FTIR) 
Fourier transform infrared spectroscopy (FTIR) is a spectroscopic technique which is used to 
obtain an infrared spectrum of absorption or emission of a solid, liquid or gas. An FTIR 
spectrometer simultaneously collects high spectral resolution data over a wide spectral range. 
The raw data is converted into the actual spectrum using a Fourier transform.[12] 
Infrared spectra were obtained using a PerkinElmer Spectrum 400 FT-IR in the range 650-4000 
cm-1. 
3.7 Particle morphology and size analysis 
The knowledge and control of the size of particles is of great importance in tablet formulation. 
This enables one to have an insight of the fundamental and derived properties of a given 
powder. The size of a particle can be related to the chemical, physical and therapeutic properties 
of a powder. 
3.7.1 Scanning electron microscopy (SEM) 
The scanning electron microscope uses a focused beam of high-energy electrons to generate a 
variety of signals at the surface of solid specimens. The signals that derive from electron-
sample interactions reveal information about the sample including external morphology 
(texture), chemical composition, and crystalline structure and orientation of materials making 
up the sample. In most applications, data are collected over a selected area of the surface of the 
sample, and a 2-dimensional image is generated that displays spatial variations in these 
properties. Areas ranging from approximately 1 cm to 5 microns in width can be imaged in a 
scanning mode using conventional SEM techniques (magnification ranging from 20 X to 
approximately 30,000 X with a spatial resolution of 50 to 100 nm).[13] 
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Micrographs were obtained using a SEM Leo 1450. Particle diameter was estimated using the 
software imageJ® by measuring the longest axis on a particle, assuming that the particles are 
spherical. 
3.8 Determination of micromeritic properties  
When formulating a tablet, it is essential to assess the fundamental and derived properties of 
the powders since these properties considerably influence dose uniformity, dissolution, 
physical stability, drug release, and absorption. 
Lamivudine, the natural polymers, and the various powder blends were assessed using the 
United States Pharmacopoeia (USP) recommended methods to determine their propensity to 
flow and compressibility. The experiments were done in triplicate and the mean was 
determined. 
3.8.1 Angle of repose 
The angle of repose is the constant, three-dimensional angle (relative to the horizontal base) 
assumed by a cone-like pile of material. Angle of repose is a characteristic related to 
interparticulate friction or resistance to movement between particles. It is calculated using the 
formula below. 
 tan (α) = height/0.5 base. 
30 g of a powder sample was sieved using sieve No. 80 in order to break agglomerates. The 
powder was allowed to flow through a clamped funnel 4 cm above a steady base. The height 
and diameter of the heap were measured. [7] 
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3.8.2 Bulk density 
The bulk density of a powder is the ratio of the mass of an untapped powder sample and its 
volume, including the contribution of the interparticulate void volume. Hence, the bulk density 
depends on both the density of powder particles and the spatial arrangement of particles within 
the powder bed. The bulk density is expressed in grams per ml (g/ml). It may also be expressed 
in grams per cubic centimetre (g/cm3). 
30 g of a powder sample was sieved using sieve No. 80 in order to break any agglomerates. 
The volume of the powder was measured using a 100 ml graduated measuring cylinder readable 
at 1 ml.[7] 
3.8.3 Tapped density 
 The tapped density of a powder is an increased bulk density attained after mechanically 
tapping a container carrying the powder sample. Tapped density is obtained by mechanically 
tapping a graduated measuring cylinder or vessel. After observing the initial powder volume 
or weight, the measuring cylinder or vessel is mechanically tapped, and volume or weight 
readings are taken until little further volume or weight change is observed.  
The same powder used to determine bulk density was used to determine tapped density. The 
cylinder was fastened to a settling apparatus and subjected to 250 taps per minute. The 
decrements in volume were recorded until no further reduction in volume was observed.[7] 
3.8.4 Compressibility index and Hausner’s ratio 
These parameters measure the susceptibility of a powder to be compressed. As such, they are 
measures of the powder’s ability to settle, and they permit an assessment of the relative 
importance of interparticulate interactions. In a flowing powder, such interactions are less 
significant, and the bulk and tapped densities will be closer in value. For poorer flowing 
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materials, there are frequently greater interparticle interactions, and a greater difference 
between the bulk and tapped densities will be observed. These differences are reflected in the 
compressibility index and the Hausner Ratio.[7] 
3.9 Drug-excipient compatibility studies 
This study was carried out to ensure that the therapeutically active drug lamivudine does not 
undergo changes when combined with the natural polymers. 
Lamivudine and individual natural polymers were mixed in a 1:1 ratio. The blended drug 
samples were stored at room temperature in poly-top vials for a week. FTIR and DSC were 
used to analyse the mixtures for any possible interaction or incompatibility.   
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3.10 Formulation of fast dispersible tablets 
3.10.1 Powder blending 
The individual powders were sieved using sieve No.80 in order to break any agglomerates 
present. Only two excipients were used in this project so as to make the innovative formulation 
as cost effective as possible, and to assess the multipurpose properties of the natural polymers 
i.e. filling, binding, and disintegrating. Several blends of lamivudine with varying 
concentrations of individual natural polymers and magnesium stearate were mixed using a 
tumbler mixer for 30 minutes. The following formulation blends were prepared (Table 3.1).  
Table 3.1: Different formulation blends prepared 
 
* L(lamivudine), B(Banana powder), I(Ispaghula husk powder), M(Magnesium stearate), 
S(superdisintegrant) 
 
 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
L (mg) 150 150 150 150 150 150 150 150 150 150 150 150 
B (mg) 3.06 3.06 8.01 17.04 27.11 46 - - - - - - 
I  (mg) - - - - - - 3.06 3.06 8.01 17.04 27.11 46 
M (mg) - 3.125 3.22 3.41 3.61 4 - 3.125 3.22 3.41 3.61 4 
S % 2 2 5 10 15 23 2 2 5 10 15 23 
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The amount of lamivudine used in the different formulations was constant in order to compare 
the innovative tablets with the branded tablets Aspen Lamivudine® 150 mg. 
This formulation approach was prompted by available literature on the use of natural polymers 
as superdisintegrants in tablet formulations. Naturally sourced superdisintegrants are generally 
used in the range 2-10 % w/w of the total tablet weight.[14] The following formula was designed 
to determine the theoretical tablet weight and the amount of excipients to be added . 
 
 
 
 
 
Ten tablets were compressed for each formulation. The formulation that displayed the best 
attributes in terms of friability, hardness and dispersion time was selected as the optimum 
formulation. Formulation F6 yielded the best tablets. A batch of 60 tablets were made from this 
formulation for further assessment and comparison with Aspen Lamivudine® as per the United 
States Pharmacopoeia recommendations. 
3.10.2 Tableting  
Tablets were compressed using the direct compression method. Direct compression was chosen 
because of its simplicity and cost effectiveness. A manually operated single punch tablet press 
was used. Different compression forces were applied (30, 35, 40, 45, 50 kN). 40 kN was found 
to be ideal in terms of conferring sufficient hardness to the tablets whilst allowing for 
instantaneous disintegration. Concave punches of 8 mm in diameter were used. The punches 
K + (x+y)W = W 
K: mass of Lamivudine 
x: magnesium stearate percentage 
y: superdisintegrant percentage 
W: tablet weight 
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and die were dusted with talc prior to compression. A 0.01 g sensitive electronic scale was used 
to weigh the required amount of powder for each individual tablet. 
3.10.3 Wet granulation  
Granulation is the process by which primary powder particles are made to adhere to form larger, 
multiparticle entities called granules. Wet granulation employs the use of a binder solution to 
improve the properties of the formulation blend in a such way that the granules possess optimal 
properties for tableting. The resulting tablets have desired quality attributes namely 
homogeneity, weight uniformity, hardness and disintegration. [15] 
Wet granulation was carried out in an attempt to improve the compactability of the formulation 
blend and reduce the friability of the final product. Granulation was done manually using a 5% 
starch paste as a binder solution. Lamivudine was mixed with unripe banana powder, few drops 
of the starch paste were added to the powder blend and stirred to form agglomerates. The 
granules were dried in an oven at 50 ºC until constant mass was attained. The required amount 
of magnesium stearate was added to the dried granules and mixed. 
3.11 Evaluation of tablets 
The innovative fast dispersible tablets were evaluated as per the USP recommendations and 
compared to Aspen Lamivudine®. 
General appearance 
An organoleptic evaluation of the tablets was effectuated to determine their overall elegance. 
The following aspects were recorded: shape, colour, odour, surface texture, physical flaws and 
consistency. 
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Tablet diameter 
Ten tablets were randomly selected from the batch. The diameter of each tablet was determined 
using a vernier caliper. The mean of the values obtained was determined. 
Tablet thickness 
The average thickness of the tablets was determined by measuring the thickness of ten 
randomly selected tablets using a vernier caliper. The mean of the values obtained was 
determined 
Weight uniformity 
To determine the weight consistency of the tablets and the deviation from the theoretical 
weight, twenty randomly selected tablets were weighed individually using a 0.001 g sensitive 
scale. The mean weight and standard deviation were determined. 
Friability  
The extent at which the outer layer of a tablet crumbles when subjected to mechanical stress 
was determined using an Erweka friability tester. Twenty tablets were randomly selected from 
the batch and dusted. The tablets were weighed and placed into the drum. The drum was rotated 
100 times and the tablets removed. The tablets were dusted and accurately reweighed. The 
friability percentage was calculated as follows: 
 
 
 
 
F: 100 X (Wi-Wf)/Wi 
Where : 
Wi: Initial weight of tablets 
Wf: Final weight of tablets 
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Hardness  
The hardness of a tablet is defined as the force applied across the diameter of the tablet in order 
to break it. The resilience of a tablet to mechanical stress imparted during handling and storage 
depends on its hardness. The hardness of the tablets was determined using a Schleuniger 
hardness tester. Ten randomly selected tablets were assessed, and the average force in newtons 
required to fracture tablets was calculated. 
Wetting time  
The wetting time of a tablet is related to the contact angle of constituent particles with water. 
The smaller the contact angle, the more favourable particle-water interactions are, and the faster 
tablet wetting occurs. It is paramount to assess the wetting time of a fast dispersible tablet to 
have an insight of its disintegrating properties. Instantaneous wetting brings about prompt 
tablet disintegration. To determine wetting time, a tablet was placed on a double folded piece 
of tissue paper and kept in a small petri dish (10 cm diameter) containing 10 ml of distilled 
water.[16] The time required for complete wetting was measured using a stop watch. The 
experiment was carried out in triplicate and the mean was determined.  
Water absorption ratio 
The extend at which the tablets absorb water prior to disintegrating was determined by placing 
a tablet on a double folded piece of tissue paper in a 10 cm petri dish containing 10 ml of 
distilled water. When complete wetting was attained, the wet tablet was weighed.[16] The 
experiment was carried out in triplicate and the mean was determined. The formula used is 
shown below. 
 
 
R = 100 (Wa-Wb) / Wb 
Wb: Weight of the tablet prior to wetting 
Wa: Weight of the wet tablet 
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In-vitro dispersion  
The time required for the tablets to disperse in distilled water and a 6.8 phosphate buffer 
solution (PBS) at room temperature was determined A petri dish (10 cm diameter) was filled 
with 10 ml of distilled water or 6.8 PBS. The tablet was carefully placed in the centre of the 
petri dish and the time for complete disintegration into fine particles was recorded.[17] 
Disintegration  
Disintegration is the physical process by which a tablet breaks down into small fragments. This 
process is monitored visually and pertains to the physical integrity of the tablet alone. 
Disintegration times were measured in vitro using the standard USP disintegration method for 
uncoated tablets. The test was carried on six randomly selected tablets using an Electrolab 
tablet disintegration tester. Deionised water and a freshly prepared 6.8 PBS at 37±0.5 ºC were 
used as the disintegration media, and the time in seconds taken for complete disintegration of 
the tablets with no palpable mass remaining in the apparatus was recorded.[7] 
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3.12 Drug release studies 
The rate and extent at which the active pharmaceutical ingredient was released from the 
different tablet formulations were determined using the USP dissolution test and a validated 
HPLC method. 
3.12.1 Dissolution 
Dissolution is the process by which the active pharmaceutical ingredient is released from the 
dosage form and dissolves into the liquid assay medium. Dissolution is monitored via chemical 
analysis and provides the approximate time required for full solubilisation of the drug under 
the test conditions 
In vitro dissolution was carried out using the USP paddle method in a Vankel V 700 (220 V) 
dissolution apparatus with temperature control provided by the Vankel VK 650 A 
Heater/Circulator Benchsaver® series. Vessels containing 900 ml of freshly prepared and de-
aerated deionised water (pH 7) was used as a dissolution medium. The setup was maintained 
at 37±0.5 ºC, and a stirring speed of 50 rpm  was applied.  A single tablet was placed in each 
vessel at time 0 minutes to commence the test.  
At predetermined time intervals (10, 20, 30, 40, 50, and 60 minutes), 5 ml aliquots were 
withdrawn from each vessel and immediately replaced with the same volume of pre-warmed 
medium to maintain constant volume and temperature.[7] The aliquots were filtered using 0.45 
µm nylon filters and stored in poly-top glass vials. 
3.12.2 High performance liquid chromatography (HPLC) analysis 
Dissolution aliquots were filtered using 0.2 µm filters, transferred to amber HPLC vials and 
sealed. Samples were analysed using water and methanol in a 70:30 ratio and lamivudine 
concentrations were determined at 275 nm. The drug release profile of the different tablet 
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formulations was determined by plotting the cumulative percentage of drug released in the 
medium against time. 
HPLC conditions  
A Kinetex C18 (150 mm × 4.6 mm, 5μ) column was attached to a Perkin Elmer Flexar™ 
HPLC. This HPLC consists of a solvent manager, LC pump and a PDA UHPLC detector. A 
cleaning programme was run to remove any residue present in the Kinetex C18 column. 
Mobile phase 
The mobile phase consisted of 70 volumes of water and 30 volumes of methanol in isocratic 
mode (70:30 ratio). 
3.12.3 Preparation of a standard stock solution 
A 1 mg/ml standard stock solution of lamivudine was made by accurately weighing  1.07 mg 
of lamivudine in a 1 ml eppendorf tube containing deionised water (pH 7). The solution was 
vortexed for two minutes, filtered using a 0.2 µm filter and transferred to an amber HPLC vial 
and sealed.  
The volume required for each standard concentration was calculated as follows: 
 
 
 
 
 
 
C1V1 = C2V2 
Where: 
C1 = 1070 µg/ml     C2 = x 
V1 = ?                      V2 = 0.5 ml 
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Table 3.2 below presents the different concentrations prepared using the standard stock solution 
Table 3.2: Standard concentrations of lamivudine  
 
 
 
 
 
 
 
 
 
 
 
Concentration (µg/ml) Volume (µl) Medium (µl) Total Volume (µl) 
1. 100 47 453 500 
2. 150 70 430 500 
3. 200 94 406 500 
4. 250 117 383 500 
5. 300 140 360 500 
6. 350 164 336 500 
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Chapter 4 
Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter presents the findings and outcomes of the 
preformulation, formulation and quality control phase of this project. 
The results are presented using tables, figures and graphs. The 
outcome of each analysis is discussed with reference to literature and 
inferences are made.  
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4.1 Identification and characterisation of the natural polymers  
This section presents the results and inferences of the different tests and analyses carried out 
on the natural polymers and their respective extracts for the purpose of identification and 
characterisation. 
4.1.1 Relevant constituents extracted from the natural polymers 
Banana starch 
Unripe banana has a high content of carbohydrates with starch being the main constituent 
accounting for about 60 to 80% on a dry weight basis.[1] The percentage yield of starch obtained 
from unripe bananas of the genus Musa by centrifugation was found to be 77% of the pulverised 
dried pulp. 
Starch is facilely available and is one of the most popular pharmaceutical tablet excipients due 
to its inertness, low cost, and use as binder, disintegrant, filler and glidant.[2] Besides its 
therapeutic and nutritional value, the high starch content of unripe banana powder (UBP) 
suggests its potential usefulness as a multipurpose tablet excipient.[3] 
Arabinoxylan 
Arabinoxylan is a gel-forming polysaccharide which comprises of about 23% arabinose and 
75% xylose on molar basis.[4] The hydrogel with a molar mass of 364,47 g/mol has a high 
swelling capacity in water, hence it can be used as a tablet disintegrant.[5] The high content of 
the hydrophilic hemicellulose arabinoxylan in ispaghula husk powder (IHP) motivated its use 
as a disintegrant in this study. 
3.22 g w/w of arabinoxylan was obtained from 7 g of the whole husk of ispaghula upon freeze-
drying the mucilaginous precipitate obtained from the alkali extract. The 46% yield was rated 
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as good in view of the fact that the hemicellulose arabinoxylan accounts for 45-60% of the 
weight of ispaghula husk.[6]  
The extraction yield of the constituents responsible for the disintegrating effect of the natural 
polymers is presented in Table 4.1 below.  
Table 4.1: Percentage yield of starch and arabinoxylan 
No Polymer Amount used Extract  Mass Percentage yield 
1 UBP 20 g Starch 15.4 g 77% 
2 IHP 7 g Arabinoxylan 3.22 g 46% 
 
 
      
 
 
                                                                                                                         
Figure 4.1: a) alkali extract of arabinoxylan b) arabinoxylan gel coagulated with acetic acid 
The photographs were taken immediately after extraction at room temperature (25 ºC). Figure 
4.1-a shows the extent at which arabinoxylan is solubilised in an NaOH at pH 13. Figure 4.1-
b shows the gelatinous nature of arabinoxylan.  
4.1.2 Organoleptic evaluation of the natural polymers 
Table 4.2 below presents the organoleptic properties of the natural polymers and their 
respective extracts (starch and arabinoxylan).  A pale-yellow powder was obtained from the 
dried pulp of unripe bananas of the genus Musa. This powder was smooth to the touch with a 
A B 
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faint-sweet and floury smell. Starch, a white smooth powder with no distinctive smell was 
obtained by centrifuging a suspension of UBP. 
IHP is a fleecy pale-brown powder, soft and gritty to the touch with a distinctive herby smell. 
No adulterants or foreign matter were found in the powder. Arabinoxylan is a white smooth 
powder with no distinctive smell. However, a faint acetic acid smell could be perceived from 
the sample suggesting the presence of residual acetic acid or sodium acetate. Acetic acid was 
used to coagulate arabinoxylan from its alkali extract. Washing of the extracted gelatinous mass 
with water after extraction might have not been sufficient to remove residual acetic acid and 
sodium acetate. Overall, UBP and IHP had desirable organoleptic properties, hence they had 
no potential to adversely impact the aesthetic appeal of the final product. 
Table 4.2: Organoleptic evaluation of the natural polymers and their respective extracts 
No Property IHP UBP Arabinoxylan Banana starch 
1 Colour Pale brown Pale yellow White White 
2 Odour Herby  Floury  Acetic acid smell No distinct smell 
3 Taste Herby taste Faint sweet No distinct taste No distinct taste 
4 Texture Soft and gritty Soft and smooth Soft and smooth Soft and smooth 
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Figure 4.2: Photographs showing the natural polymers. A) Unripe banana powder B) Ispaghula 
husk powder. Photographs taken at room temperature (25 ºC), immediately after preparing the 
powders. 
4.1.3 Phytochemical analysis 
The qualitative profile of phytoconstituents identified in the natural polymers is presented in 
Table 4.3 below. (+) indicates the presence of a phytoconstituent while (-) indicates the absence 
thereof.  Starch, saponins, phenols, proteins, tannins, lipids, flavonoids and reducing sugars 
were identified in UBP. The phytochemical profile of UBP obtained in this study is in 
concordance with literature.[7]  On the other hand, only saponins were identified in IHP (Figure 
4.3 A-H). 
The phytochemical profile of IHP obtained in this study is contradictory to what literature 
reports. Several studies have shown that the outer coat of Plantago ovata seeds contains sugars, 
sterols, fixed oils, tannins and protein in addition to the mucilaginous polysaccharide 
arabinoxylan.[8] Hence, the results obtained can be classified as “false negative’’. The difficulty 
to qualitatively identify the phytochemicals enumerated above could have been due to the 
formation of a thick hydrogel when Plantago ovata husk powder came in contact with water. 
This gel could have served as an impermeable barrier preventing reagents to come into contact 
with phytochemicals embedded in its matrix. 
 
A B 
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Starch 
Starch is the main component of UBP which accounts to about 60-80 % w/w of the dry pulp. 
The starch content of UBP drastically declines with ripening to less than 1% with sugars 
accumulating to more than 10% of the fresh fruit pulp.[9] Chemically, starch is a polysaccharide 
which is composed of glucose molecules joined together with α-d-(1-4) and/or α-d-(1-6) 
linkages. Amylose and amylopectin are the two main structural components of starch. Amylose 
is a linear slightly branched polymer which constitutes 15-20 % of starch, while amylopectin 
is an extensively branched molecule and is the major component of starch.[10] 
The blue-black colouration observed when UBP was treated with iodine is as a result of the 
formation of an intermolecular charge-transfer complex between starch and the triiode anion. 
This colorimetric method of identifying starch is the basis of iodometry.[11] 
Saponins 
A permanent froth was observed when samples of UBP and IHP were agitated with water, this 
was an indication of the presence of saponins in the analytes. Saponins are a class of plant 
secondary metabolites which form a permanent froth in aqueous media. They include 
compounds that are glycosylated steroids, triterpenoids and steroid alkaloids. Extensive 
research on saponins have shown them to possess antifungal, antiviral, antibacterial, 
anticarcinogenic, hypocholesterolemic and hypoglycaemic properties.[12] 
Phenols, Tannins 
A purplish colouration was observed when an aqueous extract of UBP was treated with ferric 
chloride. This colour change was an indication of the presence of phenols in the sample as 
coloured complex was formed between Fe3+ and the phenolic compounds present such as 
tannins. Phenolic compounds are the largest group of phytochemicals and they possess a wide 
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array of pharmacological activities some of which include antioxidant, anti-inflammatory and 
anti-tumorigenic.[13] 
Proteins 
A purplish colouration was observed when an alkali suspension of UBP was treated with 
CuSo4. This colour change is attributable to the sequential reduction of Cu3+ to Cu1+, when the 
latter binds with nitrogen ions in peptides.[14] Proteins constitute about 3-5% w/w of unripe 
banana pulp. The therapeutic and nutritional benefits of proteins and their building units amino 
acids are well known and have been extensively researched and documented.[15] 
Lipids 
The formation of a cloudy precipitate when water was added to an ethanolic suspension of UBP 
indicated the presence of lipids in the sample. Fats account for less than 2% w/w of UBP.[15] 
Lipids play several roles in the normal functioning of the body some of which include hormone 
production, cell membrane production and energy storage.[16] 
Flavonoids 
Flavonoids are ubiquitous polyphenolic compounds that occur as glucoside, aglycones and 
methylated derivatives. The reddish colouration observed when magnesium and hydrochloric 
acid were added to the ethanolic extract of UBP indicated the presence of flavonoids in the 
sample. Flavonoids are powerful antioxidants and have been reported to possess a myriad of 
pharmacological properties including antitumor, anti-inflammatory as well as antimicrobial 
properties.[17] 
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Monosaccharides 
UBP tested positive for monosaccharides. A green colouration was observed upon adding few 
drops of Benedict’s reagent to a suspension of the analyte which indicated the presence of 
reducing sugars such as glucose. Benedict’s solution is an aqueous alkaline solution of copper 
sulphate and sodium citrate. When reducing sugars are heated in the presence of an alkali, they 
are converted to enediols. Enediols are powerful reducing agents which convert Cu2+ to Cu+1 , 
followed by a red precipitate of Cu2O .[18] The intensity of the precipitate is dependent on the  
concentration of reducing sugars in the sample. A brick red precipitate indicates a high 
concentration of reducing sugars while a green colouration indicates traces of reducing sugars. 
Glucose, fructose and sucrose are the most prevalent sugars found in unripe banana powder 
with glucose being the major contributor. On average, UBP contains between 1-2% w/w of 
sugars depending on the ripening stage of the fruit and the species; this percentage usually 
increases to 15-20% in ripe bananas.[19] 
Steroids 
UBP tested negative for steroids such as cholesterol as no colour change was observed when 
the reagents were added to the analytes. This result is in concordance with literature as several 
studies have found banana to be a cholesterol free fruit.[7] 
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Table 4.3: Phytochemical profile of the natural polymers 
No Phytochemical Banana powder Ispaghula husk powder 
1 Starch + + + - 
2 Saponins + + 
3 Phenols + - 
4 Proteins +  - 
5 Tannins + - 
6 Lipids +  - 
7 Flavonoids + - 
8 Steroids - - 
9 Monosaccharides +  - 
 
Figure 4.3 below presents the different colour changes visualised during the phytochemical 
analysis of unripe banana powder and ispaghula husk powder.       
A) Starch: iodine solution(left), blue black colouration observed in unripe banana powder 
(middle), no colour changed observed in ispaghula husk powder (right) 
B) Saponins: permanent froth observed in both unripe banana powder (left) and ispaghula husk 
powder (right)  
C) Phenols/Tannins: ferric chloride (right), purplish specks observed in unripe banana 
powder(middle), no colour change observed in ispaghula husk powder (right). 
D) Proteins: copper sulphate solution (left), purplish colouration observed in unripe banana 
powder (middle), no colour change observed in ispaghula husk powder (right). 
E) Lipids: cloudy suspension observed in unripe banana powder (left), ispaghula husk powder 
(right) 
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F) Flavonoids:  reddish colouration observed unripe banana powder (left), no colour change 
observed in ispaghula husk powder (right) 
G) Steroids: no colour change observed for both powders. 
H) Monosaccharides: Benedict’s solution (right), copper colouration in ispaghula husk powder 
(middle), greenish colouration observed in unripe banana powder (left). 
                   
               
          
 
Figure 4.3 A-H: Phytochemical tests  
 
A C 
D E 
B 
H 
F 
G 
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4.1.4 Microbiological limit test 
Table 4.4 below presents the average viable count of microorganisms expressed as colony 
forming units (CFU) in tested samples of UBP and IHP. 
Table 4.4: Average CFU/g of microorganisms in incubated samples of the natural polymers 
Microorganism  Unripe banana powder Ispaghula husk powder 
Bacteria  4 x 104 CFU g-1 13 x 104 CFU g-1 
Fungi  No visible growth  No visible growth 
 
The results presented above were calculated as follows  
 
 
 
 
 
 
 
 
 
 
Fungal growth was not observed in any of the tested samples; this suggests that the natural 
polymers do not offer conducive conditions for the growth of yeasts and moulds. Microbial 
Calculations 
 
Concentration of stock solution: 0.1g/ml 
Volume of inoculum: 1 ml 
Dilution factor of inoculum: 10-3 
Average colony forming units (CFU) per plate: Banana (4 CFU), Ispaghula (13 CFU) 
CFU g-1: (Average plate count) x 103 / 0.1g  
Banana: 4 CFU x 103 /0.1g = 40000 or 4 x 104 CFU g-1 
Ispaghula: 13 CFU x 103/0.1 g = 130000 or 13 x 104 CFU g-1 
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growth was observed in the assessed sample of UBP although a preservative was added during 
the preparation thereof. IHP displayed a relatively higher bioburden compared to UBP.  
The USP total aerobic microbial count (TAMC) acceptance criteria for non-sterile non-aqueous 
pharmaceutical products intended for oral administration is 103 CFU/g. The natural polymers 
did not meet this pharmacopoeial requirement. However, there is no set pharmacopoeial limit 
for the bioburden of raw herbal pharmaceutical products.[20]  
Considering the fact that raw herbal materials are intrinsically contaminated, deviations from 
the maximum limit of 103 CFU/g are often allowed provided that the microorganisms present 
are potentially non-pathogenic. The presence of microbes in a pharmaceutical excipient can be 
quite problematic due to health implications and the adverse impact they have on the shelf-life 
and effectiveness of the product. Decontamination and sterilisation techniques can be 
employed to reduce the bioburden of naturally sourced pharmaceutical excipients on the basis 
of a favourable risk/benefit assessment. Some of these techniques include: dry heat, moist heat, 
irradiation, acid/base treatment and preservative addition.[21] 
4.1.5 Swelling capacity 
Table 4.5 presents the swelling index of the natural polymers used as superdisintegrants in this 
study. The results obtained showed that UBP has the ability to swell to more than twice its 
initial volume while IHP had a remarkable 2100 percent volume increase (21 times more). IHP 
formed an extensively gelatinised structure in water while UBP formed a suspension with a 
sediment of coarse particles whilst the fine particles were suspended within the supernatant 
(Figure 4.4). 
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The most common mechanism of tablet disintegration is by disintegrant swelling. The 
dimensional enlargement of disintegrant particles results in an omni-directional force exerted 
on surrounding particles. This force disrupts the cohesive forces that bind particles together 
resulting in the breakdown of the tablet matrix.[22] Although a high swelling index is a sought 
property for tablet disintegration, not all polymers with high swelling capacities are good tablet 
disintegrants because other factors like tablet porosity and gel formation affect the process of 
disintegration. A polymer that becomes gelatinised after swelling will most likely form a gel 
plug which impedes disintegration. The formation of a gel plug is proportional to the amount 
of disintegrant in the tablet, thus such disintegrants are only effective at low concentrations.[23] 
Although IHP displayed an high swelling capacity, a sought property for instantaneous tablet 
disintegration, the polymer may not be used at high concentrations due to the probable 
formation of a gel plug. Conversely, minimal or no gel formation in UBP suggests that the 
polymer can be utilised as a disintegrant over a wider range of concentrations and thus can 
serve as a multipurpose excipient at higher concentrations. 
Table 4.5: Swelling index of the natural polymers 
No Polymer Initial volume Final volume Swelling index 
1 Unripe banana powder 0.53 ml 1.32 ml 2.50 
2 Ispaghula husk powder 0.62 ml 13.27 ml 21.4 
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Figure 4.4: Swollen natural polymers. A) Unripe banana powder (left), ispaghula husk powder 
(right). B) Gelatinised ispaghula husk powder. C) Unripe banana powder paste. Photographs 
taken at room temperature (25 ºC) during the swelling index assessment of the polymers.  
4.1.6 pH 
The pH of aqueous dispersions of the natural polymers are presented in table 4.6 below. Both 
polymers had pH values below 7, which fall within the acidic region of the pH scale. UBP was 
found to be slightly more acidic than IHP.  
The relevance of pH testing in this study was to predict the interaction of the natural polymers 
with salivary secretions. Saliva is a hypotonic fluid which is composed of 99% water and a 
myriad of functional constituents such as electrolytes, proteins, mucins, immunoglobulins, and 
nitrogenous compounds. Saliva is slightly acidic with pH oscillating between 6 and 7.[24] The 
pH values of the natural polymers suggest that they are susceptible to form weak acidic 
solutions in an aqueous medium. Generally, acidic substances are known to elicit a sour taste 
in the mouth thereby causing unpalatability. A correlation exists between sourness and acidity 
i.e. sourness increases with decreasing pH. Also, a decrease in the pH of saliva (≤ 5.5) as result 
of the intake of acidic substances creates a conducive environment for enamel 
demineralisation.[25] However, considering the pH modulating effect of saliva and its buffering 
capacity attributable to the presence of urea, phosphates and bicarbonates, it is unlikely that the 
presence of the natural polymers in the oral cavity will elicit a sour taste.[26] Also, the amount 
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of polymer used in the innovative fast dispersible tablet may not be significant enough to 
decrease the pH of the oral cavity and cause an undesirable mouth feel.  
Table 4.6: pH of the natural polymers 
No Polymer pH value 
1 Unripe banana powder 5.2 
2 Ispaghula husk powder 5.9 
 
4.1.7 Loss on drying 
Table 4.7 presents the moisture content of the natural polymers obtained by desiccation. The 
relevance of this analysis was to evaluate the stability of the natural polymers based on their 
respective water content, as there is a correlation that exists between the stability of botanically 
sourced powders and moisture content. Also, the presence of moisture in a powder can impact 
the flowability and compressibility thereof. The propensity of a powder to flow decreases with 
increasing moisture due to an increase in particle cohesiveness as a result of the formation of 
liquid bridges between individual particles.[27] Adequate moisture in a powder can be beneficial 
in reducing powder adhesion to dies and punches owing to the lubricating properties of 
water.[28]  Interparticulate binding force increases as moisture content increases until a 
saturation point is reached. However, the effect of moisture on the micromeritic properties of 
a powder is highly dependent on the intrinsic nature thereof.[29]  
IHP met pharmacopoeial specifications for moisture content as the USP monograph stipulates 
that the water content of an analysed sample of ispaghula husk should not exceed 12% w/w.[20] 
UBP was found to have a higher moisture content than IHP. Unfortunately, no monograph or 
official specifications for the quality assessment of UBP are available.  
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Desiccation by oven drying is the most common and most feasible method for water analysis. 
This method is based on the loss in mass after drying a sample. This moisture analysis 
technique is however criticisable because other volatile compounds beside water can contribute 
to the loss in mass of the sample. Also, the water content value does not hint at the nature of 
moisture in the sample i.e. whether it is free, bound, inherent or surface moisture.[30] The 
presence of moisture in a naturally sourced powder enhances degradation through microbial 
growth and water dependent biochemical reactions. Consequently, extending the shelf life of a 
powder entails reducing the availability of water for degradation reactions.[31] A high water 
content in a powder is however not absolutely proportional to microbiological activity since 
microorganisms might have restricted access to bound moisture.[30] Besides moisture content, 
water activity i.e. the ratio of the vapour pressure of water in a powder to the water vapour of 
pure water at the same temperature also influences microbial growth. The lower limit water 
activity for all microorganisms is 0.60aw. At low moisture levels fungal growth is inhibited, but 
moisture contents around 14% or above offer conducive conditions for fungal growth.[31]  
In a study to investigate the effect of moisture and packaging on the shelf life of wheat flour, 
the flour sample having 9% moisture content was shown to be adequate with regards to the 
shelf life of wheat flour. Also, storage conditions and the nature of the packaging material were 
found to influence the moisture content of the samples and their microbiological load.[32] It can 
thus be inferred that the moisture content of the natural polymers powders used in this study is 
not potentially detrimental to their integrity and stability. 
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Table 4.7: Percentage loss on drying of the natural polymers  
No Polymer Percentage loss on drying 
1 Unripe banana powder 8.6% 
2 Ispaghula husk powder 7.3% 
 
4.1.8 Thermal analysis 
Hot stage microscopy(HSM) 
Unripe banana powder 
Figure 4.5-A shows hot stage microscopy images of UBP. No physical change was observed 
between room temperature and 99 ºC. At 100 ºC, temperature at which the boiling point of 
water occurs, solvent extrusion and bubbling was observed. This indicated the presence of 
moisture in the sample. The physical aspect of the powder remained unchanged between 100 
ºC and 190 ºC. At 200 ºC, a colour change from pale yellow to light brown was observed.  The 
discolouration steadily intensified from light brown to dark brown due to increased thermal 
degradation of the powder. At 300 ºC, UBP was in an advanced degradation stage suggesting 
that most of its constituents had undergone decomposition. 
Banana starch 
In view of the fact that UBP has a myriad of components, it was fitting to analyse its major 
constituent in order to get a detailed insight of the thermal behaviour of the polymer. Figure 
4.5-B shows hot stage microscopy imageries of starch extracted from UBP. Bubbling was 
observed at 100 ºC indicating the presence of moisture in the sample. As observed with UBP, 
discolouration commenced around 200 ºC and intensified with increased thermal degradation 
of the sample. No noticeable thermal events other than those observed in UBP were visualised 
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in this analysis suggesting that the thermal behaviour of UBP is almost exclusively determined 
by starch. 
Ispaghula husk powder  
Hot stage microscopy images of IHP are shown in figure 4.5-C below. No noticeable change 
was observed between room temperature and 230 ºC. Bubbling due to evolving moisture was 
not evident as with UBP. Discolouration commenced around 200 ºC and intensified with 
increased thermal degradation of the powder. At 300 ºC, ispaghula husk appeared to be highly 
calcined. This suggests that virtually all the constituents of IHP are decomposed around this 
temperature. 
Arabinoxylan 
The thermal behaviour of IHP was further investigated by analysing its major constituent 
arabinoxylan. No noticeable change was visualised between room temperature and 90 ºC. 
Solvent extrusion and bubbling were observed at 100 ºC as shown in figure 4.5-D indicating 
the presence of moisture in the analyte. Partial melting of the powder was observed at 150 ºC. 
Above 150 ºC, the amount of liquid extruding from the powder increased. At 250 ºC, the colour 
of the unmelted portion of the sample changed from white to dark brown suggesting the onset 
of degradative reactions. 
Arabinoxylan is a copolymer which is composed of two monosaccharide sugars of the 
aldopentose kind namely arabinose and xylose.[5] Arabinose and xylose melt around 164 ºC 
and 150 ºC respectively.[33, 34] The partial melting of the powder around 150 ºC  suggests that 
the monosaccharide xylose had melted. The increase in the amount of liquid extruding from 
the sample around 180 ºC shows that both sugars had transitioned from solid to liquid. The 
sugar residues where most probably cleaved from the hemicellulose chain during alkali 
extraction and/or during coagulation with acetic acid. Unmelted crystalline solids lingering in 
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the analyte above 180 ºC hint at the presence of impurities in the sample. These impurities are 
most likely sodium acetate crystals formed during the extraction of arabinoxylan from IHP. 
The hemicellulose arabinoxylan was extracted from IHP using sodium hydroxide and 
coagulated with acetic acid. The formation of sodium acetate as the yield of the reaction 
between sodium hydroxide and acetic acid is depicted in the equation below. 
CH3COOH(aq) + NaOH(aq)                      H2O(l) + NaCH3COO(aq) 
Sodium acetate is a colourless deliquescent salt which melts around 324 ºC.[35] The presence 
of sodium acetate in arabinoxylan shows that the extraction technique used does not yield a 
product of high purity. The dark brown discolouration visualised at 250 ºC can be attributed to 
the caramelisation of arabinose and xylose and decomposing hemicellulose. 
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21ºC 100 ºC 200 ºC 250 ºC 300 ºC 
Figure 4.5-A: HSM images of unripe banana powder 
300 ºC 250 ºC 200 ºC 100 ºC 21 ºC 
Figure 4.5-C: HSM images of ispaghula husk powder 
300 ºC 21 ºC 200 ºC 100 ºC 250 ºC 
Figure 4.5-B: HSM images of banana starch 
21 ºC 100 ºC 180 ºC 150 ºC 250 ºC 
Figure 4.5-D: HSM images of arabinoxylan 
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Differential scanning calorimetry(DSC) 
Unripe banana powder 
The DSC curve of UBP (figure 4.6-A) reveals a shallow endothermic peak at 340 ºC. This can 
be attributed to the decomposition of UBP as observed using HSM. 
Banana starch 
The DSC thermogram of starch extracted from UBP (figure 4.6-B) reveals a shallow 
endothermic peak at 305 ºC. This temperature falls within the range of temperatures at which 
the decomposition of starch occurs.[36] The observations made are in concordance with the 
HSM imageries of banana starch discussed earlier. 
Ispaghula husk powder 
The DSC curve of IHP (figure 4.6-C) reveals a sharp exothermic peak at 310 ºC. This 
temperature falls within the range of temperatures at which the hemicellulose arabinoxylan 
decomposes.[37] The observations made are in concordance with the HSM imageries of IHP. 
Arabinoxylan 
The DSC thermogram of arabinoxylan extracted from IHP (figure 4.6-D) reveals a shallow 
endothermic peak around 160 ºC. This temperature is within the melting range of the 
constituent sugars of arabinoxylan which are arabinose and xylose.[33, 34] This enthalpy change 
confirmed the presence of the aforementioned sugars in the analysed sample. Another shallow 
endothermic peak can be observed around 320 ºC. This might be as the result of the melting of 
residual sodium acetate crystals found in the sample and/or the decomposition of arabinoxylan. 
The observations made are in concordance with the HSM imageries of arabinoxylan discussed  
earlier.  
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Figure 4.6-A: DSC curve of unripe banana powder Figure 4.6-B: DSC curve of banana starch 
Figure 4.6-C: DSC curve of ispaghula husk powder Figure 4.6-D: DSC curve of arabinoxylan 
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Thermogravimetric analysis  
Unripe banana powder 
The TGA thermogram of UBP (figure 4.7-A) reveals a 9.80% (n=3) loss in mass between 20 
and 150 ºC. This mass loss can be attributed to the evolution of moisture and highly volatile 
constituents as observed with the halogen moisture analyser. A 50% loss in mass can be 
observed between 300 and 350 ºC. This degradation step is attributable to the decomposition 
of starch within the powder. Above 350 ºC, the steady mass loss is as a result of the further 
pyrolysis of banana powder into carbonaceous and inorganic residues. These observations are 
in concordance with the HSM and DSC analysis results of UBP.  
Banana starch 
The TGA curve of banana starch (figure 4.7-B) is almost identical to that of UBP. This suggests 
that the thermal properties of UBP are determined by its major constituent starch. A weight 
loss of 9.8% (n=3) can be observed at 150 ºC due to dehydration of the sample. A degradation 
point around 350 ºC can be attributed to the pyrolytic decomposition of starch. These 
observations reaffirm the results of the HSM and DSC analysis of banana starch discussed 
earlier. 
Ispaghula husk powder 
The TGA thermogram of IHP (figure 4.7-C) reveals a 9.7%(n=3) loss in mass at 150 ºC 
attributed to the loss of moisture and highly volatile components. No degradation point can be 
observed around the melting range of the constituent sugars of IHP i.e. 150-160 ºC. This 
suggests that the sugars are highly confined within the fibrous network of ispaghula husk.  The 
degradation point observed around 320 ºC can be attributed to the decomposition of the 
hemicellulose arabinoxylan and cellulose. Further pyrolysis of the sample into carbonaceous 
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and inorganic residues is responsible for the steady mass loss observed above 320 ºC.  These 
observations are in concordance with the HSM and DSC analysis  results. 
Arabinoxylan 
The TGA curve of arabinoxylan (figure 4.7-D) reveals a mass loss of 3%(n=3) at 110 ºC due 
to dehydration of the sample. The subsequent thermal event observed at 160 ºC can be 
attributed to the melting of the constituent sugars of arabinoxylan i.e. arabinose and xylose. 
The degradation point around 325 ºC coincides with the melting point of sodium acetate, thus 
indicating the presence of the salt in the sample. Also, the decomposition of arabinoxylan 
which occurs around this temperature can be attributed to this thermal event. These 
observations reaffirm the results of the HSM and DSC analysis of arabinoxylan. 
 
 
 
 
 
 
 
 
 
 
 
 
0
20
40
60
80
100
120
0 200 400 600
W
ei
gh
t 
(%
)
Temperature (ºC)
 
0
20
40
60
80
100
120
0 200 400 600
W
ei
gh
t 
(%
)
Temperature (ºC)
Figure 4.7-A: TGA curve of unripe banana powder 
 
Figure 4.7-B: TGA curve of banana starch 
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4.1.9 Spectroscopy 
Fourier transform infrared spectroscopy(FTIR) 
 FTIR spectra of the natural polymers and their respective extracts are shown in figure 4.8. 
Table 4.8 provides a list of functional groups found in cellulose and hemicellulose and their 
corresponding wavelengths. Figure 4.9-A and B depicts the chemical structure of the natural 
polymers with annotated key functional groups.   
Unripe banana powder 
The FTIR spectrum of UBP (figure 4.8) reveals a broad peak at 3278.37 cm-1 attributed to the 
vibration of the hydroxyl groups (O-H). The peak observed at 2925.49 cm-1 is as a result of the 
C-H stretching of the constituents of starch, which are amylose and amylopectin. The peak at 
1630.66 cm-1 reveals the presence of water molecules tightly bound within the powder. The 
band at 1076.17 cm-1 is attributable to a complex mode involving the CH2OH side chain of 
amylose.  Stretching modes in amorphous starch present in banana powder are responsible for 
the peak at 1000 cm-1. 
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Figure 4.7-C: TGA curve of ispaghula husk powder Figure 4.7-D: TGA curve of arabinoxylan 
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Banana starch 
The FTIR spectrum of banana starch (figure 4.8) is almost identical to that of UBP with no 
major shift in the peaks. This suggests that starch is the main constituent of UBP. The peaks 
observed on the UBP spectrum at 3278.37 cm-1, 2925.49 cm-1, 1630.66 cm-1, 1076.17 cm-1, 
and 1000 cm-1, can be observed on the banana starch spectrum at 3293.50 cm-1, 2930.34 cm-1, 
1638.23 cm-1, 1076.69 cm-1, and 1000 cm-1 respectively. Signals present at 927.89 cm-1, 859.88 
cm-1, and 762.33 cm-1 are due to β-glycosidic linkages between glucose residues in amylose 
and amylopectin chains. 
Ispaghula husk powder 
The FTIR spectrum of IHP (figure 4.8) reveals the very complex nature of the analyte since 
only few characteristic peaks are present on the spectrum. The band at 3298.91 cm-1 is 
attributed to the stretching of hydroxyl groups (-OH).  Vibration of the C-H group is 
represented by a peak at 2924.41 cm-1. The signal observed at 1635.02 cm-1 is as a result of 
absorbed water since ispaghula husk has a high water affinity. The peak at 1410.97 cm-1 can 
be attributed to the C-H, O-H, or C-O bending vibration of the constituents of ispaghula husk. 
Arabinoxylan 
The FTIR spectrum of arabinoxylan (figure 4.8) reveals more characteristic peaks pertaining 
to hemicelluloses as compared to the spectrum of IHP. The bands present at 3412.30 cm-1, 
3278.07 cm-1, 3164.57 cm-1 can be assigned to the stretching of the hydroxyl groups (-OH). 
The signal present at 1636.97 cm-1 is attributable to the bending mode of bound water 
molecules. Skeletal vibration of C-C and C-O functional groups is responsible for the peaks 
present at 1400 cm-1 and 1339.01 cm-1. The peak present at 1019.57 cm-1 is due to the stretching 
and bending vibration of the C-C, C-O, and C-O-C functional groups found in hemicellulose. 
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Dominant β-glycosidic linkages between monosaccharides units in hemicellulose i.e. xylose 
and arabinose, are responsible for the peaks present at 928.10 cm-1 and 796.41 cm-1. 
Table 4.8: Characteristic of cellulose and hemicellulose in the FTIR fingerprint region[38] 
 
Wavelength (cm-1) Cellulose assignment Hemicellulose assignment 
Anomeric region (950-700 
cm-1) 
A small sharp band 
Dominant β-glycosidic 
linkages between glucose 
residues in cellulose 
Dominant β-glycosidic 
linkages between the 
monosaccharide units in 
hemicellulose  
 
1200-1000 C-C, C-O-C and C-O 
stretching and bending 
vibration 
C-C, C-O-C and C-O 
stretching and bending 
vibration 
1400-1300 CH2 wagging (crystallised 
cellulose I), C-OH in plane 
bending (amorphous 
cellulose), 
CH bending  
C-C and C-O skeletal 
vibration 
1378 C-H ester band due to partial 
acetylation of hydroxyl 
groups 
C-H ester band due to partial 
acetylation of hydroxyl 
groups 
1425 CH2 bending (crystallised I 
and amorphous cellulose) 
C-H and C-O vibration 
in hemicellulose 
1640 Bending mode of absorbed 
water 
Bending mode of absorbed 
water 
1735  C=O stretching of 
unconjugated ketone 
aldehydes and carboxyl 
groups 
2900 – 2800  C-H stretching and CH 
bond deformation of 
CH2-CH3 groups 
3000-2800 Stretching of asymmetric 
and symmetric methyl 
and methylene cellulose 
groups 
 
3600-3400 Stretching of O-H group  
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Figure 4.8: FTIR spectra of the parent powders 
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Purple: C-H group, Blue: β-glycosidic linkage, Green: CH2OH side chain, Red: hydroxyl group 
Figure 4.9-A: chemical structure of the starch polymer amylopectin with annotated key 
functional groups  
 
 
 
 
 
 
 
Purple: C-C group, Green: β-glycosidic bond, Gold: C-O group, Red: hydroxyl group, Blue: 
C-O-C group 
Figure 4.9-B: chemical structure of arabinoxylan with annotated key functional groups  
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4.2 Identification and characterisation of the active ingredient  
The active ingredient lamivudine was identified and characterised by means of thermal and 
spectroscopic tools. The melting point of lamivudine was determined using HSM and DSC, 
while key functional groups of lamivudine were identified using FTIR spectroscopy as 
discussed below.  
4.2.1 Thermal analysis  
Hot stage microscopy   
HSM imageries of lamivudine are shown in figure 4.10. No noticeable change was observed 
in the physical appearance of lamivudine between 21 ºC and 170 ºC. No solvent extrusion or 
evolution of gases were observed; this suggests the absence of moisture in the sample. Melting 
of lamivudine commenced at 170 ºC, and at 180 ºC, complete phase transition of the drug from 
solid to liquid had occurred. It can thus be inferred that the drug powder used in this study was 
of high purity as no other phase transition besides the melting of lamivudine was observed. 
Also, the melting point of lamivudine was found to be around 177 ºC as stipulated by 
literature.[39]  
 
 
 
 
Figure 4.10: HSM images of lamivudine 
 
 
            
21 ºC 100 ºC 160 ºC 170 ºC 180 ºC 
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Differential scanning calorimetry  
The DSC thermogram of lamivudine (figure 4.11) reveals a sharp endothermic peak at 177 ºC. 
This temperature falls within the melting range of lamivudine stipulated by literature, thus 
confirming the purity of the drug sample used in this study.[39] The observations made are in 
concordance with the results obtained in the HSM analysis. 
 
Figure 4.11: DSC thermogram of lamivudine  
4.2.2 Spectroscopy  
Fourier transform infrared spectroscopy 
The FTIR spectrum of pure lamivudine (figure 4.8) reveals a characteristic peak at 1634.93 
cm-1 which can be attributed to the carbonyl group present in the cystidine nucleus. The amino 
and hydroxyl groups present in lamivudine are responsible for the characteristic peaks observed 
at 3324.16 cm-1 and 3195.40 cm-1. Peaks present at 1285.96 cm-1 and 1158.65 cm-1 are 
attributable to the asymmetrical and symmetrical stretching of the C-O-C functional group 
found in the oxathiolane ring of lamivudine.  
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Table 4.9 provides a list of functional groups which can be found in lamivudine and their 
corresponding wavelengths. Figure 4.12 depicts the chemical structure of lamivudine with 
annotated key functional groups 
Table 4.9: Functional groups and their corresponding wavelengths[40 
Wavelength (cm-1) Functional groups Compounds 
3600–3000 OH stretching Acid, methanol 
2860–2970 C–Hn stretching Alkyl, aliphatic 
1700–1730  Aromatic 
1510–1560 C=O stretching Ketone and carbonyl 
1632 C=C Benzene stretching ring 
1613, 1450 C=C stretching Aromatic skeletal mode 
1470–1430  O–CH3 Methoxyl–O–CH3 
1440–1400 OH bending Acid 
1402 CH bending  
1232 C–O–C stretching Aryl-alkyl ether linkage 
1215 C–O stretching Phenol 
1170, 1082 C–O–C stretching vibration Pyranose ring skeletal 
1108 OH association C–OH 
1060 C–O stretching and C–O 
deformation 
C–OH (ethanol) 
700–900 C–H Aromatic hydrogen 
700–400 C–C stretching  
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Blue: hydroxyl group, Green: C-O-C group in oxathiolane ring, Purple: carbonyl group in 
cystidine nucleus, Red: amino group 
Figure 4.12: chemical structure of lamivudine with annotated key functional groups 
4.3 Particle size and morphology analysis 
The particle size and shape of the parent powders were assessed using scanning electron 
microscopy (SEM). The data obtained from this assessment was used to predict key powder 
behaviours as they relate to tabletting properties of the powders.  
4.3.1 Particle morphology analysis 
Unripe banana powder 
SEM micrographs of UBP (figure 4.13-A) below reveal a heterogenous particle population. 
Particles are oval shaped, roughly spherical with a smooth surface morphology. Cohesiveness 
is evident amongst the particles as specks of agglomerates can be observed. 
Ispaghula husk powder 
Figure 4.13-B below shows SEM micrographs of IHP. Particles have an irregular rectangular 
morphology with rough dented surfaces. IHP shows a relatively less varied particle population 
as compared to UBP. Cohesive interactions between particles are restricted and agglomeration 
is not evident.  
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Lamivudine 
SEM micrographs of lamivudine (figure 4.13-C) reveal a heterogenous particle population. The 
photomicrographs show irregular shaped crystalline structures with defined edges and smooth 
surfaces. Interparticulate cohesive interactions and agglomeration are evident. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
    
Figure 4.13-A: SEM images of unripe banana powder 
Figure 4.13-B: SEM images of ispaghula powder 
Figure 4.13-C: SEM images of lamivudine 
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4.3.2 Particle size analysis 
Particle size was determined by measuring the diameter of individual particles i.e. the longest 
axis length, with the assumption that each particle is a sphere. This analysis was carried out to 
assess the correlation between the characteristics of individual particles and powder properties. 
The data obtained was computed into statistical parameters as depicted below (table 4.10 and 
table 4.11) and inferences were made. A cumulative frequency particle size distribution cure 
of the parent powders is shown in figure 4.14. 
Table 4.10: Particle size ranges of the parent powders and their respective frequency 
percentage 
 
Range (µm) Lamivudine Unripe banana powder Ispaghula husk powder 
0 < x ≤ 5 82.4 12.9 3 
5< x ≤ 10 11.6 20.8 5.5 
10 < x ≤ 15 4 17.5 - 
15< x ≤ 20 2 24 11 
20 < x ≤ 40 - 22 14 
40 < x ≤ 60 - 2.8 22 
60 < x ≤ 80 - - 28 
80 < x ≤ 100 - - 11 
100 < x ≤ 120 - - - 
120 < x ≤ 140 - - - 
140 < x < 160 - - 5.5 
 
 
Frequency percentage (%). Sample size (n)= 200 
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Table 4.11: Particle size distribution of the parent powders with statistical parameters 
No Parameter  Lamivudine Banana Ispaghula  
1 Mode 4 µm 20 µm 80 µm 
2 Range 0.5≤ x ≤20 µm  1≤ x ≤50 µm 5≤ x ≤150 µm 
3 Mean particle size 3.9 µm 19 µm 60 µm 
4 Median 2 µm 14 µm 52 µm 
  
 
Figure 4.14: Particle size distribution of the individual parent powders vs cumulative 
percentage 
Unripe banana powder 
The particle size distribution plot of UBP (Figure 4.15) reveals a non-symmetric and positively 
skewed distribution i.e. the measures of central tendency which are mean, median and mode 
do not equate to the same value. The average particle size and the most common particle size 
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recorded were found to be 19 µm and 20 µm, respectively. UBP also had varied particle size 
distribution with particle diameter ranging between a minimum of 1 µm to a maximum of 50 
µm.  
 
 
Figure 4.15: Particle size distribution of unripe banana powder  
 
Ispaghula husk powder 
The particle size distribution graph of IHP (figure 4.16) reveals a positively skewed asymmetric 
curve. Particle diameter ranged between 5 to 150 µm, the mean particle size and modal value 
were found to be 60 and 80 µm, respectively. Amongst the three powders analysed, IHP 
recorded the largest particle size and had a wider particle size distribution range, albeit having 
the least particle diameter variation. 
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Figure 4.16: Particle size distribution of ispaghula husk powder 
 
Lamivudine 
The particle size distribution plot of the active pharmaceutical ingredient is represented in 
figure 4.17 below. The graph reveals an asymmetrical curve heavily skewed to the right.  The 
average particle diameter and the most recurrent particle diameter recorded were 3.9 and 4 µm 
respectively. Particle size ranged from a minimum of 0.5 µm to a maximum of 20 µm. 
Lamivudine exhibited a relatively narrow particle size range compared to the natural polymers 
but had a significantly varied particle size population. 
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Figure 4.17: Particle size distribution of Lamivudine 
4.3.3 Relevance of particle size and morphology in tablet formulation 
The knowledge of particle size and morphology is crucial in tablet preformulation studies as it 
enables the formulator to predict key powder behaviours which include flowability, and 
compressibility. These powder attributes influence the integrity and the characteristics of the 
resultant product considerably.  
Particle size greatly influences powder flowability which in turn affects tablet content 
uniformity. It has been well established that flow-propensity increases with increasing particle 
size owing to gravity. Also, fine particles are less inclined to flow due to substantial adhesion 
forces between the particles which restrict powder motion.[41] Powder compactness increases 
with decreasing particle size due to an increase in interparticulate cohesion. The smaller the 
particle size, the smaller the interstices between the particles.[42] This was visualised on the 
SEM micrographs of the powders (figures 4.13-A,B,C); IHP with a relatively large mean 
particle diameter exhibited poor particle cohesiveness as compared to UBP and lamivudine 
which had relatively smaller particles and displayed significant particulate cohesiveness. 
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Additionally, the overall micromeritic properties of the powder is greatly influenced by its 
uniformity i.e. its particle size distribution.[43]  
A wide particle size distribution is beneficial in formulating a resilient tablet because the fine 
particles fill the voids between the larger particles resulting in a more compact network.[44] 
Table 4.12 below describes the characteristics of various particle size ranges and the impact on 
powder flow. 
Table 4.12: Characteristics of different particle size ranges. Adapted from Axelsson.[45] 
Size range (µm) Component Bulk Characteristic 
3000-30000 Grain/lump Fragmented 
solid 
Free flowing 
100-1000 Granule Granular solid Flows easily with cohesive effect if 
contains high percentage of fines 
10-100 Particle Granular powder May display cohesiveness 
1-10 Particle Superfine 
powder 
Highly cohesive; difficult to handle 
<1 Particle Ultrafine 
powder 
Extremely difficult to handle 
 
Findings pertaining to the effect of particle morphology on powder properties are equivocal, 
and it is bewildering to appraise the role particle morphology plays on powder micromeritics 
without alluding to particle size. The influence of particle morphology on powder attributes 
varies greatly with particle size and distribution of the sample, as such general statements about 
this effect cannot be made. Coarse particles (larger than 0.5mm) which are smooth and 
spherical generally have a higher propensity to flow compared to rough, sharp-edged non-
spherical particles. Markedly rough particles are believed to flow better than smooth particles 
due to restricted interactions between the former. Also, particles with rough surfaces can 
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enhance the compactness of a powder since the presence of dents on the particles enable 
particles to interlock thereby enhancing interparticulate adhesion.[46] 
4.4 Micromeritic properties of the parent powders 
The ability of the powders to settle and the influence of interparticulate interactions on the 
overall properties of the powders were investigated using the recommended USP techniques. 
The results obtained are presented in table 4.13 below. 
Table 4.13: Micromeritic properties of the parent powders 
No Property Banana powder Ispaghula husk powder Lamivudine 
1 Angle of repose (º) 34.3 31.2 38.6 
2 Bulk density (g/cm3) 0.53 0.62 0.47 
3 Tapped density (g/cm3)  0.81 0.77 0.76 
4 Compressibility index (%) 34.0 19.4 36.0 
5 Hausner ratio 1.53 1.24 1.62 
  
Table 4.14 below depicts the relationship between the micromeritic properties of a powder and 
its propensity to flow. 
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Table 4.14: The relationship between angle of repose, compressibility index, Hausner ratio 
and flowability. Adapted from Carr.[47] 
Flow character Compressibility index (%) Hausner ratio Angle of repose (º) 
Excellent ≤10 1.00-1.11 25-30 
Good 11-15 1.12-1.18 31-35 
Fair 16-20 1.19-1.25 36-40 
Passable 21-25 1.26-1.34 41-45 
Poor 26-31 1.35-1.45 46-55 
Very poor 32-37 1.46-1.59 56-65 
Extremely poor ˃38 ˃1.60 ˃60 
 
4.4.1 Angle of repose 
This property is related to interparticulate friction or motion resistance between particles. 
Despite having several drawbacks (e.g. varying results), this technique continues to be used in 
the pharmaceutical industry as a valuable tool for assessing powder flowability and predicting 
manufacturing setbacks.[20] As anticipated, IHP displayed the smallest angle of repose while 
lamivudine powder recorded the largest angle. Based on their respective settling geometries, 
the flowability of IHP and UBP was rated as good while that of lamivudine powder was rated 
as fair. These results suggest that the angle of repose is inversely proportional to particle size. 
The greater the particle size, the smaller the angle of repose. Nevertheless, other factors such 
as particle size distribution, particle morphology, particle surface morphology, interparticulate 
cohesiveness and the presence of solvents also influence the geometry of a settling powder.[48] 
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4.4.2 Compressibility index 
This is one of the most accepted and straightforward techniques of assessing the propensity of 
a powder to flow. This technique has been proposed as an indirect measure of bulk density, 
particle size and morphology, moisture content, surface area and interparticulate cohesiveness 
of powders as these factors can influence the observed compressibility index.[20]  IHP displayed 
the lowest compressibility index amongst the three powders. The percentage compressibility 
index of IHP corresponds to a fair flow character while the values obtained for UBP and 
lamivudine correspond to a very poor flow character. These results suggest that the 
interparticulate interactions which restrict powder flow are less pronounced in IHP compared 
to dehydrated banana powder and lamivudine. Since flowability is an indication of the 
compressibility of a powder, it can be deduced that IHP has a relatively high propensity to 
compression as compared to UBP and lamivudine.  
4.4.3 Hausner ratio  
Although not an absolute property of a material, Hausner’s ratio provides an indication of the 
flowability of a powder and hence its compressibility. This value depicts the relationship 
between the tapped density of a powder and its bulk density. In a free-flowing powder where 
interparticulate interactions are relatively less pronounced, the difference between tapped 
density and bulk density is minimal. The reverse is true for powders with considerable 
interparticulate interactions, a significant difference between tapped density and bulk density 
can be observed.[20]  The difference between the tapped and bulk densities of IHP was relatively 
minimal compared to UBP and lamivudine. The Hausner’s ratio of IHP was rated as fair in 
terms of flow behaviour while the values obtained for UBP and lamivudine were rated as very 
poor and extremely poor, respectively. 
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Overall, IHP displayed satisfactory micromeritic properties suggesting that it is a suitable 
candidate for direct compression. The results obtained for UBP and lamivudine were not 
satisfactory and therefore they may not be good candidates for direct compression. However, 
literature reports that powders with very unsatisfactory micromeritic properties can be 
successfully formulated into tablets by direct compression using suitable flow aids and binders, 
or by employing granulation.[49] The poor micromeritic properties of UBP and lamivudine 
indicates the presence of strong interparticulate cohesive forces which restrict powder flow and 
hence decreases their propensity to be compressed. The trend observed in this study indicates 
that flowability increases with increasing particle size. IHP with the largest particle sizes 
displayed the best flow characteristics while lamivudine with the smallest particle sizes 
displayed the worst flow characteristics. The values obtained from the three different flow 
assessment techniques used were in concordance with each other suggesting that this study 
provides a detailed assessment of the fundamental and derived properties of the powders. 
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4.5 Drug-excipient compatibility studies 
4.5.1 Differential scanning calorimetry (DSC) 
DSC is highly preferred over other conventional techniques for the detection of 
incompatibilities between drugs and excipients in the preformulation phase since it requires a 
small amount of sample, and the analysis can be carried out in a short period of time.[50] Also, 
DSC enables the formulator to predict potential issues that may arise with the use of a particular 
excipient (e.g. reducing the potency and shelf-life of the drug by forming complexes with the 
active pharmaceutical ingredient), thus, the excipient can be rejected or substituted at an early 
stage of product formulation.[51] 
 It is presumed that the thermal properties of the blend (enthalpy change, melting point, etc.) is 
the sum of the thermal properties of the individual components should the components be 
compatible with each other.[50] An absence or a significant shift in the melting point of a 
component, appearance of new peaks and/or variation in enthalpies are indications of 
incompatibilities. Despite the fact that DSC is a highly beneficial and reliable technique, 
confusion may arise, as such, careful interpretation of the results and/or the use of non-thermal 
techniques for comparison is highly recommended.[51]  
The DSC thermograms of individual components were compared to thermograms obtained 
from 1:1 physical mixtures of the active pharmaceutical ingredient and the natural polymers.  
The lamivudine + UBP DSC thermogram (figure 4.16-A) reveals an endothermic peak at 177 
ºC, which coincides with the melting point of lamivudine. Consequently, it can be inferred that 
lamivudine remained unchanged within the mixture. Also, no new peaks can be observed on 
the curve suggesting that no incompatibility arose. However, no peak can be observed around 
300 ºC, the temperature at which UBP is expected to decompose. The absence of a peak around 
this temperature might be due to the complex nature of UBP.  
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An endothermic peak can be seen at the melting point of lamivudine (177 ºC) on the lamivudine 
+ IHP DSC curve (figure 4.16-A). A very shallow endothermic peak can be observed around 
320 ºC, attributable to the decomposition of hemicellulose. No new peaks or shift in enthalpy 
can be observed on the thermogram. Consequently, it can be deduced that no incompatibilities 
arose from the mixture of lamivudine and IHP. 
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Figure 4.18-A DSC thermogram of lamivudine + 
unripe banana powder 
Figure 4.18-B: DSC thermogram of lamivudine + 
ispaghula husk powder 
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4.5.2 Fourier transform infrared spectroscopy (FTIR) 
This spectroscopic technique is sensitive to the structure and environment of organic 
compounds. Besides providing invaluable information on the solid-state behaviour of active 
pharmaceutical ingredients and their formulations, FTIR can be used as a compatibility 
screening tool since the vibrational changes serve as indicators of potential intermolecular 
interactions among the components of a formulation. Pharmaceutical interactions that results 
in dehydration, polymorphic changes, hydrate formation, desalting or transformation of 
amorphous to crystalline and vice versa during formulation can be detected using this tool. The 
presence of overlapping peaks on the spectra is however a major setback in this analysis.[52,53] 
Lamivudine + unripe banana powder 
No major shift in peaks of pure lamivudine was observed on the FTIR spectrum of combined 
lamivudine and UBP (Figure 4.17). The characteristic peak corresponding to the carbonyl 
group of the cystidine nucleus of lamivudine observed at 1634.93 cm-1 on the pure drug 
spectrum can be observed at 1635.85 cm-1 on the drug-excipient spectrum. The amino and 
hydroxyl functional groups signalled at 3195.40 cm-1 on the pure drug spectrum are presented 
at 3197.04 cm-1 on the drug-excipient spectrum. Asymmetrical and symmetrical stretching of 
the C-O-C functional group found in the oxathiolane ring of lamivudine which can be seen at 
1285.96 cm-1 and 1158.65 cm-1 on the pure drug spectrum, is presented at 1286.13 cm-1 and 
1157.48 cm-1 on the combined spectrum. It can thus be deduced that no incompatibilities exist 
between lamivudine and UBP since no major vibrational changes were observed on the 
combined spectrum. 
Lamivudine + ispaghula husk powder  
No major shift in peaks of pure lamivudine was observed on the FTIR spectrum of combined 
lamivudine and IHP (figure 4.19). The characteristic peak corresponding to the carbonyl group 
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of the cystidine nucleus of lamivudine observed at 1634.93 cm-1 on the pure drug spectrum can 
be observed at 1633.99 cm-1 on the drug-excipient spectrum. The amino and hydroxyl 
functional groups signalled at 3324.16 cm-1 and 3195.40 cm-1 on the pure drug spectrum are 
presented at 3325.19 cm-1 and 3197.21 cm-1 on the drug-excipient spectrum. Asymmetrical 
and symmetrical stretching of the C-O-C functional group found in the oxathiolane ring of 
lamivudine which can be seen at 1285.96 cm-1 and 1158.65 cm-1 on the pure drug spectrum, is 
presented at 1285.92 cm-1 and 1158.82 cm-1 on the combined spectrum. It can thus be deduced 
that no incompatibilities exist between lamivudine and IHP since no major vibrational changes 
were observed on the combined spectrum. 
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Figure 4.19: FTIR spectra of 1:1 mixtures of lamivudine and the natural polymers 
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4.6 Tableting 
4.6.1 Powder blending 
The active pharmaceutical ingredient lamivudine was blended with varying concentrations of 
the natural polymers. Magnesium stearate was added to the powder blends to enhance 
flowability. In an attempt to make the innovative product as cost effective as possible, no other 
excipient was used in this study. This approach highlights the uniqueness of this project since 
the use of the natural polymers as multipurpose excipients was investigated.   
Compression 
Twelve different powder blends were formulated and a batch of ten tablets was compressed for 
each formulation using different compression forces. The different formulations used are 
shown in table 4.15 below. The tablets were assessed for friability, resistance to crush and in-
vitro dispersion time. The formulation which yielded the best product i.e. the optimum 
formulation was retained and upscaled.  
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Table 4.15: Different formulation blends prepared 
 
* L(lamivudine), B(Banana powder), I( Ispaghula husk powder), M(Magnesium stearate), 
S(superdisintegrant) 
Formulation F1 
This powder blend could not be compressed into a solid mass at any of the employed 
compression forces.  
Formulation F2 
A solid mass was obtained when compressed at 50 kN. The resultant tablet was very brittle and 
crumbled in the friabilator. The average crushing strength and dispersion time recorded was 
5N and 10±3 seconds respectively. 
Formulation F3 
No significant improvement was observed with this formulation. The tablets compressed at 50 
kN were slightly more resilient than the tablets compressed with the F2 formulation blend. 
Capping was observed, and the tablets crumbled in the friabilator within 5 revolutions. 
 F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
L (mg) 150 150 150 150 150 150 150 150 150 150 150 150 
B (mg) 3.06 3.06 8.01 17.04 27.11 46 - - - - - - 
I  (mg) - - - - - - 3.06 3.06 8.01 17.04 27.11 46 
M (mg) - 3.125 3.22 3.41 3.61 4 - 3.125 3.22 3.41 3.61 4 
S % 2 2 5 10 15 23 2 2 5 10 15 23 
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Complete dispersion in water at 25 ºC occurred within 15±2 seconds. The highest crushing 
force observed was 7 N. 
Formulation F4 
Considerable improvement was observed with this formulation. The powder blend was 
compressed into a solid mass at 40, 45, and 50 kN. The most resilient tablets were obtained at 
50 kN. The tablets were brittle and fragmented during the friability assessment within 5 
revolutions. The highest crushing force observed was 17 N and dispersion in water occurred 
within 13±1 sec. 
Formulation F5 
The powder blend was compressed into a solid mass at 35 kN, the resultant tablet crumbled at 
the touch. Tablets with an average crushing strength of 25 N and a dispersion time of 25±2 sec 
were obtained at 40 kN. These tablets were fragmented during the friability test. Virtually all 
the tablets compressed at 45 kN and 50 kN were capped. 
Formulation F6 
As observed with formulation F5, the incidence of capping was high at the compression forces 
of 45 kN and 50 kN. The tablets compressed at 40 kN had an average crushing strength of 40±5 
N and dispersion in water occurred within 45±3 seconds. A loss in mass of 18 % was recorded 
during the friability test. 
Formulation F7 
This powder blend could not be compressed into a solid mass at any of the employed 
compression forces.  
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Formulation F8 
No improvement observed with this compression. No solid mass was obtained at any of the 
employed compression forces.  
Formulation F9 
Considerable improvement was observed with this formulation. Tablets were successfully 
compressed at 40, 45 and 50 kN. Compression forces 40 and 45 kN yielded very brittle tablets 
which crumbled at the touch. Relatively more resilient tablets were obtained at 50 kN with an 
average crushing strength of 10 N. The average dispersion time recorded was 20±2 seconds. 
Formulation F10 
A high incidence of capping was observed at 50 kN.  Tablets with an average crushing strength 
of 15 N and an average dispersion time of 15±1 seconds were obtained at 40 kN. The tablets 
obtained at 35 kN were brittle and crumbled at the touch.  
Formulation F11 
An increase in crushing strength and dispersion time was observed with this formulation. The 
incidence of capping was high at 45 and 50 kN. Tablets with an average crushing strength of 
18 N and an average dispersion time of 85±10 seconds were obtained at 40 kN. The tablets 
became tacky when in contact with water and constant agitation was needed for complete 
disintegration.  
Formulation F12 
Tablets compressed at 40 kN showed improved crushing strength and an increase in dispersion 
time as compared to the tablets compressed with the F11 formulation blend. A thick gelatinised 
mass was formed when the tablets were in contact with water consequently, vigorous agitation 
was required to completely disintegrate the tablets. The average crushing strength and 
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dispersion time recorded were 25 N and 165 ±20 seconds, respectively. The tablets were 
cleaved in the friabilator within 10 revolutions.  
Observations  
Using the natural polymers as multipurpose excipients in the different formulations made it 
impossible to assess their disintegrating properties below concentrations of 5% w/w since their 
binding effect was made manifest above this concentration. Owing to the poor compressibility 
of lamivudine, the properties of the tablets were highly dependent on the amount of natural 
polymer in the formulation blend. An equilibrium had to be reached between compression force 
and the percentage of superdisintegrant in the tablet since these two variables influenced tablet 
crushing strength and dispersion time. An increase in compression force led to an increase in 
crushing strength and an increase in the incidence of capping at higher compression forces. 
Tablets formulated with lower percentages of superdisintegrant were relatively more brittle as 
compared to tablets containing higher percentages. This suggests that the binding effect of the 
natural polymers increases with increasing concentrations. Also, an increase in the amount of 
superdisintegrant in the tablet led to a decrease in dispersion time up to a saturation point where 
dispersion time begun to increase. This correlation is depicted in figure 4.20 below. 
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Figure 4.20: A plot of dispersion time against superdisintegrant percentage  
 
Although it was clearly shown that the natural polymers used in this study possess substantial 
disintegrating properties, it was quite challenging to accurately quantify their disintegrating 
effect. In the case of UBP, formulation F2 which contained the least amount of 
superdisintegrant unexpectedly displayed the shortest in-vitro dispersion time. However, the 
tablets with the least amount of superdisintegrant were the most friable and displayed the 
lowest resistance to crush. This indicates that the tablets containing the lowest amount of 
superdisintegrant were relatively more porous due to their relatively low binding strength. 
Literature reports that porosity enhances tablet disintegration owing to the presence of loose 
interstices which allow the free circulation of water in and out of the tablet matrix.[54] 
Consequently, dealing with three different variables i.e. porosity, superdisintegrant 
concentration and tablet hardness which considerably influence tablet dispersion time rendered 
the task of assessing the disintegrating effect of the natural polymers strenuous. It would have 
been fitting to make use of a multipurpose tablet excipient such as mannitol in order to gain a 
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detailed insight of the disintegrating properties of the natural polymers over a wide range of 
concentrations. However, the use of another tablet excipient in this formulation would have 
defied the purpose of this study since the aim was to formulate a tablet at minimal cost with 
the least possible excipients. Also, the natural polymers were selected on the basis that they 
would play several roles in the formulation blends i.e. disintegration, binding and filling.  
Although IHP proved to have better swelling properties than UBP which is an indication of 
superior disintegrating properties, it was shown that IHP cannot serve as a superdisintegrant at 
concentrations greater than 10% w/w due to the formation of a highly gelatinised structure 
which incumbers tablet disintegration by obstructing water permeation. Also, UBP was shown 
to display better binding properties than IHP and thus can serve as a superdisintegrant over a 
wider range of concentrations. Tablets compressed using formulation F6 at 40 kN yielded the 
best product, as such this formulation was retained as the optimum formulation.  
 
 
 
 
 
 
 
 
 
 
http://etd.uwc.ac.za/
168 
 
4.7 Optimum formulation 
Formulation F6 was retained as the optimum formulation. The master formula is presented 
below. 
Master formula 
 
 
 
 
 
 
 
The master formula was upscaled and a batch of 60 tablets was compressed. The working 
formula is presented in the table below. 
Table 4.16: Working formula of the optimum formulation  
 
Ingredient Master formula Working formula 5 % excess Final amount 
Lamivudine 150 mg 9000 mg 450 mg 9600 mg 
Banana 46 mg 2760 mg 138 mg 2944 mg 
Mg stearate 4 mg 240 mg 12 mg 256 mg 
     Total  12.8 g 
 
 
Lamivudine 150 mg tablet 
                                                                                                    
Lamivudine……………………………………. 150 mg            
Unripe banana powder………………………… 46 mg   
Magnesium stearate……………….…………… 4 mg 
Talc …………………………………….………  qs 
Theoretical weight……………………………… 200 mg 
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4.7.1 Micromeritic properties of the optimum formulation 
The micromeritic properties of the optimum formulation blend were determined and the results 
obtained are displayed in table 4.17 below. Lamivudine was blended with UBP and the flow 
properties of the powder blend were assessed. Subsequently, magnesium stearate was added to 
the powder blend and the micromeritics properties of the final mixture were determined. 
Table 4.17: Micromeritic properties of the optimum formulation blend 
Property Lamivudine +Banana  Lamivudine + Banana + Mg stearate 
Angle of repose (º) 51 31 
Bulk density (g/cm3) 0.53 0.70 
Tapped density (g/cm3) 0.90 0.98 
Carr’s index 41.6 27.8 
Hausner’s ratio 1.7 1.4 
 
Although the amount of powder used for this assessment was smaller than the recommended 
amount (30 g)[20] because of the limited amount of the active ingredient available, the results 
obtained nevertheless gave the formulator a general overview of the tabletting properties of the 
optimum formulation blend. The role of magnesium stearate as a flow enhancer was appraised. 
The lamivudine and UBP blend displayed a very poor flow propensity overall, inferior to the 
flow properties of the individual powders. The addition of magnesium stearate drastically 
improved the flow properties of the formulation. A good settling geometry was noted although 
the compressibility index and Hausner ratio remained poor.  
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4.7.2 Compression 
The optimum formulation blend was compressed using four different compression forces. 40 
kN was found to be ideal in terms of conferring sufficient resilience to the tablet and allowing 
for rapid tablet disintegration. A high incidence of capping was observed when compression 
forces above 40 kN were employed. Compression forces below 40 kN yielded brittle and less 
robust tablets. UBP was found to possess good tablet binding properties, a correlation was 
observed between tablet crushing strength and the amount of UBP in the tablet. Tablets with a 
higher concentration of dehydrated powder were found to be more resilient at any given 
compression force.  This correlation is shown in figure below 4.21. 
 
Figure 4.21: Plot of resistance to crush against superdisintegrant percentage 
A fairly linear relationship was observed between tablet crushing strength and 
superdisintegrant percentage.  
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4.7.3 Wet granulation  
Attaining a low friability percentage was a major challenge in this study, the average 
percentage mass loss recorded when the tablets were subjected to the friability test was 18%. 
This value exceeds by far the USP maximum friability limit of 1%.[20] Wet granulation was 
employed in an attempt to render the product less friable. Enough powder to compress 60 
tablets was granulated. The procedure employed is shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lamivudine was blended with 
unripe banana powder for 30 
minutes. 
Few drops of a 5% starch 
suspension were added to the 
powder blend as a granulating 
solution. The mixture was 
granulated manually in a mortar. 
Magnesium stearate was added 
to the dried granules and the 
granules were agitated to evenly 
spread the flow aid. Tablets were 
compressed individually using a 
single punch tablet press. 
The granules were dried in a 
convection oven until constant 
mass was achieved for a 
substantial amount of time. 
Theoretical granules weight:      12.544 g 
Granules weight post drying:     12.167 g 
Mass of Mg stearate added:        0.2483 g 
Final weight:                               12.42 g 
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4.8 Quality assessment of the innovative and branded tablets 
The innovative tablets were evaluated as per the USP specifications and compared to a brand 
available on the South African market. 
4.8.1 Organoleptic evaluation 
Sensory appraisal of the tablets was effectuated to determine their overall aesthetic appeal. The 
results obtained are displayed in table 4.18 below and the tablets are shown in figure 4.22. 
Table 4.18: Organoleptic properties of the innovative and branded tablets 
No Property Innovative tablets Branded tablets 
1 Shape Round Rhomboid 
2 Colour Greyish-white Creamy white 
3 Odour No distinct odour No distinct odour  
4 Surface texture Smooth Smooth  
 
The tablets had an overall satisfactory physical appearance. No flaws or inconsistencies were 
detected on the tablets, and no repulsive odour was perceived.  
 
 
 
 
 
 
Figure 4.22: Photographs of the assessed tablets. A) Innovative B) Branded 
  
 A B 
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4.8.2 Tablet mensuration  
Metric assessment of the tablet was effectuated, and the results obtained are presented in table 
4.19 below. 
Table 4.19: Mensuration of the innovative and branded tablets 
No Property Innovative tablets Branded tablets 
1 Diameter (mm) 8 14 
2 Thickness (mm) 3 4 
3 Average weight (mg) 215.0 333.33 
 
Tablet size 
The branded tablets were found to have a relatively larger diameter and thickness than the 
innovative tablets. This is evident considering the significant difference in mass between the 
branded tablets and the innovative tablets. Also, the trapezoidal shape of the branded tablets 
accounts for their larger size, since the longest axis length was recorded as the diameter. A 
smaller tablet size is beneficial for the manufacturer because relatively small packaging and 
less storage space are required.[55] Fast dispersible tablets designed with minimal ingredients 
are not only cost effective but are patient friendly since the amount of residual tablet fragments 
in the mouth which can cause poor mouth feel is considerably reduced.[56]  
Weight uniformity  
To assess the weight uniformity of the branded and the innovative tablets, the standard weight 
deviation from the mean weight of 20 tablets was calculated and expressed as a percentage. 
The results obtained are presented in table 4.20 below. 
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Table 4.20: Standard deviation from mean tablet weight 
Parameter Innovative tablets Branded 
Average tablet weight (g) 0.215 0.333 
Standard deviation 0.0154 0.0091 
% Standard deviation 7.2 2.7 
 
The USP specifies that the percentage deviation from the mean tablet weight should not exceed 
7.5% for tablets weighing between 80 and 250 mg, and 5% for tablets weighing more than 250 
mg.[19] Although both the branded tablets and the innovative tablets met the USP prerequisites 
in their respective categories, the comparator displayed superior weight uniformity. This 
assessment is very crucial in ensuring the uniformity of the active pharmaceutical ingredient in 
the final product especially for drugs which have a narrow therapeutic index. This is also a 
reflection of the uniformity of the powder blend and the level of accuracy with which powders 
were weighed for individual tablets. 
4.8.3 Friability  
The percentage friability of the branded tablets and the innovative tablets (directly compressed 
and wet granulated) was determined and the results obtained are presented in table 4.21 below. 
The USP stipulates that the percentage loss in mass for a conventional tablet should not exceed 
1% of the mean tablet weight.[20] The branded tablets met pharmacopoeial specifications with 
a 0.13% mass loss. Both the directly compressed and the wet granulated innovative tablets did 
not meet pharmacopoeial requirements. The directly compressed tablets displayed an 
extremely high friability of 18% while a mass loss of 2.1% was recorded for the wet granulated 
innovative tablets. Although the USP does not provide specific requirements for the friability 
assessment of fast dispersible tablets, a 2% mass loss is an acceptable friability percentage for 
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a fast dispersible tablet given that FDTs are manufactured to be more porous and less resilient 
than conventional tablets to allow for rapid tablet disintegration.[57] Consequently, adequate 
packaging should be used in order to minimise mechanical damage to the tablets. The drastic 
improvement observed with the wet granulated innovative tablets suggests that wet granulation 
was effective in optimising the directly compressed tablets thus yielding a more satisfactory 
product.  
Table 4.21: Percentage friability of the branded and innovative tablets 
Parameter Branded tablets Innovative (DC*) Innovative (WG*) 
Initial weight (g) 6.660 4.420 4.294 
Final weight (g) 6.651 3.182 4.203 
Percentage loss (%) 0.13 18 2.1 
*DC: directly compressed, WG: wet granulated 
4.8.4 Hardness 
The robustness of the branded and innovative tablets was assessed by measuring the resistance 
to crush or the force in Newtons required to cleave or fragment a single tablet. Tablets need a 
certain amount of resilience to be able to withstand mechanical stress during manufacturing 
handling, packaging, transportation and storage. Twenty randomly selected tablets were 
assessed from the three formulations and the average crushing force was calculated. Generally, 
a crushing strength between 40 to 80 Newtons is acceptable for uncoated tablets.[20] As 
anticipated, the branded tablets were found to be the most resilient with an average crushing 
strength of 106.3 Newtons (table 4.22). Considering the difference in mass between the 
branded tablets and the innovative tablets, and the fact that conventional swallow tablets are 
generally more robust than fast dispersible tablets, it is admissible for the branded tablets to 
display a greater resistance to crush. Additionally, the larger diameter of the comparator also 
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contributes to its greater resistance to crush since larger tablets require a greater force to cause 
fracture.[58] 
Surprisingly, the directly compressed innovative tablets inexplicably displayed a greater 
resistance to crush than the wet granulated innovative tablets although the former was 
extremely friable. The directly compressed innovative tablets had an average resistance to 
crush of 40.3 Newtons while the wet granulated tablets had an average resistance to crush of 
20.7 Newtons. This was quite perplexing because wet granulation generally yields more robust 
tablets than direct compression for the same powder blend.[59] However, resistance to crush is 
not an absolute indication of tablet strength, since some powder blends when compressed into 
hard tablets tend to cap on attrition losing their upper portions.[60] This is the plausible 
explanation to the low resistance to crush displayed by the wet granulated tablets since most 
tablets fractured by capping when subjected to the hardness test. Also, monthly assessments of 
the wet granulated innovative tablets did not reveal any significant increase in friability or 
reduction in resistance to crush whereas the directly compressed innovative tablets were found 
to be completely fragmented within two months of storage in an airtight container with a 
desiccating agent. This suggests that for a poorly compressible powder blend, wet granulation 
is essential in producing a relatively more resilient and long-lasting product. 
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Table 4.22: Crushing strength of the comparator and innovative tablets in Newtons 
Number Branded Innovative (DC*) Innovative(WG*) 
1 108 39 15 
2 88 49 20 
3 113 41 25 
4 79 32 20 
5 108 28 18 
6 118 39 24 
7 111 47 17 
8 134  39 21 
9 96  50 23 
10 108  39 24 
Mean 106.3  40.3 20.7 
*DC: directly compressed, WG: wet granulated 
4.8.5 Wetting time  
The amount of time required for complete wetting of the different tablets is presented in table 
4.23. The directly compressed innovative tablets achieved complete wetting within 10±2 
seconds while an average wetting time of 13±2 seconds was recorded for the wet granulated 
innovative tablets. The branded tablets achieved complete wetting within 660±90 seconds. This 
assessment is however trivial for conventional tablets which are meant to be swallowed.  In 
view of the results obtained for the innovative tablets, it can be deduced that UBP possesses 
outstanding wetting properties and hence good disintegrating properties.  
Wetting is the ability of a liquid to remain in contact with a solid surface as a result of 
intermolecular interactions when the two surfaces come into contact.[61] Wetting time is 
dependent on the wettability of a solid i.e. the ability of a solid surface to reduce the surface 
tension of a liquid in contact with it in such a way that it spreads over the solid surface and 
adheres to it.  Wettability is influenced by particle shape and morphology, hydrophilicity and 
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the contact angle between water and individual particles.[62] Generally, rough and round 
particles tend to be less hydrophobic than smooth and elongated particles, hence they display 
superior wetting properties.[63] Materials which are intrinsically hydrophilic tend to display 
superior wetting properties compared to hydrophobic materials due to favourable interactions 
with water molecules.[64] The angle of contact between water molecules and individual particles 
quantifies the wettability of a solid surface via Young’s equation as shown in figure 4.23. 
 
 
 
 
 
 
 
Figure 4.23: Young’s equation and contact angle 
Wettability increases with decreasing contact angle. A contact angle below 90º is favourable 
for wetting and indicates that water will spread over the surface considerably while a contact 
angle above 90º is an indication of poor wetting and minimal contact of the surface with 
water.[65] 
Although the wetting time of a fast dispersible tablet is greatly determined by the wetting 
properties of the superdisintegrant, the wetting properties of the other constituents will also 
affect the time required for complete wetting.[54] The presence of hydrophobic constituents can 
increase the time required for complete tablet wetting by restricting surface interactions with 
Young’s equation 
ɣsv= ɣsl + ɣlvcosθ 
Where 
θ is the contact angle  
ɣsv is the solid surface free energy 
ɣsl is the solid/liquid interfacial free energy 
ɣlv is the liquid surface free energy  
 
Depiction of contact angle 
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water. In the case of the innovative tablets, the presence of magnesium stearate could have 
delayed complete wetting of the tablets by restricting interactions with water molecules due to 
its hydrophobic nature.[66] However, considering the percentage of magnesium stearate used, 
the effect of such hydrophobic restrictions would have been inconsequential.  
4.8.6 Water absorption ratio 
This test assesses the water uptake behaviour of fast dispersible tablets. It is an indication of 
the efficiency of a superdisintegrant within the tablet matrix i.e. the swiftness at which a 
superdisintegrant draws water into the tablet matrix to create sufficient pressure to facilitate 
disintegration.[67] The average water absorption ratio of the directly compressed and wet 
granulated formulations was found to be 112±7 and 105±4, respectively. These results were 
deemed satisfactory as the amount of water absorbed by the tablets was sufficient to cause 
instantaneous disintegration by virtue of the swelling index of UBP (table 4.23).  
Table 4.23: Wetting time and water absorption ratio of the different tablet formulations 
Assessment  Branded tablets Innovative (DC)  Innovative (WG) 
Wetting time (s) 660±90 10±2 13±2 
Water absorption ratio (%) - 112±7 105±4 
 
4.8.7 In-vitro dispersion 
Table 4.24 presents the average time in seconds required for the different tablet formulations 
to breakdown into smaller fragments in deionised water and a 6.8 phosphate buffer solution at 
21º C. This assessment is a preview of the pharmacopoeial disintegration test. It enables the 
formulator to estimate the time required for a tablet to disintegrate should a patient opt to 
disperse the dosage form in a small amount of water prior to administration. The average 
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dispersion time recorded for the branded tablets was 840±60 sec in deionised water and 980±40 
sec in the phosphate buffer solution. The directly compressed innovative tablets displayed an 
average dispersion time of 45±3 sec in deionised water and 31±2 sec in the phosphate buffer 
solution. An average dispersion time of 57±4 sec in deionised water and 36±2 sec was recorded 
for the wet granulated formulation. The relatively faster dispersion of the directly compressed 
tablets is an indication of a very porous structure as a result of weaker binding forces that 
operate within the tablet matrix. The more porous a tablet is, the faster the dispersion due to 
the presence of more openings on the tablet surface which enhance permeation.[54] Wet 
granulation increases the binding forces between particles thereby reducing the interstices 
between them.[59] Consequently, it requires a longer time for the solvent to break through the 
tightly packed matrix. 
Table 4.24: In-vitro dispersion times in seconds of the different tablet formulations  
Medium Branded Innovative(DC) Innovative(WG) 
Deionised water 840±60  45±3  57±4  
6.8 Phosphate buffer 980±40  31±2   36±2  
 
The in-vitro dispersion timeline of the wet granulated innovative tablet is shown in figure 4.24 
below. A tablet was placed in the centre of a petri dish containing deionised water and 
photographs were taken at different time intervals.  
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Figure 4.24: Dispersion timeline of the wet granulated innovative tablets 
a) Tablet in dry petri dish b) Considerable wetting of the tablet can be observed at 10 sec c) 
Diffusion of the drug from the swollen tablet can be observed at 20 sec d) Gradual 
disintegration of the tablet at 30 sec e) Considerable disintegration of the tablet at 40 sec f) 
Complete dispersion of the tablet with swollen residues at 60 sec 
4.8.8 Disintegration study 
The average time required for the branded and innovative tablets to breakdown into smaller 
fragments in a neutral and buffered medium is presented in table 4.25 below.  Both the branded 
and the innovative tablets met the USP prerequisites for the disintegration of uncoated tablets 
given that complete disintegration of the assessed tablets occurred within 30 minutes.[20] An 
average disintegration time of 780±26 sec in deionised water and 960±20 sec in the 6.8 
phosphate buffer solution was recorded for the branded tablets. The innovative tablets 
disintegrated in both media within 60 seconds thus fulfilling the fundamental prerequisite for 
   
   
A C 
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fast dispersible tablets which entails instantaneous disintegration.[68] The disintegration of the 
branded tablets was relatively faster in water whereas the innovative tablets disintegrated faster 
in the phosphate buffer solution. This suggests that saliva will offer a propitious environment 
for the prompt disintegration of the innovative tablets at body temperature since it is a buffered 
medium. 
Table 4.25: Average disintegration time in seconds for the comparator and wet granulated 
innovative tablets 
Medium Branded tablet Innovative tablets 
Deionised water  780±26               50±3  
6.8 Phosphate buffer   960±20               35±2  
 
Disintegration is the precursor and a key determining factor of dissolution. The faster the 
disintegration process the quicker the active pharmaceutical ingredient is released from the 
tablet matrix. The higher the extent of disintegration the more drug is released from the dosage 
form at a faster rate. Basically, the breakdown of a tablet into smaller components increases 
the available surface area for permeation and drug diffusion.[65,69] This is depicted by Noyes-
Whitney’s equation. 
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As shown in the above equation , an increase in surface area (A) leads to an increase in the rate 
at which the active pharmaceutical ingredient (API) goes into solution. This suggests that 
adding a superdisintegrant such as UBP into a tablet formulation should enhance disintegration 
as well as dissolution. The equation also shows that the rate of dissolution is decreased by the 
thickness of the concentration gradient(d). Consequently, superdisintegrants that have the 
propensity to form gelatinous structures in water such as IHP might decrease the rate at which 
the API is released into solution.  
 
 
 
 
 
 
Noyes-Whitney equation[65] 
 
dm = A D (Cs – Cb) 
                                           dt          d 
Where 
dm/dt = dissolution rate of the solute (kg. s-1) 
m = mass of dissolved material (Kg) 
t = time (s) 
A = surface area of solute particle (m2) 
D = diffusion coefficient (m. s-1) 
d = thickness of the concentration gradient (m) 
Cs = particle surface concentration (moles/L) 
Cb = concentration in the solvent (moles/L) 
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This chapter gives an account of the HPLC method validation 
process and the outcome thereof, alongside a comparative 
assessment of the drug release patterns of the branded and 
innovative tablets.  
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5.1 HPLC method validation 
Chapter 2 identified and discussed four articles as a reference point to design an HPLC method 
to analyse the drug release patterns of the branded and innovative tablets. The information 
sourced from these articles was compiled and used to develop a HPLC method  elaborated in 
chapter 3. The method was assessed using standard validation parameters  which include 
system suitability, specificity, accuracy, precision, limit of detection (LOD) and limit of 
quantification (LOQ), robustness and linearity.  
5.1.1 System suitability  
The HPLC setup was assessed for resolution, column efficiency and repeatability to ensure the 
adequacy of the method for the analysis of lamivudine for both the branded and innovative 
formulations. The parameters investigated include theoretical plates, tailing factor and 
retention time.  
Lamivudine standard concentrations prepared with deionised water (100, 150, 200, 250, 300, 
350 ug/ml) were used. Injections were made in triplicate for each concentration and the mean 
value for each parameter was determined as presented in table 5.1 below.  
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Table 5.1: System suitability data (channel 285:10:400:10) 
Conc. 
(ug/ml) 
Theoretical plates 
(Foley-Dorsey) 
Theoretical plate 
(Tangential) 
Tailing factor Retention time 
(Minutes) 
100 1671.167 2328.461 1.434 0.988 
150 1593.351 2155.967 1.459 0.991 
200 1529.319 1925.282 1.457 0.993 
250 1496.942 1620.485 1.421 0.996 
300 1430.302 1478.414 1.418 0.997 
350 1383.205 1333.941 1.380 1.000 
 
Column efficiency  
The efficiency of a column is depicted by the number of theoretical plates i.e.  N = 16(tR/wb)2. 
The narrower the peak, the greater the number of plates. The greater the number of theoretical 
plates, the greater the resolving power (Figure 5.1) 
 
Figure 5.1: Determination of column efficiency[1] 
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The column efficiency of the standard samples of lamivudine was higher at lower 
concentrations. Inverse proportionality between the concentration of lamivudine and the 
number of theoretical plates was evident. It can thus be inferred that lower concentrations of 
lamivudine yield higher column efficiency. Consequently, lower concentrations of lamivudine 
were adequate for this analysis.  
Tailing factor 
Tailing factor measures and provides a means to quantify the extent of tailing of a peak. The 
results obtained from running lamivudine standard samples were found to be ideal as they did 
not exceed the non-ideal 2 ≤ value. The resultants peaks however did not depict the Gaussian 
peak since the tailing factor exceeded 1. Although the peaks deviated from the ideal Gaussian 
peak, they were still considered acceptable given that the tailing factors did not exceed 1.5. 
The retention times recorded for the standard samples of lamivudine demonstrated an ideal 
system suitability. The mean retention time was found to be 0.99 minutes rounded up to 1. The 
relative standard deviation (RSD) was 0.45%. This result is considered ideal as it shows that 
the variation between the retention times of the different concentrations is trivial. This indicates 
that the chosen setup was consistent and reproducible for all the assessed concentrations.  
A dissolution test using deionised water as medium was conducted and aliquots were 
withdrawn from a chosen vessel at predetermined time intervals (10, 20, 30, 40, 50, 60 
minutes). The samples were used to obtain system suitability data for the branded and 
innovative tablets as shown in tables 5.2 and 5.3.  
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Table 5.2: System suitability data of the innovative samples (channel 285:10:400:10) 
Parameters* 10 20 30 40 50 60 
TP(FD) 3517.90 3798.66 3735.97 3713.54 3753.99 3757.93 
TP(T) 6682.76 6561.45 6980.04 6964.09 6856.00 7190.34 
Tailing factor 1.60 1.47 1.48 1.49 1.51 1.47 
RT 1.003 0.99 0.99 1.000 1.001 1.004 
 
Table 5.3: System suitability data of the branded samples (channel 285:10:400:10) 
Parameters* 10 20 30 40 50 60 
TP(FD) 4147.12 3819.60 3745.17 3601.10 3552.42 3656.16 
TP(T) 8237.61 7592.29 6656.70 6459.73 6740.20 6455.74 
Tailing factor 1.51 1.49 1.46 1.47 1.47 1.46 
RT 1.003 1.006 1.005 0.987 0.987 0.990 
* TP(FD): Theoretical plates (Foley-Dorsey), TP(T): Theoretical plates (Tangential), RT: 
Retention time (minutes) 
The number of theoretical plates for both the innovative and branded samples were high, 
exceeding the minimum of 2000 plates hence depicting column efficiency. The number of 
plates further yielded sharper peaks and less peak separation. Consequently, it can be deduced 
that the column was highly efficient.  
Ideally, a peak should adopt the Gaussian shape with a tailing factor of 1. Both the innovative 
and branded samples had tailing factors above 1 but not exceeding 2. The average tailing factor 
for the innovative samples was 1.504 while the average tailing factor for the branded samples 
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was 1.48. Tailing for both the innovative and branded samples is illustrated by figures 5.2 and 
5.3. 
 
Figure 5.2: Graphical representation of tailing for the innovative sample at 60 minutes 
 
Figure 5.3: Graphical representation of tailing for the branded sample at 60 minutes 
The retention times for both the innovative and branded samples were recorded and the mean 
value vas determined. The average retention time of the innovative samples was 1.00 while the 
average retention time of the branded samples was 0.99. The relative standard deviation of the 
retention times was 0.23% for the innovative samples and 0.95% for the branded samples. This 
indicates that deviation from the recorded set of data is inconsequential. Overall, it required 1 
minute for the injected sample to be detected by the HPLC system. Consequently, the 
suitability of the setup was corroborated by the theoretical plate values, tailing factor, retention 
time and a lack of deviation from the data set. 
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Purity  
The branded sample was found to have a purity of 1.26 while the purity of  the innovative 
sample was 1.19. The closer the purity value is to 1 the purer the sample. Since the purity of 
the innovative sample is closer to the ideal value, it can be deduced that it is of superior purity 
than the branded sample i.e. fewer impurities were co-eluted with the active pharmaceutical 
ingredient (API). The innovative sample was expected to display an inferior purity since it 
contains a botanically sourced excipient. Instead, the branded sample displayed an inferior 
purity.  The ideal Gaussian peak shape (Figure 5.4) was not depicted by the innovative samples 
since tailing was observed (tailing factor of 1.52) showing some of lamivudine solutes being 
retained by the stationary phase. 
 
Figure 5.4: Non-ideal Gaussian peak shape for the innovative tablets with tailing factor of 1.52 
The analysed peak of the branded tablets (Figure 5.5) also failed to depict the ideal Gaussian 
peak shape. Tailing of the peak was apparent where the tailing factor was found to be 1.44. The 
tailing factors of the innovative and branded samples are however acceptable since they did 
not exceed the maximum tailing factor of 1.5. 
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Figure 5.5: Non-ideal Gaussian peak shape for the branded tablets with tailing factor of 1.44 
Tailing observed in both the innovative and branded lamivudine samples may be due to the 
utilisation of the C-18 column. In this column, pure hydrophobic retention mechanism is 
employed where half of the surface that constitutes silica is unbounded. The exposed silanol 
functional groups on the surface might have interacted with the samples. These functional 
groups are prone to interact with basic solutes such as lamivudine, hence prolonging the 
retention of these solutes on the stationary phase. Furthermore, the presence of trace metals in 
the silica matrix may have contributed to the tailing due to their ability to increase the acidity 
of the silanols, thereby enhancing interactions between silanols and lamivudine solutes.  
5.1.2 Specificity 
The impact inactive ingredients (excipients in both the innovative and branded samples) have 
on the assay of the API within the tablet formulation was assessed. The chromatograms 
revealed no interfering peaks within the region of lamivudine (Figures 5.2 and 5.3). 
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5.1.3 Accuracy  
To determine the accuracy of a system, a minimum of nine determinations over a minimum of 
three concentration levels covering the specified range should be carried out. Due to unforeseen 
circumstances with regards to the apparatus used, the percentage of analyte recovered after 
spiking samples in a blank was unattainable. Consequently, attaining a reference and asserting 
the accuracy of the setup was not possible. Nevertheless, a mean recovery assay should be 
within the range of 100 +/- 5.0% at each concentration over the assessed range. 
5.1.4 Precision 
The precision of the method was determined by performing intra-day and inter-day studies, 
and the repeatability precision levels were evaluated. For intra-day studies, prepared samples 
were analysed in triplicate within the same day. For inter-day validation, concentrations were 
assessed within three separate days. The relative standard deviation percentage (% RSD) values 
obtained from the peak area of lamivudine were assessed and were found to be below 0.007 
for all the six samples analysed (Table 5.4). This indicates that the method used was precise 
since a good repeatability was obtained.  
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Table 5.4 : Precision data for lamivudine standard concentrations 
Lamivudine Con. (ug) Mean absorbance Standard deviation RSD (%) 
100 1918842.77 7320.51 0.004 
150 2848465.44 18577.65 0.007 
200 3665872.15 18678.00 0.005 
250 4372885.94 36183.88 0.008 
300 5034368.87 20294.57 0.004 
350 5557221.95 19287.49 0.003 
Total 23397657.11   
 
5.1.5 Limit of Detection (LOD) and Limit of Quantification (LOQ)  
The limit of detection (LOD) and the Limit of Quantitation (LOQ) are parameters that are used 
to determine the smallest detectable concentration of an analyte. However, it is not a certainty 
with regards to stated experimental conditions. The most common techniques for estimating 
and determining detection and quantitation limit make use of the  standard deviation of the 
blank, extrapolations from the calibration line at low concentrations, visual definition and 
signal-to-noise ratio. The signal-to-noise ratio method is carried out by measuring the peak-to-
peak noise under the retention time. This measurement can be done by making use of an auto-
integrator system of the apparatus, or by manually assessing the chromatogram.[1,2] The 
following equation is used to determine signal-to-noise values: 
S/N = 
 
 
 
H represents the signal peak height on the chromatogram generated by the analyte in solution. 
It is measured from the maximum of the peak to its baseline. The difference in height between 
the highest and lowest peak of the noise generated on the chromatogram is denoted by h. 
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Table 5.5: Limit of detection by signal-to-noise ratio 
Injection No H - Signal Height (mAU) h - height of noise (mAU) S/N Ratio 
1 24,83 3,50 7,09 
2 26,43 4.00 6,61 
3 25,60 3,50 7,31  
 
The mean LOD value was found to be 7,00 which is double the accepted value between 2 and 
3. There are several factors that affect the LOD value generated from analysis of the 
chromatogram. However, these might not all be relevant to the experimental procedure 
conducted. The wavelength used in this analysis may not have been optimal based on the  UV 
max of the analyte. The best wavelength for selectivity is not necessarily the most ideal 
wavelength for detector response since most organic compounds are known to have a strong 
absorbance around 200 nm. Consequently, the use of a wavelength less than the UV max may 
increase the response in some instances.[3] The S/N ratio could also be enhanced by increasing 
the amount of sample injected. Injection of samples may not always be complete and could be 
hindered due to air entrapment in vessels as well as inadequate closure of the HPLC vials. 
5.1.6 Robustness  
Robustness assesses the validity of a method by measuring how well the method withstands 
small changes made to the operating parameters. These parameters are changed one at the time 
and may include flow rate, wavelength and mobile phase composition.[1] No robustness test 
was conducted specifically to validate this method. The parameters that could have been varied 
to assess  the robustness of this method include wavelength and mobile phase composition 
ratio. The innovative and branded samples were both assessed using wavelengths of 275 nm 
and 285 nm. Both samples had a mean retention time of one minute at both wavelengths. 
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Altering the mobile phase by changing the water to methanol ratio from 70:30 (%v/v) to 75:25 
(%v/v) or 65:35 (%v/v) could have been effectuated to assess the robustness of this method 
5.1.7 Linearity and range 
Under the optimised conditions, a calibration curve was used for lamivudine. Six standard 
samples of different concentrations were prepared. The corrected peaks were used to construct 
the calibration curve and to determine linearity range, regression equation, correlation 
coefficient, slope, standard errors of slope and standard errors of intercept. The plot of 
absorbance of each sample against their respective lamivudine concentration (Figure 5.6) was 
found to be linear in the range of 100 ug/ml – 350 ug/ml, using regression analysis of the linear 
equation for lamivudine Y= mx + c with correlation coefficient of r2= 0,99  Linearity data 
obtained from the measurements are given in Table 5.6.   
Linearity data for Lamivudine 
The linearity was determined by assessing different concentrations (100 ug/ml – 350 ug/ml) of 
the lamivudine standard solution. The calibration curve was constructed by plotting the 
concentration of standard samples against mean peak areas and the regression equation was 
computed. The parameters are shown in Table 5.6 below. 
Table 5.6: Linearity data of lamivudine standards 
No Concentration (ug/ml) Peak Area Retention time 
1 100 1918842.77 0.989 
2 150 2858939.73 0.992 
3 200 3676649.63 0.994 
4 250 4353962.33 0.996 
5 300 5023039.47 0.998 
6 350 5548591.87 0.998 
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Figure 5.6: Regression curve of lamivudine standard solution 
 
Table 5.7: ANOVA Statistical Analysis of lamivudine standard solution 
  df SS MS F Significance F 
Regression 1 1E+14 1E+14 1308,986 3,48E-06 
Residual 5 3,83E+11 7,65E+10 
  
Total 6 1,01E+14       
 
Where: 
“df” - Are the degrees of freedom (df) associated with the sources of variance.  The total 
variance has N-1 degrees of freedom.  The df value corresponds to the number of estimated 
coefficients subtracted by 1. As the value of df rises, the likelihood of a significant test also 
rises. Hence the importance of sample size; the larger the sample size the easier it is to obtain 
a significant result.   
0
1000000
2000000
3000000
4000000
5000000
6000000
7000000
100 150 200 250 300 350 400
A
b
so
rb
an
ce
Concentration (µm)
Actual
Predicted
http://etd.uwc.ac.za/
205 
 
“SS” – The sum of squares (SS) measures the total variation among the values.   
“MS” - The Mean Squares (MS), is the SS divided by their respective df. 
“F” - tests the overall significance of the regression curve.  It tests the null hypothesis that all 
the coefficients are equal to zero.  This tests the full data set against one with no variables and 
with the estimate of the dependent variable being the mean of the values of the dependent 
variable.  The F value is the ratio of the mean regression SS divided by the mean error SS.   
“Significance of F” - This indicates the probability that the Regression output could have been 
obtained by chance. A small Significance of F confirms the validity of the Regression output. 
 
Table 5.8: Regression statistics of lamivudine standard solution 
Regression Statistics 
Multiple R 0,995 
R Square 0,999 
Adjusted R Square 0,987 
Standard Error 155343,27 
Observations 6 
 
Table 5.9: Standard curve parameters of lamivudine standard solution 
 
2 Standard 
Error 
t Stat P-value Lower 
95% 
Upper 
95% 
Lower 
95.0% 
Upper 
95.0% 
Intercept 598379.15 178733.2 3.0 0.03 102136.3 1094622 102136.3 1094622 
X 
Variable1 
14646.30 742.68 19.72 3.9E-05 12584.28 16708.32 12584.28 16708.32 
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5.2 Dissolution 
The validated HPLC method was used to analyse the drug release pattern of lamivudine from 
the branded and innovative tablets. The data obtained was used to plot a dissolution curve using 
extrapolated concentrations of the various aliquots withdrawn at the set time intervals (Figure 
5.10). The release rate data was evaluated using different models namely Zero order, First 
order, Higuchi and Korsmeyer & Peppas function. Considering the fact that the drug release 
pattern of a conventional tablet (branded) was compared to that of a fast dispersible tablet 
(innovative), the purpose of this study was not to improve the drug release rate of the former, 
but instead to ascertain that the latter meets one of the key requirements of FDTs i.e. rapid 
dissolution.  
The regression value of lamivudine was found to follow the Zero order release pattern.  The 
assay showed that the innovative tablets attained complete dissolution within 10 minutes whilst 
the branded tablets attained complete dissolution within 30 minutes (Table 5.11). Both the 
branded and innovative tablets met the USP prerequisites for the dissolution of uncoated 
tablets. The USP stipulates that the time required for the complete dissolution of an assayed 
batch of uncoated tablets should not exceed 30 minutes.  
The regression graph clearly depicts the direct proportionality between absorbance and 
lamivudine concentration. Higher concentrations of lamivudine yielded higher absorbance 
values and stronger peaks. The absorbance data of the branded samples clearly depicted this 
correlation as different absorbance values were obtained at the various time intervals. 
Conversely, the innovative samples had a narrow range of absorbance values due to the abrupt 
increase in concentration as a result of the complete release of the drug within 10 minutes. This 
abrupt release of the API from the innovative tablets can be attributed to the instantaneous 
disintegration of the tablets due to the presence of the superdisintegrant UBP. 
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Table 5.10: Dissolution rate profile of the branded and innovative tablets 
Time (minutes) Concentration (µM) 
Branded tablets 
Concentration (µM) 
Innovative tablets 
10 97.56 146.09 
20 129.92 156.98 
30 151.18 159.94 
40 154.75 160.46 
50 156.42 160.17 
60 158.45 160. 02 
Standard deviation 21.77 5.14 
 
 
Figure 5.7: Dissolution curve of the branded and innovative tablets 
The rapid dissolution of the innovative tablet was envisaged since it disintegrated in water 
instantly. As elucidated by Noyes-Whitney’s equation, disintegration increases the surface area 
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of the solutes exposed to the medium which in turn increases the rate of dissolution as the API 
diffuses freely from the dissociated tablet matrix. It can thus be deduced that the rate and extent 
of disintegration is a reflection of the rate at which the API is released from the tablet matrix. 
The reverse is true for the branded tablet which had a lengthy disintegration and subsequently 
displayed a relatively slow dissolution rate. The two main advantages of rapid dissolution are 
quick onset of action and enhanced bioavailability. Quick onset of action implies that the 
therapeutic effect of the drug is initiated promptly since the drug is made available at the site 
of action swiftly while enhanced bioavailability indicates an increase in the amount of the drug 
available for absorption. While the former might not be very significant as far as antiretroviral 
therapy is concerned, the latter is a sought property for antiretroviral formulations since 
adequate amounts of drug absorbed into the body contribute to therapeutic success.  
Drug release data can also be used by the formulator to assess the uniformity of the dosage 
form with respect to the amount of API present in each unit. This reflects the homogeneity of 
the powder blend and the accuracy with which the powder was weighed for each individual 
tablet. Substantial deviation from the set amount of API per dosage form unit poses the risk of 
underdosing or overdosing. While underdosing can lead to resistance and treatment failure, 
overdosing can lead to toxicity and unwanted effects of the drug especially for highly potent 
drugs and drugs with a narrow therapeutic index. Both the branded and innovative tablets 
attained 100 % drug release indicating the tablets assessed each contained the expected 150 mg 
of lamivudine.  
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Chapter 6 
Limitations and recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter highlights the main setbacks encountered in this 
project and suggests approaches that can be used to adequately 
optimise the formulated tablet into a marketable product. 
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6.1 Limitations 
Several challenges were encountered throughout the completion of this project some of which 
were resolved in the process. For example, the issue of friability was overcome by making use 
of wet granulation. The nature of this project was self-limiting in that the parent powders 
displayed poor tableting properties with regards to flowability and compressibility. Also, the 
use of the natural polymers as multipurpose excipients in view of reducing the cost associated 
with formulation made it difficult to obtain a product of high integrity.  
Another major setback was the tableting machine used for this project. A single punch 
manually operated tablet press was used to compress the innovative tablets (figure 6.1). This 
entailed that an adequate amount of powder had to be weighed accurately for each individual 
tablet. This process was lengthy and increased the risk of spillage, inaccurate powder 
measurement and demixing as a result of the powder blend standing still for a long period of 
time. These issues could affect the uniformity and integrity of the resultant tablets.  
 
Figure 6.1: Tablet press used for compression 
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6.2 Recommendations  
6.2.1 Using banana starch instead of unripe banana powder 
Literature reports that unripe banana powder (UBP) possesses a myriad of phytochemicals and 
nutrients which are beneficial to the human body.[1] However, the presence of fibres, proteins, 
sugars, and other phytochemicals might adversely affect the flowability, compressibility and 
binding properties of the powder. Also, these phytochemicals offer a propitious environment 
for microorganisms to thrive since they serve as nutrients for bacteria and fungi. A high 
bioburden will thus affect the integrity and abridge the shelf life of the powder. Since starch 
accounts for more than 70% of UBP and is almost entirely responsible for the binding and 
disintegrating properties of the powder, it is well suited to make use of pure banana starch as 
an excipient rather than using the whole powder.[2] Starch can be extracted from banana powder 
by centrifugation or alkali extraction. The innovative tablets can be optimised by replacing 
banana powder with banana starch and comparatively assessing the two formulations. 
6.2.2 Taste assessment and taste masking  
Palatability plays a major role in ensuring adherence to a prescribed treatment for both 
paediatric and adult subjects. Tablets that are bitter or leave an unpleasant feel in the mouth are 
usually aversive to patients and are a major hindrance to treatment completion. Most drugs are 
intrinsically bitter and impart an unpleasant taste to the tablet into which they are formulated.[3] 
It is thus imperative to conduct a taste assessment on a newly formulated tablet especially for 
fast dispersible tablets given that they come into contact with the tongue for a substantial 
amount of time. Taste assessment can be carried out in-vivo by making use of healthy 
volunteers and in-vitro by making use of analytical gustatory tools such as the electronic tongue 
(E-tongue®). Although the former is an ideal and straight forward approach, it is not quite 
feasible at this level of research since it requires ethical approval and necessitates a large group 
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of volunteers to obtain sufficient data. An electronic tongue is an instrument designed to screen 
the taste attributes of oral formulations in a rapid timeframe. An electronic gustatory system is 
usually composed of varied taste sensors, a sample table, an amplifier and a computer for data 
recording. Taste sensors are capable of detecting the chemical compounds which are 
responsible for taste and elicit responses in a similar way human taste buds do (Figure 6.2).[4] 
It will be fitted to assess the innovative tablet with an electronic gustatory device to be 
cognisant of its palatability and be guided on how to improve its taste. 
 
Figure 6.2: Comparison between the tongue and an electronic gustatory device 
Coating, flavouring and taste-masking are the techniques commonly employed to camouflage 
or attenuate the unpleasant taste of drugs in tablets. Flavouring remains the most cost effective 
and straight forward technique consisting of incorporating a flavouring excipient into the 
powder blend prior to compression. Commonly used tablet flavouring agents in the 
pharmaceutical industry include banana, mint, strawberry and vanillin. Strawberry and vanillin 
are suitable flavouring agents for the innovative tablets since both flavours are tolerated by 
paediatrics as well as adult subjects.[5] Also, the addition of an excipient such as mannitol to 
http://etd.uwc.ac.za/
214 
 
the innovative formulation could be beneficial. Mannitol is a multipurpose excipient which is 
commonly used in orodispersible tablets because of its pleasant mouth feel.[6]  
6.2.3 Stability assessment of the innovative tablets 
The purpose of stability testing is to provide evidence on how the quality of a drug or a dosage 
form varies with time under the influence of environmental factors such as light, humidity and 
temperature. This assessment enables the formulator to establish a shelf life for the product, 
recommend suitable packaging and storage conditions, and identify drug-excipient or 
excipient-excipient incompatibilities. Also, the information obtained from stability testing can 
be useful for the optimisation of the product.[7] It is thus imperative for the innovative tablets 
to be assessed for stability. An accelerated stability study as per the International Council for 
Harmonisation (ICH) guidelines can be conducted at 40 ºC/ 75RH over a period of 3 months. 
Tablets should be assessed for weight uniformity, hardness, friability, disintegration time, and 
dissolution at regular intervals and the data should be comparatively assessed. Thermal and 
spectroscopic tools should also be employed to detect any drug-excipient incompatibility and 
degradation.[8]  
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Conclusion 
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Conclusion  
 
The aim of this study which consisted in developing a cost effective fast dispersible tablet of 
lamivudine using alternative excipients and conventional techniques was successfully 
achieved. The innovative tablets displayed rapid disintegration (50 s in water, 35 s in 6.8 
phosphate buffer solution) thus fulfilling the key requirement for fast dispersible tablets.  
The natural polymers which were selected for this study were characterised and their ability to 
be used as multipurpose tablet excipients was assessed. Ispaghula husk powder albeit having a 
high swelling capacity, a sought characteristic for superdisintegrants, displayed poor binding 
properties and a narrow range of superdisintegrating activity since a drastic reduction in its 
disintegrating effect was observed at concentrations above 10 % w/w as a result of the 
formation of a gelatinous mass. This gelatinous mass impeded disintegration by serving as a 
barrier to the penetration of water into the tablet matrix. This suggests that Ispaghula husk 
powder may not be used as a multipurpose excipient in a tablet formulation but rather as a 
superdisintegrant at low concentrations amid other excipients serving as binders and fillers.  
Unripe banana powder on the other hand displayed satisfactory disintegrating as well as 
binding properties. Although the disintegrating effect of unripe banana powder decreased with 
increasing concentration of the natural polymer subsequent to reaching its saturation point, an 
increase in its binding effect was observed and the final product nevertheless disintegrated 
rapidly. Consequently, it can be deduced that unripe banana powder can serve as a 
multipurpose excipient and be used at concentrations above 10% w/w without a substantial 
decrease in its super disintegrating effect or the risk of gel formation.  
Ispaghula husk powder and unripe banana powder were found to be compatible with the active 
pharmaceutical ingredient lamivudine since no incongruity was observed on the DSC curves 
and the FTIR spectra of the 1:1 drug-excipient mixtures. However, stability studies under 
http://etd.uwc.ac.za/
218 
 
accelerated conditions alongside antiviral testing should be undertaken to ascertain whether the 
natural polymers do not adversely impact the integrity and the therapeutic activity of 
lamivudine throughout the shelf life of the innovative tablets. 
Lamivudine powder which was found to have poor material properties with regards to 
flowability and compressibility was successfully compressed with unripe banana powder and 
magnesium stearate using direct compression. However, the resultant tablets were highly 
friable and unevenly compressed. Wet granulation was shown to drastically reduce the 
friability of the innovative tablets whilst allowing the tablets to disintegrate rapidly. The 
innovative tablets displayed rapid disintegration and rapid dissolution as opposed to the 
branded tablets. This suggests that natural polymers with super disintegrating properties such 
as unripe banana powder are effective at reducing the disintegration time and dissolution time 
of tablets. 
 A HPLC method suitable for the assay of lamivudine in a tablet formulated with a natural 
polymer was validated and was successfully used for the drug release analysis of the innovative 
and branded tablets. The purity and absorbance of lamivudine were unaltered by the presence 
of unripe banana as revealed by the HPLC data.  
Despite the numerous challenges encountered, the objectives of this study were met. With 
adequate optimisation, the innovative tablets can be introduced into the pharmaceutical market. 
This tablet is socioeconomically sound in that it is convenient, patient friendly and cost 
effective.  
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